Document:

Exhibit 4.1

 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE
24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 [...***...] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
COMMISSION

 

DISTRIBUTION AGREEMENT

 

BETWEEN

 

CORREVIO INTERNATIONAL SARL

 

AND

 

BASILEA PHARMACEUTICA INTERNATIONAL
LTD.

 

Dated as of September 11, 2017

 

     

    CONFIDENTIAL

    

 

TABLE OF CONTENTS

 

	ARTICLE 1 DEFINITIONS	1
	ARTICLE 2 APPOINTMENT AND PARTIES’ GENERAL CONDUCT	10
	ARTICLE 3 COMMERCIALIZATION	15
	ARTICLE 4 REGULATORY MATTERS AND PHARMACOVIGILANCE	16
	ARTICLE 5 SUPPLY OF PRODUCT	22
	ARTICLE 6 MANUFACTURING STANDARDS AND QUALITY ASSURANCE	25
	ARTICLE 7 ASSUMED AND ACTUAL TRANSFER PRICE; PAYMENT TERMS	29
	ARTICLE 8 EXECUTION PAYMENT; REGULATORY PAYMENTS; MILESTONE PAYMENTS	32
	ARTICLE 9 REPRESENTATIONS AND WARRANTIES	32
	ARTICLE 10 INTELLECTUAL PROPERTY	36
	ARTICLE 11 INDEMNIFICATION AND LIABILITY	38
	ARTICLE 12 INSURANCE	39
	ARTICLE 13 CONFIDENTIAL INFORMATION	40
	ARTICLE 14 TERM; TERMINATION	42
	ARTICLE 15 RECORDS AND AUDITS	44
	ARTICLE 16 NOTICES	44
	ARTICLE 17 MISCELLANEOUS	45
	SCHEDULE 1	 
	SCHEDULE 2	 
	SCHEDULE 3	 
	SCHEDULE 4	 
	SCHEDULE 5	 
	SCHEDULE 6	 
	SCHEDULE 7	 
	SCHEDULE 8	 
	SCHEDULE 9	 

 

    	 	i	 

    CONFIDENTIAL

    

 

DISTRIBUTION AGREEMENT

 

THIS DISTRIBUTION AGREEMENT dated
as of September 11, 2017 (the “Effective Date”) is made by and between Correvio International Sàrl, a corporation
organized and existing under the laws of Switzerland with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland
(hereinafter “Cardiome”), and Basilea Pharmaceutica International Ltd., a corporation organized and existing under
the laws of Switzerland, with offices at Grenzacherstrasse 487, CH-4058, Basel, Switzerland (hereinafter “Basilea”).
Cardiome and Basilea may be referred to herein individually as a “Party” or collectively as the “Parties.”

 

WITNESSETH:

 

WHEREAS, Basilea owns and/or has the exclusive
right to certain technology, intellectual property rights and confidential and/or proprietary information relating to the Product;

 

WHEREAS, Basilea is engaged in the research,
development, manufacturing and commercialization of pharmaceutical products and has been granted Marketing Authorisation of the
Product in certain countries of the Territory;

 

WHEREAS, Cardiome is engaged in the registration,
promotion and commercialization of pharmaceutical products in the Territory;

 

WHEREAS, Basilea wishes to grant Cardiome
an exclusive license to commercialize the Product in the Territory, and Cardiome wishes to accept such license, subject to the
terms and conditions of this Agreement;

 

NOW, THEREFORE, in consideration of these
premises and the covenants and agreements set forth herein, and intending to be legally bound thereby, the Parties hereby agree
as follows:

 

ARTICLE 1
DEFINITIONS

 

As used in this Agreement, the following
terms shall have the meanings set forth below.

 

		1.1	“Actual Transfer Price” means the price in Swiss Francs payable by Cardiome for each
Bulk Vial of the Product determined in accordance with Article 7.

 

		1.2	“Affiliate(s)” means, with respect to each Party, any corporation, firm, partnership
or other entity or Person which directly or indirectly controls or is controlled by or is under common control with that Party.
For purposes of this definition, “control” (including, with correlative meaning, the terms “controlled by”
and “under common control with”) shall be presumed to exist if one of the following conditions is met: (a) in the case
of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to
vote for the election of directors of such corporate entity or any direct or indirect parent of such corporate entity, and (b)
in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with
the power to direct the management and policies of such non-corporate entities.

 

     

    CONFIDENTIAL

    

 

		1.3	“Agreement” means this Distribution Agreement and all Schedules hereto as the same
may be amended, supplemented or otherwise modified from time to time.

 

		1.4	“Applicable Law” means (i) any applicable statute, statutory instrument or any other
legislative instrument having the force of law; (ii) any applicable judgment of a relevant court of law which is binding precedent
in any applicable jurisdiction, in each case in force at any time during the Term; and (iii) all applicable guidance, directions,
codes of practice, self-regulation, determination, regulations or professional standards either issued by a Regulatory Authority
or applicable to the relevant activity.

 

		1.5	“Assumed Transfer Price” means the assumed transfer price in Swiss Francs for each
Bulk Vial of the Product determined in accordance with Article 7.

 

		1.6	“Authorisation” means all applicable licenses, registrations and governmental approvals
and permits that may be necessary to permit the importation, transportation, distribution, Manufacturing and the Selling of the
Product in the Territory, including the marketing authorisation and any necessary pricing, reimbursement and formulary listing
applications, as such licenses, registrations, approvals or permits are granted by the applicable Regulatory Authority and other
authorities in the Territory.

 

		1.7	“Basilea Core Materials” shall have the meaning set forth in Section 3.6(a).

 

		1.8	“Basilea Indemnitees” shall have the meaning set forth in Section 11.1.

 

		1.9	“Basilea Information” means information owned or Controlled by Basilea, in whatever
format recorded, including the Dossier and the Know-how, which relates to the Product, including but not limited to (i) information
relating to the manufacture of the Product including information relating to contract manufacturers and the manufacturing supply
chain of the Product, including API (active pharmaceutical ingredient), fill finish, packaging; (ii) information relating to the
pricing and reimbursement of the Product outside the Territory; (iii) information relating to the Commercialization of the Product
outside the Territory, including advertising and promotional strategies; (iv) information relating to the competitive positioning
of the Product, including market research reports; (v) information relating to the Intellectual Property protecting the Product,
including Patents, Trade Marks and inventions on which patent applications have not been filed; (vi) distribution information (including
storage recommendations); (vii) pharmacovigilance data, and any other information relating to the Commercialization of the Product
which is not generally ascertainable.

 

		1.10	“Basilea IP” means the Know-How, the Trademarks, the Domains, and the Patents.

 

		1.11	“Bulk Vial” means Finished Product excluding secondary packaging.

 

		1.12	“Business Day” means any day other than Saturday, Sunday or any day on which banks
located in Switzerland are authorized or obligated to be closed.

 

		1.13	“Cardiome Core Materials” shall have the meaning set forth in Section 3.6(b).

 

    	 	2	 

    CONFIDENTIAL

    

 

		1.14	“Cardiome Indemnitees” shall have the meaning set forth in Section 11.1(b).

 

		1.15	“Claim or Proceeding” means any claim, action, suit, proceeding or arbitration including
any Governmental Authority action, notification, investigation or audit.

 

		1.16	“Clawback/Payback” has the following meanings: (a) Clawback means a mandatory reimbursement
system unilaterally imposed on Cardiome by a competent Regulatory Authority allowing a Third Party to recoup from Cardiome all
or part of the discounts/rebates granted on sales of Products; (b) Payback means a mandatory financial mechanism unilaterally imposed
on Cardiome by a competent Regulatory Authority that requires Cardiome to refund revenues if Cardiome’s sales of Product
exceed a previously determined or agreed target-budget.

 

		1.17	“Clawback/Payback/Managed Entry Requirements Report” has the meaning set forth in Section
7.7(a).

 

		1.18	“Commercialization” or “Commercialize” means all activities directed to
importing, transporting, distributing, warehousing, advertising, marketing, promoting, selling or otherwise using the Product in
the Territory.

 

		1.19	“Commercialization Plan(s)” means the commercialization plan(s) to be prepared by Cardiome
pursuant to Section 3.1 and the template provided in Schedule 1.

 

		1.20	“Commercial Launch Plan” means the plan providing the estimated timeline for the registration
of the Product (in countries in the Territory where the Product is not yet registered) and for the First Commercial Sale Date by
Cardiome of the Product, the template for which is set out in Schedule 4.

 

		1.21	“Commercially Reasonable Endeavours” means efforts that are comparable to those used
by the pharmaceutical industry, and are financially reasonable in the relevant region or in the Territory for products that have
a similar commercial potential and are at similar stages in the product life cycle measured by the facts and circumstances including
present and future market potential, medical and clinical considerations, present and future regulatory environment and competitive
market conditions.

 

		1.22	“Confidential Information” has the meaning defined in Article 13.

 

		1.23	“Control” means, with respect to any information, patent, know-how, trade mark or other
intellectual property right, possession by a Party of the ability to grant the right to access or use, or to grant a license or
a sublicense to, such information, patent, know-how, trade mark or other intellectual property right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party and “Controlled” shall have a correlative
meaning.

 

		1.24	“Core European Territory” means Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech
Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands,
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Switzerland, the United Kingdom of Great Britain, and Northern Ireland.

 

    	 	3	 

    CONFIDENTIAL

    

 

		1.25	“Current Good Manufacturing Practices” or “cGMP” mean all applicable standards
and Applicable Law relating to manufacturing practices for products (including ingredients, testing, storage, handling, intermediates,
bulk and finished products) promulgated by the United States Food and Drug Administration or any other Governmental Authority (including,
without limitation, EU or member state level) , including but not limited to standards in the form of laws, guidelines, advisory
opinions and compliance policy guides and current interpretations of the applicable authority or agency thereof (as applicable
to pharmaceuticals, biologicals and over the counter products and ingredients), as the same may be updated, supplemented or amended
from time to time.

 

		1.26	“Customer(s)” means any Third Party administering or prescribing the Product.

 

		1.27	“Deduction Cap” shall have the meaning provided in Section 1.57.

 

		1.28	“Delivery” has the meaning provided in Section 5.2, and “Deliveries”, “Delivers”
or “Delivered” have the corresponding meaning.

 

		1.29	“Details” means the communication by a sales representative during a personal visit
to a member of the target prescriber audience (a) involving face-to-face contact at the target prescriber’s place of work,
(b) describing in a fair and balanced manner the relevant characteristics of the Product, and (c) using the Basilea Core Materials
and/or the Cardiome Core Materials in an effort to increase the prescribing preferences of the Product.

 

		1.30	“Domains” mean the domains set out in Schedule 3 and any other domains dedicated for
the Product owned or Controlled by Basilea, which may be used in Commercialization of the Product in the Territory.

 

		1.31	“Dossier” means the harmonized registration files relating to the Product in electronic
common technical document (eCTD) format prepared by or on behalf of Basilea or its Affiliates in the form used for the decentralized
registration procedure in the European Union and subsequent Mutual Recognition Processes/Repeat-Use Procedures related to the Product,
as such harmonized registration files may be amended from time to time.

 

		1.32	“Drug Substance” means the active pharmaceutical ingredient of the Product ceftobiprole
medocaril (BAL 5788)

 

		1.33	“Effective Date” shall have the meaning set forth in the preamble above.

 

		1.34	“European Union PIP” means activities and studies relating to the paediatric investigation
plan for the Product required by the Regulatory Authority(ies) in the European Territory, together with any amendments and updates
required by such Regulatory Authority(ies) from time to time.

 

		1.35	“Execution Payment” shall have the meaning set forth in Section 8.1.

 

    	 	4	 

    CONFIDENTIAL

    

 

		1.36	“Facility” means the facility or facilities owned and operated by Contract Manufacturing
Organizations (CMOs) specified in the Dossier (as amended from time to time) and used by Basilea to manufacture, store, or package
the Product hereunder.

 

		1.37	“Field” means the treatment, prevention, diagnosis, control and maintenance of all
diseases and disorders in humans.

 

		1.38	“Finished Product” means Qualified Person Released Product in its final market form
(vials) after packaging and labeling in accordance with the Specifications to be distributed in the Territory.

 

		1.39	“First Commercial Sale Date” means each date of the first commercial sale of Finished
Product to Customer by or on behalf of Cardiome in each country of the Territory.

 

		1.40	“First Commercial Supply Date” means the first date on which Basilea first supplies
Finished Product to Cardiome (with the exception of the Inventory).

 

		1.41	“Force Majeure Event” shall have the meaning set forth in Section 17.5.

 

		1.42	“Forms” shall mean a purchase order acknowledgment form or similar routine document
as specified in Section 17.9.

 

		1.43	“GDP” means the Good Distribution Practice as specified in Articles 76 to 85 of Directive
2001/83/EC of the European Parliament and of the Council of 6 November 2001 and the guidelines for Good Distribution Practice as
promulgated in “Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use” (2013/C
343/01), as amended from time to time.

 

		1.44	“Government” means all levels and subdivisions of any relevant government (i.e., local,
regional, or national and administrative, legislative, or executive).

 

		1.45	“Governmental Authority” means any duly authorized court, tribunal, arbitrator, agency,
commission, official or other instrumentality of any federal, state, province, county, city or other political subdivision, domestic
or foreign.

 

		1.46	“Insolvent Party” shall have the meaning set forth in Section 14.3.

 

		1.47	“Intellectual Property” means (a) any processes, trade secrets, inventions, industrial
models, designs, methodologies, drawings, formulae, procedures, techniques, clinical data or technical or other information or
data, manufacturing, engineering and technical drawings necessary or useful in the registration, packaging, manufacture, use or
sale of the Product, and (b) registered trade marks, trade mark applications, unregistered trade marks, trade dress, copyrights,
know-how, Patents covering the Product or any components thereof or improvements thereof, in both (a) and (b) as owned or Controlled
by Basilea.

 

		1.48	“Inventory” shall have the meaning set forth in Section 2.10.

 

    	 	5	 

    CONFIDENTIAL

    

 

		1.49	“Know-how” means all existing or future proprietary unpatented information, owned or
Controlled by Basilea relating to the Product including but not limited to ideas, processes, trade secrets, inventions, industrial
models, designs, methodologies, drawings, formulae, procedures, techniques, records, clinical data or technical or other information
or data, manufacturing, engineering and technical drawings and other information which is necessary for obtaining and maintaining
the Marketing Authorisation or which is useful in the research, development, registration, packaging, manufacture, use or sale
of the Product and all data contained in the Dossier and other relevant pharmacological, toxicological, metabolic, non-clinical
and clinical data.

 

		1.50	“Latent Defect” means a defect to the Product already present at the time of Delivery
of the Product to Cardiome but not detected despite inspection by Cardiome or any of its Affiliates in accordance with this Agreement.

 

		1.51	“Losses” means any and all losses, damages, liabilities, costs and expenses (including
legal fees and expenses).

 

		1.52	“Minimum Order Quantities” shall be the minimum amounts of Product which may be ordered
in each Purchase Order as listed in Schedule 6.

 

		1.53	“Minimum Transfer Price” shall be [...***...] per Bulk Vial of Product.

 

		1.54	“Marketing Authorisation” means such formal approval from a Regulatory Authority as
is necessary for the commercial marketing, sale, and use of pharmaceutical products within a country of the Territory (but excluding
Pricing and Reimbursement Approval).

 

		1.55	“Marketing Authorisation Application” means an application to the appropriate Regulatory
Authority for Marketing Authorisation for the Product in any particular jurisdiction and all amendments and supplements thereto.

 

		1.56	“National Marketing Authorisation” means the approval from a Regulatory Authority in
the EU on a national level for the Product based upon a Mutual Recognition Processes/Repeat-Use Procedure under the Dossier.

 

		1.57	“Net Sales” shall mean the gross amounts (excluding VAT or other similar taxes) invoiced
by or on behalf of Cardiome, its Affiliates and/or Sublicensees (the “Selling Party”) for sales of the Product to Third
Parties (other than Sublicensees), less the following deductions, paid and specifically related to the Product by Cardiome, its
Affiliates and/or Sublicensees using U.S. GAAP applied on a consistent basis:

 

		(a)	[...***...];

 

		(b)	[...***...];

 

		(c)	[...***...]; and

 

		(d)	[...***...].

 

    	 	6	 

    CONFIDENTIAL

    

 

In no event shall any particular
amount identified above be deducted more than once in calculating Net Sales (i.e., no “double counting” of reductions).
Sales of the Product between Cardiome and its Affiliates and/or Third Party Sublicensees and/or Third Party Distributors for resale
shall be excluded from the computation of Net Sales, but the subsequent resale of the Product by an Affiliate or Sublicensee, as
applicable, to a Third Party shall be included within the computation of Net Sales.

 

Notwithstanding anything to the
contrary herein, Cardiome’s disposal or use of the Product for regulatory, Development or charitable purposes when such disposal
or use is not a sale (meaning that Cardiome receives no benefit either in cash or in kind for such disposal or use and issues no
invoice related to such disposal or use), such as clinical trials, preclinical trials, compassionate use, named patient use, or
indigent patient programs, without consideration, shall not be deemed a sale for the purposes of computation of the Net Sales clause.
All supply for such purposes shall be purchased by Cardiome from Basilea at the Minimum Purchase Price pursuant to Section 7.3.

 

In no event shall the deductions
provided in paragraph d) exceed a total of [...***...] of the gross revenues (the “Deduction Cap”).

 

For the avoidance of doubt, Clawback/Payback/
Managed Entry Requirements shall follow the terms set forth in Section 7.7(a) and are not permissible deductions from Net Sales.

 

For all deductions listed above,
to the extent that Cardiome sells a grouped set of products in which the Product is included, the applicable discount, allowance,
rebates and other deductions for the Product in such arrangement for purposes of calculating Net Sales shall be the average discount,
allowance, rebate or other deductions for the group set of products (as compared to the non-discounted prices of the respective
products when sold separately) multiplied by the fraction X/(X + Y), where X = the average discount, allowance, rebate or other
deductions of the Product when sold separately (in percentage) and Y = the average discount, allowance, rebate or other deductions
of other products in the group when sold separately (in percentage). An example of such calculation is attached to this Agreement
in Schedule 7.

 

		1.58	“Non-EU Eastern European Territory” means Albania, Bosnia and Herzegovina, Israel,
Macedonia, Montenegro, San Marino, and Serbia.

 

		1.59	“Patents” means the patents and patent applications, including patent extensions, provisional
applications, divisions, continuations, continuations in part, substitutions, renewals, registrations, revalidations, reissues
or additions, supplementary protection certificates, and applications and all foreign counterparts thereof, or any future patents
or patent applications, owned and/or Controlled by Basilea or its Affiliates covering the Product, its manufacture or use, including
the patents as listed in Schedule 2.

 

		1.60	“Person” means any natural person, entity, corporation, general partnership, limited
partnership, proprietorship, other business organization, trust, union, association or Governmental Authority.

 

    	 	7	 

    CONFIDENTIAL

    

 

		1.61	“Product” means any formulations and pharmaceutical dosage forms of ceftobiprole medocaril.

 

		1.62	“Purchase Order” means a written or electronic order form submitted by Cardiome to
Basilea for the purchase and supply of Product in accordance with the terms of this Agreement.

 

		1.63	“Qualified Person” has the meaning provided in the Quality Agreement.

 

		1.64	“Qualified Person Release” has the meaning provided in Section 5.2 and further specified
in the Quality Agreement and “Qualified Person Released” has the correlative meaning.

 

		1.65	“Quality Agreements” means those supplemental quality provisions set forth in agreements
between Basilea and Cardiome relating to the Product which will be agreed after the Effective Date in accordance with Section 6.1.

 

		1.66	“Recall” means a recall, correction or market withdrawal and shall include any post-sale
warning or mailing of information.

 

		1.67	“Records” means any books, documents, accounting procedures and practices and other
data, regardless of type or form, of all matters relating each Party’s performance of its obligations under this Agreement
that enable that Party to demonstrate compliance with such obligations, including, without limitation, its compliance with Applicable
Law.

 

		1.68	“Regulatory Authority” means anybody having regulatory authority over any part of Basilea’s
or Cardiome’s business or the activities contemplated under this Agreement, in whatever jurisdiction.

 

		1.69	“Repeat-use Procedure” means the process for submission of an application for a National
Marketing Authorisation in an EU member state based upon a granted Marketing Authorization in another EU member state.

 

		1.70	“Safety Data Exchange Agreement” shall have the meaning set forth in Section 4.4.

 

		1.71	“Selling Party” shall have the meaning set forth in Section 1.57.

 

		1.72	“Specifications” means the specifications for the manufacture, processing, packaging,
labeling, testing and testing procedures, shipping, storage and supply of the Product, including all formulae, know-how, raw materials
requirements, analytical procedures and standards of quality control, quality assurance and sanitation, attached to the Quality
Agreement.

 

		1.73	“Submission” means a submission by or on behalf of either Party or its Affiliates to
a Regulatory Authority with respect to the Product, which may include, but shall not be limited to, submissions with respect to
the Product for variations, notifications, renewals, PSUR, labeling and artwork.

 

		1.74	“Term” shall have the meaning set forth in Section 14.1.

 

    	 	8	 

    CONFIDENTIAL

    

 

		1.75	“Territory” means the Core European Territory and the Non-EU Eastern European Territory.

 

		1.76	“Tests” means any quantitative structure activity relationship (QSAR) analysis and
any in vitro and in vivo testing of impurities and degradants in the Product, Product substance, Product substance
intermediates and raw materials for the purpose of structural identification and/or toxicological categorization and/or toxicological
qualification in accordance with ICH M7. For the avoidance of doubt, Tests does not mean any standard analytical quality controls
related to supplied Product.

 

		1.77	“Third Party” means any Person other than Cardiome, Basilea and their respective Affiliates.

 

		1.78	“Third Party Distributor” means any Third Party supporting Cardiome or any of its Affiliates
with the provision of local Product distribution services or Commercialization of the Product in any country of the Territory.
For the avoidance of doubt, Wholesalers and logistic service providers are not Third Party Distributors.

 

		1.79	“Third Party Licensee” means any Third Party which is granted a sublicense by Cardiome
in accordance with Section 2.1(b).

 

		1.80	“Trade Marks” shall mean the trade marks set out in Schedule 3 and any other trademarks
and/or logos and/or trade dress of the Product owned or Controlled by Basilea, which will be used in Commercialization the Product
in the Territory.

 

		1.81	“Transition Period” and “Initial Transition Period” have the meaning given
to them in the Transitional Services Agreement.

 

		1.82	“Transitional Services Agreement” is that agreement attached as Schedule 9 to this
Agreement.

 

		1.83	1.83“VAT” means any value added tax or similar payment.

 

		1.84	“Wholesaler” means any Third Party which purchases Product from Cardiome or any of
its Affiliates and resells Product on its own account to Customers. For the avoidance of doubt, Wholesalers are not Third Party
Distributors.

 

The definitions in this Article 1 shall
apply equally to both the singular and plural forms of the terms defined. As used in this Agreement, (i) the words “include”,
“includes” and “including” shall be deemed to be followed by the phrase “without limitation”;
(ii) the words “hereof”, “herein”, “hereby” and derivatives or similar words refer to this
entire Agreement; (iii) all references to Articles and Sections shall be deemed references to Articles and Sections of this Agreement
and all references to Schedules shall be deemed references to Schedules to this Agreement, unless the context shall otherwise require;
(iv) whenever this Agreement refers to a number of days, such number shall refer to calendar days unless otherwise specified; and
(v) references to “Basilea” or to “Cardiome” shall be deemed to include each one’s Affiliates, unless
expressly stated to the contrary.

 

    	 	9	 

    CONFIDENTIAL

    

 

ARTICLE 2
APPOINTMENT AND PARTIES’ GENERAL CONDUCT

 

		2.1	License Grant and Sublicenses.

 

		(a)	License Grant. With effect from the Effective Date, Basilea grants to Cardiome an exclusive,
non-assignable license in the Territory in the Field under the Basilea IP to register and Commercialize the Product in the Territory
and a co-exclusive (along with Basilea), non-assignable license under the Basilea IP to develop the Product in the Territory for
Commercialization in the Territory. For the avoidance of doubt, the license does not include the right for Cardiome to manufacture
the Product.

 

		(b)	Sublicenses.

 

		(i)	Cardiome has the right to grant a sublicense to the license granted under Section 2.1(a) to any
of its Affiliates.

 

		(ii)	Cardiome shall notify Basilea in advance of the identity and planned role of any Third Party Licensees,
Third Party Distributors and any other Third Party (with the exception of Wholesalers) which Cardiome or its Affiliates intend
to use in Commercialization of the Product in order to enable Basilea adequate time to perform due diligence on such Third Parties.
Cardiome will not grant a sublicense to any such Third Party without Basilea’s prior written consent (such consent not to
be unreasonably withheld).

 

		(iii)	All permitted sublicenses under 2.1 (b) shall be consistent with the terms of this Agreement.

 

		(iv)	Notwithstanding any permitted sublicense, all obligations under this Agreement, including but not
limited to reporting, planning, and financial obligations, remain with Cardiome.

 

		2.2	Basilea Obligations. Basilea shall, in each case as Cardiome reasonably requires in the
performance of its obligations under this Agreement:

 

		(a)	supply the Product to Cardiome;

 

		(b)	maintain the harmonized Dossier for the Product, submit any amendments to the Dossier, and manage
the Mutual Recognition Process/Repeat-Use Procedures for the Product in the Territory;

 

		(c)	provide Cardiome on an ongoing basis with such Basilea Information (including but not limited to
the Dossier) reasonably requested by Cardiome to fulfill its obligations under this Agreement;

 

		(d)	comply with and complete the requirements of the European Union PIP; and

 

    	 	10	 

    CONFIDENTIAL

    

 

		(e)	at its sole cost and expense retain full and exclusive rights, title and interest to, and maintain
the registrations (as applicable) for all Basilea IP that Basilea or its Affiliates own or Control during the Term.

 

		2.3	Cardiome Obligations. Cardiome shall:

 

		(a)	register and Commercialize the Product in the Territory in line with the Commercial Launch Plan
and thereafter in line with subsequent Commercialization Plans and actively promote the use and sale of the Product in order to
maximize sales of the Product in the Territory;

 

		(b)	undertake all national regulatory activities in the Territory, maintain the National Marketing
Authorisations in the Territory, and provide regulatory support to Basilea during any Mutual Recognition Process/Repeat-Use Procedures
concerning countries in their Territory pursuant to Sections 4.1 and 4.2;

 

		(c)	purchase the Product exclusively from Basilea and for Commercialization in the Territory; and

 

		(d)	fulfill any and all of its obligations hereunder in accordance with all Applicable Law related
to, including but not limited to, the registration, approval, marketing, promotion, distribution and sale of the Product, including
GDP and all applicable local pharmaceutical industry codes and guidelines.

 

		2.4	Restriction. Cardiome shall, and shall procure that its Affiliates and any Third Party Distributors
and Third Party Licensees and Wholesalers shall, refrain from actively Commercializing the Product to Third Parties outside the
Territory. Commercializing outside the Territory shall mean approaching or soliciting Third Parties outside the Territory, including,
but not limited to, the following actions: (i) visits; (ii) sending unsolicited mail (including email); (iii) advertising in media,
on the internet or other promotions, where such advertising or promotion is specifically targeted at Customers outside the Territory;
(iv) online advertisements addressed to Customers outside the Territory and other efforts to be found specifically by users outside
the Territory, including the use of territory based banners on Third Party websites and paying a search engine or online advertisement
provider to have advertisements or higher search rankings displayed specifically to users outside the Territory; and (v) advertising
or promotion in any form, or translation of Product-related website/s into a language other than an official language of the Territory,
that would not reasonably have been carried out but for the likelihood that it will reach Customers outside the Territory.

 

		2.5	Commercially Reasonable Endeavours. Both Parties shall use their Commercially Reasonable
Endeavours in performance of their obligations under this Agreement.

 

		2.6	Non-compete. To the extent permitted by Applicable Law, during the Term (on a country-by-country
basis), Cardiome shall not, directly or indirectly market, sell or promote within the Territory any [...***...] In case of a breach
by Cardiome of this Section 2.6, Basilea may terminate the Agreement in accordance with Section 14.4(b).

 

    	 	11	 

    CONFIDENTIAL

    

 

		2.7	No Material Adverse Impact. Cardiome shall not carry out any activity in the implementation
of this Agreement in its Territory that has or is reasonably likely to have any material adverse impact on the Product outside
the Territory, meaning a materially negative impact on the development, regulatory status, manufacturing or commercialization of
the Product (a “Material Adverse Impact”), without Basilea’s prior consent (such consent not to be unreasonably
withheld or delayed). The following shall not trigger this Section 2.7: (i) pricing reductions unilaterally imposed by a Regulatory
Authority in the Territory; (ii) mandatory recalls required by a Regulatory Authority in the Territory; iii) actions imposed by
Regulatory Authorities in the Territory for safety reasons such as: clinical trial suspension, change in labelling or market restrictions,
or distribution of Dear Health Care Professional (DHCP) letters; and iv) any case where Cardiome as marketing authorization holder
in the Territory or its responsible person for distribution; or the Qualified Person responsible for batch certification determines
that Product that has been distributed in the Territory must be recalled.

 

		2.8	Joint Steering Committee.

 

		(a)	The Parties will, upon execution of the Agreement, set up a joint committee (“Joint Steering
Committee” or “JSC”) which shall consist of three (3) representatives from each Party (or such other number as
may be agreed by the Parties). The JSC will facilitate communications between the Parties with respect to the obligations and responsibilities
set out in this Agreement, including but not limited to reviewing, sharing and discussing the implementation of the Commercial
Launch Plan, the Commercialization Plan, as well as commercialization strategies, such as brand strategies and Product positioning
and life cycle management, and any other topics the Parties consider useful for the optimisation of this Agreement.

 

		(b)	General Committee Membership and Procedures.

 

		(i)	Membership: The Parties shall appoint representatives to the JSC who have appropriate expertise.
The JSC shall have co-chairpersons; each Party may select from their representatives a co-chairperson for the JSC. Each Party may
change its representatives or designated co-chairperson by written notice to the other Party. The co-chairpersons of the JSC shall
be jointly responsible for calling meetings and preparing and circulating an agenda and any materials in advance of each meeting.
The Party who hosted or requested the JSC meeting shall prepare the minutes of the meeting within thirty (30) days.

 

		(ii)	Meetings: Meetings of the JSC will be held at least every six (6) months, including by audio
or video teleconference with the consent of each Party; provided that at least one (1) meeting per year of the JSC shall be held
in person. The JSC shall meet alternately at each Party’s location. Each Party shall be responsible for all of its own expenses
of participating in the JSC. Ad hoc meetings shall be held for urgent or important matters upon the request of a Party.

 

    	 	12	 

    CONFIDENTIAL

    

 

		(iii)	Working Groups: The Parties may establish one or more working groups of the JSC from time
to time as and when it deems appropriate to discuss specific aspects of the commercialization of the Product.

 

		2.9	Operational Transfer of Activities and Transitional Services Agreement.

 

		(a)	Operational Transfer of Activities.

 

		(i)	Starting from the Effective Date, the Parties shall cooperate together through the JSC and through
such other meetings and communication as needed, in order to plan and effectuate the transfer of operational activities from Basilea
to Cardiome. The Parties shall cooperate to enable Basilea to transfer such information and activities and provide support, and
Cardiome to undertake the activities and responsibilities, as specified in this Agreement including but not limited to the following
sections: Section 3.6 (transfer of Basilea Core Materials), Article 4 (transfer of regulatory information and responsibility),
Section 4.4 (negotiation of SDEA), Section 4.7 (transfer of market access information and responsibility), Section 5.6 (discussion
of Artwork proposed by Cardiome), Section 6.1 (negotiation of Quality Agreements), and Section 6.7 (Basilea instructions regarding
transport, storage and distribution of Product). Such activities shall be without charge on the part of either Party (unless such
charge is specified in the relevant provision of the Agreement).

 

		(ii)	As part of Basilea’s obligation to provide Cardiome on an ongoing basis with such Basilea
Information reasonably requested by Cardiome to fulfill its obligations under this Agreement pursuant to Section 2.2(c), Basilea
shall provide to Cardiome the following:

 

		(A)	within thirty (30) days of Effective Date, a complete copy of the Dossier, a copy of all National
Marketing Authorisations in the Territory, a copy of all related material Submissions to Regulatory Authorities and material responses
from Regulatory Authorities, and an overview of any regulatory obligations or commitments for each country;

 

		(B)	within ten (10) days of the Effective Date, the Basilea Core Materials;

 

		(C)	within ten (10) days of the Effective Date, a list of all contracted or already discussed Investigator
Initiated Trials (IITs);

 

		(D)	within twenty (20) days of the Effective Date, an overview of Basilea’s market access and
pricing and reimbursement activities in the Territory, a copy of all material communications with all market access and pricing
and reimbursement authorities, and, promptly after Cardiome’s request, a copy of the data cited by Basilea in such communications;
and

 

    	 	13	 

    CONFIDENTIAL

    

 

		(E)	at a date to be agreed by the Parties within thirty (30) days of the Effective Date, Basilea shall
provide one day of in-person tender management and product training to Cardiome at Cardiome’s Geneva office.

 

		(b)	Transitional Services Agreement.

 

		(i)	Initial Transition Period. With effect from the Effective Date and until completion of the
Initial Transition Period, all commercial sales of the Product shall be for Cardiome’s benefit, at Cardiome’s cost
and risk, subject to the terms of this Agreement and the Transitional Services Agreement (TSA), which is attached as Schedule 9.
During the Initial Transition Period (as defined in the TSA), Basilea shall, as particularly set forth in the TSA, continue to
operate the business in normal course and Cardiome shall receive the benefit of the sales of the Product from which shall be deducted
Basilea’s costs of operating the business.

 

		(ii)	Other Transitional Services. Further, under the Transitional Services Agreement, Cardiome
can request and Basilea may provide certain additional transitional services deemed an Other Transitional Services during the Term
of the Transitional Services Agreement.

 

		2.10	Inventory. Attached to this Agreement as Schedule 8 is an estimate of Basilea’s inventory
of Finished Product on a country-by-country basis for the Territory as of the Effective Date (the “Inventory”) with
associated expiry dates. Basilea shall, ten (10) days prior to the end of the Initial Transition Period (on a country-by-country
basis, if the Initial Transition Period ends on different dates in different countries), confirm the expected remaining amount
of the Inventory at that time. Cardiome shall purchase the actual Inventory as of the end of the Initial Transition Period at the
Assumed Transfer Price (with a later true-up based upon Net Sales reports pursuant to the mechanism provided in Section 7.2, on
invoice from Basilea) if said Inventory has at least [...***...] of shelf-life remaining on the Finished Product. Cardiome
shall have a right of return for any Inventory that it is unable to sell due to either (i) too short shelf life (despite Cardiome
having used its Commercially Reasonable Endeavours to sell such Inventory) or (ii) requirement of Regulatory Authority for repackaging
or overstickering which one or both Parties are unable to fulfill using its (or their) Commercially Reasonable Endeavours. Basilea
shall Deliver the Inventory to Cardiome EXW (Facility) and under the Delivery terms provided in Section 5.2 and 5.3; for the avoidance
of doubt, Sections 5.5 and 5.6 shall not apply to Cardiome’s purchase of the Inventory. Cardiome shall pay such invoice by
wire transfer, within sixty (60) days of receipt thereof, into an account designated by Basilea.

 

    	 	14	 

    CONFIDENTIAL

    

 

ARTICLE 3
COMMERCIALIZATION

 

		3.1	Commercialization, Commercialization Plans and Sales Forecast. Cardiome shall Commercialize
the Product in the Territory. Cardiome will provide Basilea with the country-specific Commercialization Plans for the Product to
Basilea for its review and comment within one (1) month of the Effective Date, including the information listed in Schedule 1 and
shall provide the Commercial Launch Plan in the format provided in the template set forth in Schedule 4. Updated plans will be
provided as such updates are generated by Cardiome, and no less often than on an annual basis, to Basilea for its review and comment
by September 30 of each calendar year.

 

		3.2	Promotion. Cardiome shall actively Commercialize the Product in the Territory and provide
information and support related to the Product to physicians and other persons with a professional interest in the study and prescription
of the Product. The promotion of the Product shall include, but is not limited to: (i) direct selling and including regular Details
by Cardiome’s marketing/sales staff to provide Product information; and (ii) other lawful steps taken to draw the interest
of physicians and other prescribers such as organizing conferences, seminars, physician training sessions, lectures, mailings with
announcements and product brochures, publications in professional magazines, and participation in trade exhibitions or symposia.

 

		3.3	Authorised Indications Only. Cardiome shall not promote the Product for uses or indications
other than those specifically defined in the Product’s Marketing Authorisations for the Territory.

 

		3.4	Sales Force. Cardiome shall maintain a well-trained, effective sales force to ensure the
proper fulfilment of all of its Commercialization obligations in the Territory, including training and maintaining a sales force
in the Territory at least in such number and/or compilation to effectively implement the Commercialization Plan. For the first
two years of commercialization of the Product, Basilea shall provide to Cardiome a total of up to three (3) days per year with
Product training in English at a location of Basilea’s choosing .

 

		3.5	Compliance with Law. Cardiome shall instruct its sales force and other representatives to
comply with any Applicable Law (including relevant industry codes) related to Cardiome’s Commercialization and medical affairs
activities.

 

		3.6	Marketing Materials.

 

		(a)	Basilea shall provide Cardiome with copies, whether electronic or otherwise, of representative
samples in English of core promotional literature and advertisements for the Product used by Basilea in the markets where Basilea
commercializes the Product prior to the Effective Date (‘‘Basilea Core Materials”). Basilea shall subsequently
provide to Cardiome any substantial or material updates to the messages or information included in the Basilea Core Materials within
ten (10) days of any such Basilea Core Materials updates.

 

		(b)	Cardiome shall use the Basilea Core Materials to create similar promotional literature and advertisements
for the Product to Commercialize the Product in the Territory (“Cardiome Core Materials”). Cardiome shall customize
the Cardiome Core Materials as appropriate for each country where it Commercializes the Product, including by obtaining professional
translations of the Cardiome Core Materials into the official language(s) of the Territory.

 

    	 	15	 

    CONFIDENTIAL

    

 

		(c)	To the extent that Cardiome wishes to vary materially from the Basilea Core Materials in the messages
or information included in its Cardiome Core Materials, Cardiome shall provide to Basilea copies of such changes (in English) together
with an explanation (in English) of the necessity for such changes for Basilea’s review and approval. Basilea will conduct
a timely review (maximum twenty (20) business days) of such Cardiome Core Materials and will either confirm that Cardiome may use
such Cardiome Core Materials, or request that reasonable changes are made.

 

		(d)	Cardiome shall provide Basilea with a copy of all Cardiome Core Materials (in English) and of all
country marketing materials based thereon (in original language) and shall permit Basilea to share the Cardiome Core Materials
on a confidential basis with any Basilea Affiliate or license partner in order to allow Basilea to coordinate its global sales
and promotion of the Product.

 

		(e)	Cardiome shall ensure that the Cardiome Core Materials, training materials, and any representations
made in relation to the Product comply with all Applicable Law and accurately represent Basilea’s current view of or approach
in relation to the Product, including scientific content, communication and global marketing strategy as that view or approach
has been communicated to Cardiome by Basilea, for example in the JSC.

 

		3.7	Exclusive License Notification. To the extent permitted by Applicable Law, Cardiome shall
indicate on the Cardiome Core Materials (including any internet site) and on the packaging of the Product, that the Product is
exclusively licensed by Basilea to Cardiome in the Territory.

 

ARTICLE 4
REGULATORY MATTERS AND PHARMACOVIGILANCE

 

		4.1	Regulatory Responsibility in Core European Territory.

 

		(a)	Cardiome’s Responsibilities.

 

		(i)	The Product is approved in certain EU countries under a decentralized procedure and Basilea holds
National Marketing Authorisations in the Territory in Austria, Belgium, France, Germany, Italy, Luxembourg, Spain, and the UK as
of the Effective Date. Promptly after the Effective Date, Basilea shall transfer all National Marketing Authorisations in these
countries to Cardiome.

 

		(ii)	Basilea has completed the Repeat-Use Procedure for Ireland, Poland, and Portugal but has not yet
received National Marketing Authorisations in these countries. Once Basilea receives the National Marketing Authorisations in these
countries, Basilea shall transfer them to Cardiome

 

    	 	16	 

    CONFIDENTIAL

    

 

		(iii)	Basilea holds a Marketing Authorization in Switzerland. Promptly after the Effective Date, Basilea
shall transfer the Marketing Authorisation for Switzerland to Cardiome.

 

		(iv)	For any countries in the Core European Territory in which the Product is not yet registered, Cardiome
shall notify Basilea of its intent to register the Product in such countries in line with the Commercial Launch Plan. Basilea shall
thereafter initiate a Repeat-Use Procedure in such country within six (6) months of receipt of Cardiome’s notice of its intent
to register in such country (such six (6) month period being elongated if there is an ongoing or urgent planned regulatory process
not allowing the filing of the Repeat-Use Procedure within such timeframe). Once Basilea receives the National Marketing Authorisations
in such countries, Basilea shall transfer them to Cardiome or, upon Cardiome’s request, to Cardiome’s approved Third
Party Sublicensees (pursuant to Section 2.1).

 

		(v)	After transfer of the National Marketing Authorisations from Basilea pursuant to Sections 4.1(a)(i),
(ii) or (iv), or transfer of the Marketing Authorisation for Switzerland pursuant to Section 4.1(a)(iii), Cardiome shall be the
National Marketing Authorisation holder of all National Marketing Authorisations in the Core European Territory. Cardiome shall
undertake all national regulatory activities and procedures including preparing and filing Submission of national variations and
Submission of the national phase after the end of any harmonized EU procedure in the required format, e.g. eCTD, NeeS, etc.

 

		(vi)	For the avoidance of doubt, Cardiome shall conduct all regulatory activities under its responsibility
as specified in Sections 4.1(a)(i)-(v) at its own cost, including but not limited to any costs Cardiome incurs in maintaining the
National Marketing Authorisations and any Third Party costs incurred by Basilea related to these activities including the costs
for filing for Marketing Authorisation Applications in countries where the Product is not yet registered.

 

		(b)	Basilea’s Responsibilities. Basilea will be responsible to oversee and maintain the
harmonized Dossier and submit changes to the harmonized Dossier as needed, for instance related to variations and Repeat-Use Procedures
pursuant to Section 4.1(a)(iv). Cardiome shall bear the submission costs and any Third Party costs incurred by Basilea (but not
Basilea’s internal costs) for any such changes to the harmonized Dossier. For the avoidance of doubt, Basilea shall bear
any submission costs for changes to the harmonized Dossier which are related solely to countries outside the Territory, or which
are related to Basilea’s own decisions to change manufacturing processes or the locations or identities of manufacturing
parties.

 

    	 	17	 

    CONFIDENTIAL

    

 

		4.2	Regulatory Responsibility in Non-EU Eastern European Territory. Cardiome will be responsible
for and bear the cost of all regulatory activities in the Non-EU Territory and will be the Marketing Authorization Holder of all
Authorisations gained in the countries of such territory. Cardiome shall prepare and file all Submissions in the Non-EU Eastern
European Territory. Cardiome shall undertake such activities pursuant to the regulatory timelines and plans included in the Commercial
Launch Plan and in the Commercialization Plans.

 

		4.3	Transfer of Regulatory Information and Cooperation.

 

		(a)	Within thirty (30) days of the Effective Date, Basilea will provide to Cardiome the regulatory
information specified in Section 2.9(a)(i)(A).

 

		(b)	The Parties will cooperate as necessary to effectuate the transfer of responsibilities from Basilea
to Cardiome and in particular the transfer of any Authorisations promptly after the Effective Date (in the case of Authorisations
existing as of the Effective Date) and promptly after grant of the Authorisation (in the case of Authorisations not yet granted
as of the Effective Date). Cardiome shall prepare any necessary documentation of transfer for Basilea’s review and signature
and Basilea shall review and sign (including with any legally required notarization or other formal requirements). Each Party shall
bear its own cost for such activities.

 

		(c)	Upon reasonable request of either Party, the other Party will provide support in responding to
questions from Regulatory Authorities related to the Product.

 

		(d)	Cardiome shall obtain and maintain all licenses and permits required for it to Commercialize the
Product in the Territory, including but not limited to a Wholesaler Dealer License which Cardiome shall hold through an Affiliate
located in the EU.

 

		4.4	Regulatory Submission Responsibilities.

 

		(a)	Both Parties shall keep each other duly informed of any contacts, communications, correspondence
and meetings with Governmental and Regulatory Authorities concerning the Marketing Authorizations and/or the Product and which
might affect the Parties’ collaboration under this Agreement.

 

		(b)	For all material Submissions which Cardiome plans to make to Regulatory Authorities for the Product
in the Territory, Cardiome shall, at least twenty (20) Business Days prior to the intended date of Submission, provide a copy of
such Submission, including any Type II variations or renewals (in English) to Basilea for Basilea’s review and reasonable
comments which shall be incorporated.

 

		(c)	For all Submissions which Basilea plans to make to Regulatory Authorities for the Product in the
Territory, Basilea shall, at least twenty (20) Business Days prior to the intended date of Submission, provide a copy of such Submission
(in English) to Cardiome for its review and comment, with reasonable comments to be incorporated.

  

    	 	18	 

    CONFIDENTIAL

    

  

		(d)	Cardiome shall also (i) promptly inform Basilea of (A) the acceptance by any Regulatory Authority
in the Territory of any Submission by Cardiome (or by any Affiliate or Third Party on its behalf), (B) the approval by any Regulatory
Authority in the Territory of any Submission by Cardiome (or on its behalf) (including the grant of an Authorisation) or (C) any
other change in the regulatory status of any Authorisation, in no event later than ten (10) Business Days after receipt by Cardiome
of notice of the applicable event described in the foregoing (A), (B) and (C), and (ii) provide Basilea with a copy of all (A)
Submissions by Cardiome (or on its behalf) to a Regulatory Authority in the Territory, in English and in editable electronic CTD
format, or another editable format, where CTD format is unavailable and (B) any approvals by any Regulatory Authority in the Territory
of any Submission by Cardiome (or on its behalf) (including the grant of an Authorisation), within ten (10) Business Days after
making such Submission or receiving such approval.

 

		(e)	Basilea shall use Commercially Reasonable Endeavours to inform Cardiome about material changes
to the Dossier (such as a change in manufacturer) which will require Submissions to Regulatory Authorities pursuant to Section
4.1(b), and Cardiome shall have the obligation to make corresponding Submissions in Non-EU Eastern European Territory and Switzerland.

 

		4.5	Safety Data Exchange Agreement and Master Global Safety Database.

 

		(a)	Within twenty (20) days of the Effective Date, the Parties shall enter into a safety data exchange
agreement (“Safety Data Exchange Agreement”) describing the procedures which Basilea and Cardiome shall implement and
the responsibilities that both Parties will assume in order to ensure that: (i) the relevant safety information relating to the
Product is exchanged in a timely manner; and (ii) that both Parties can fulfil their respective pharmacovigilance obligations under
Applicable Law.

 

		(b)	Basilea shall have the responsibility of creating and maintaining the master global safety database
for the Product.

 

		(c)	Prior to execution of the Safety Data Exchange Agreement and during the Initial Transition Period,
Pharmacovigilance in the Territory shall be the responsibility of Basilea.

 

		(d)	After execution of the Safety Data Exchange Agreement and after completion of the Initial Transition
Period, Pharmacovigilance in the Territory shall be the responsibility of Cardiome.

 

		4.6	Cardiome’s Obligations Related to Studies and Tests. Subject to Section 4.7, Cardiome
shall have the obligation to conduct all development activities for the Territory, as follows:

 

		(a)	Cardiome shall perform any activities required to fulfill post-approval commitments in the Territory
and shall implement the risk management plan by performing the surveillance studies described therein. As of the Effective Date,
three surveillance studies have been contracted and are a part of the risk management plan which has been approved by the Regulatory
Authority. Cardiome shall not require Basilea’s prior approval to conduct such activities, but shall keep Basilea informed
of its performance of such activities through regular reports, such as in the JSC.

 

    	 	19	 

    CONFIDENTIAL

    

  

		(b)	In its discretion, Cardiome may support investigator initiated trials (“IITs”) related
to the Product. Prior to providing such support, Cardiome shall inform Basilea of the planned IIT protocol and shall allow Basilea
an opportunity to comment thereon.

 

		(c)	With the prior written approval of Basilea (in its sole discretion, not to be unreasonably withheld),
Cardiome may (i) conduct any non-clinical or clinical study involving the Product and/or (ii) perform any Tests related to the
Product.

 

		(d)	Cardiome shall be responsible for conducting all activities specified in Sections 4.6(a)-(c) and
shall bear all related costs. Pharmacovigilance requirements related to such activities shall be described in the Safety Data Exchange
Agreement. Cardiome shall conduct all clinical studies in compliance with the current Declaration of Helsinki on Ethical Principles
for Medical Research Involving Human Subjects, as well as according to ICH guideline (E6) for good clinical practice (cGCP). All
data and reports from such activities conducted by Cardiome shall be maintained in compliance with Applicable Law and cGCP by Cardiome
and shall be made available in timely fashion to Basilea in a standard industry format and media allowing reproducibility and independent
analysis. Cardiome shall own all such data and reports and hereby grants to Basilea full use free of charge of all such data and
reports in perpetuity, for any purpose related to the development, manufacturing, Regulatory Approval and commercialization of
the Product, including the right to provide such data and reports to Basilea’s Affiliates and license partners.

 

		4.7	Basilea’s Obligations Related to Studies and Tests. Subject to Section 4.6, Basilea
will be responsible for, and bear the cost of conducting and supporting the European Union PIP and any Investigator Initiated Trial
(IIT) and/or any other non-clinical or clinical study that was contracted prior to the Effective Date. Basilea will conduct the
European Union PIP in compliance with Applicable Law.

 

		4.8	Basilea’s Ongoing Phase 3 Program. As of the Effective Date, Basilea is planning a
Phase 3 clinical program in SAB and ABSSSI, and potentially at a later date in CAP with the goal of a registration in the United
States. Such studies could, if successful, enable an application for a label extension in the Territory for SAB and/or ABSSSI.
The following shall apply with respect to this Phase 3 clinical program:

 

		(a)	Basilea shall be solely responsible to conduct and bear the costs for this phase 3 clinical program,
and shall conduct such program in its sole discretion, including making any decision to cease conducting such program;

 

    	 	20	 

    CONFIDENTIAL

    

 

		(b)	All data and knowledge produced from the Phase 3 clinical program shall be considered Know-How
under this Distribution Agreement and therefore is licensed to Cardiome with no further compensation other than as specified in
this Distribution Agreement. For the avoidance of doubt, the milestone in Section 8.2(b) shall be due in the event that the Product
is approved with an indication for SAB in the countries specified in such Section;

 

		(c)	Basilea will inform Cardiome of the identity of the hospitals and investigators in the Territory
with whom it plans to conduct any such clinical studies;

 

		(d)	Basilea will discuss with Cardiome through the JSC the outcome of the Phase 3 program and its plan
to update the core harmonized Dossier for the Product as soon as reasonably possible upon completion of the studies, and Cardiome
shall thereafter update the Commercial Launch Plan and/or the Commercialization Plan. The Parties shall thereafter cooperate to
make such Submissions (pursuant to Section 4.4) as necessary to update the Dossier, in accordance with Article 4.1(b) and 4.2.

 

		4.9	Market Access.

 

		(a)	Basilea will, to the extent allowed by Applicable Law, transfer all market access and pricing and
reimbursement activities for the Product in the Territory to Cardiome promptly after the Effective Date. Thereafter, Cardiome will
be responsible for gaining and maintaining national market access (including pricing, reimbursement and health technology assessments)
and for market access on a regional, local and hospital level in the Territory. Upon Cardiome’s reasonable request, Basilea
will at its own cost provide support and consultation in regard to compilation and negotiation of health technology assessments
dossiers and other related documents relevant for the respective Regulatory Authorities. Cardiome shall keep Basilea informed and
share with Basilea documents related to Cardiome’s market access and pricing and reimbursement activities with the Regulatory
Authorities.

 

		(b)	If a Governmental or Regulatory Authority in the Territory provides significant incentives relating
to the Commercialization in order to secure access to new anti-infective medicines, the Parties shall discuss in good faith the
appropriate distribution between the Parties of such incentives.

 

		4.10	Cessation of Regulatory or Commercialization Activities. If Cardiome plans to cease regulatory
or Commercialization activities in a country or countries in the Territory, Cardiome shall inform Basilea through the JSC and there
shall be a JSC discussion of such plan to ensure compliance with law and all regulatory requirements in such country or countries.
For the avoidance of doubt, Cardiome’s obligation with respect to regulatory and Commercial activities in the Territory is
to use its Commercially Reasonable Endeavours.

 

    	 	21	 

    CONFIDENTIAL

    

 

ARTICLE 5
SUPPLY OF PRODUCT

 

		5.1	Exclusive Supply. Cardiome shall purchase all of its requirements of the Product exclusively
from Basilea.

 

		5.2	Delivery. “Deliver,” “Delivered” and/or “Delivery” shall
mean the delivery of Product by Basilea to Cardiome in the form of Finished Product (vials) EX-WORKS manufacturer (Incoterms 2010),
which means Basilea delivers the Product when it places the Product at the disposal of Cardiome at a Facility chosen by Basilea,
not loaded on any collecting vehicles and not cleared for export. Delivery location as of the Effective Date is at the premises
[...***...] Basilea shall provide Qualified Person Release (meaning the certification by a Qualified Person that Product is manufactured
in accordance with the requirements of the relevant authorizations pursuant to Annex 16 to the EU Guide to Good Manufacturing Practice)
and certificates of compliance and certificates of analysis with each batch of Product at Delivery.

 

		5.3	Stock. Cardiome shall maintain an appropriate stock of the Product for the Territory to
ensure timely delivery to Wholesalers, Third Party Distributors, Third Party Licensees or Customers.

 

		5.4	Minimum Purchase Quantities.

 

		(a)	A five-year plan (starting with the first full calendar year after the Effective Date) for the
annual minimum quantities of Product to be purchased by Cardiome in Germany, France, UK, and Italy is attached as Schedule 5 and
a five-year plan for the annual minimum quantities of Product to be purchased by Cardiome in other countries in the Territory shall
be agreed by the Parties within three (3) months of the Effective Date (the quantities included in such attached plan and the quantities
in the plan that will be agreed are “Minimum Purchase Quantities”). By the end of the fourth calendar year included
in this five-year plan Cardiome shall propose Basilea the Minimum Purchase Quantities for the following five calendar years, which
shall then be mutually agreed. Subsequent five year periods shall be planned in the same manner.

 

		(b)	Cardiome shall purchase not less than the Minimum Purchase Quantities listed in the five-year plans.

 

		(c)	As the Minimum Order Quantity may be in excess of the Minimum Purchase Quantity for a certain country
in a certain year, if Cardiome in fact orders an amount of Product which is equivalent to or greater than the Minimum Order Quantity
and is in excess of the Minimum Purchase Quantity for that country for the relevant year, then such excess amount (calculated as
the difference between the amount ordered and the Minimum Purchase Quantity in a country) shall be credited against the next year’s
Minimum Purchase Quantity for such country. Such credit shall carry forward only one year and shall not be applied to any subsequent
years.

 

    	 	22	 

    CONFIDENTIAL

    

 

		(d)	If Cardiome fails to purchase the Minimum Purchase Quantities (on a country-by-country basis) in
any calendar year, the Parties shall discuss in good faith the reasons underlying Cardiome’s failure to meet such requirement,
any corrective measures that Cardiome could take to potentially meet such requirement in future years, and whether the Minimum
Purchase Quantities should be adjusted for a certain country or countries or for a certain time period. If Cardiome fails to purchase
the Minimum Purchase Quantities for two consecutive calendar years in a certain country, Basilea may terminate the Distribution
Agreement for that country in accordance with Section 14.4(f).

 

		(e)	If upon launch of a generic version of the Product or upon any other significant market change
within the Territory, Cardiome reasonably determines that such generic competition or significant market change requires an adjustment
of the Minimum Purchase Quantities or Minimum Transfer Price, the Parties shall discuss in good faith an adjustment of the respective
Minimum Purchase Quantities and/or Minimum Transfer Price for the relevant country.

 

		5.5	Order Forecasts, Purchase Orders and Shelf Life.

 

		(a)	Cardiome shall provide Basilea with the following order forecasts:

 

		(i)	within forty-five (45) days of the Effective Date a non-binding eighteen (18) month forecast of
Cardiome’s estimated orders including the Delivery dates of such orders (number of packs of Finished Product per stock keeping
unit) of the Product for each country in the Territory (“Initial Order Forecast”);

 

		(ii)	no later than six (6) months prior to the First Commercial Supply Date, and in each calendar month
thereafter, a rolling forecast of Cardiome’s estimated orders including the Delivery dates of such orders (number of packs
of Finished Product per stock keeping unit) of the Product for each country in the Territory for the eighteen (18) month period
commencing with the month in which such forecast is provided (“Rolling Order Forecast”).

 

		(b)	The quantities of Product included in the first six (6) months of each Rolling Order Forecast shall
be binding (“Binding Quantities”). For the avoidance of doubt, in each monthly update of the Rolling Forecast, the
remaining five (5) months of the preceding Binding Quantities remain binding in each Rolling Order Forecast.

 

		(c)	Cardiome shall issue written Purchase Orders no later than six (6) months prior to the proposed
Delivery date for Product and for amounts no less than provided in the Minimum Order Quantities.

 

		(d)	The Purchase Orders shall include quantities of Product within a range of ninety percent (90%)
to one hundred and ten percent (110%) of the Binding Quantities. If Cardiome wishes to issue a Purchase Order in excess of such
limits, Cardiome shall inform Basilea in due advance and Basilea shall have the right to respond to such request in its sole discretion.
For the avoidance of doubt, the total quantities of Product purchased in any calendar year shall not fall short of the Minimum
Purchase Quantities.

 

    	 	23	 

    CONFIDENTIAL

    

 

		(e)	Upon receipt of a Purchase Order, Basilea shall confirm receipt and issue an acceptance form, confirming
quantities and the target Delivery date, which shall be within forty-five (45) days of the proposed Delivery date indicated on
the Purchase Order.

 

		(f)	In the event that Basilea anticipates any delay in Delivery of Product, Basilea shall inform Cardiome
in writing of such delay and provide Cardiome with the updated Delivery date as soon as practicable.

 

		(g)	In the event of any conflict between the provisions of this Agreement, any Purchase Order, Basilea’s
acceptance form or related invoice form, the provisions of this Agreement shall govern and control.

 

		(h)	[...***...]

 

		5.6	Artwork.

 

		(a)	No later than at the time of issuing the first Purchase Order for each country, Cardiome shall
provide Basilea with all relevant information to perform secondary packaging for such country, including but not limited to art
work, blister imprints, label, patient information leaflet and folding box or carton (together “Artwork”). Cardiome
shall be responsible for confirming that Artwork complies with Applicable Law. Notwithstanding the above, for as long as it is
permitted by the applicable Regulatory Authorities for Cardiome to sell Product using the currently approved Basilea Artwork, Cardiome
may issue Purchase Orders for Product which bears the currently approved Basilea Artwork.

 

		(b)	Basilea shall within thirty (30) days of receipt of the Artwork from Cardiome send to Cardiome
a proof-for-print Artwork for Cardiome’s final approval which Cardiome shall provide within ten (10) days of receipt of the
proof-for-print. Basilea shall thereafter procure that Finished Product for the relevant country is produced using the Cardiome-approved
Artwork.

 

		(c)	For all Purchase Orders following the first order of Product for each country, Cardiome shall inform
Basilea if there shall be any change to the Cardiome-approved Artwork. Cardiome shall notify Basilea of any changes to the Artwork
in line with the timelines set out in Sections 5.6(a) and (b).

 

		(d)	To the extent that any errors in Artwork in the Finished Product were present in the proof-of-print
Artwork approved by Cardiome, Cardiome shall bear all costs of replacement or correction. In case errors occur which were not present
in the proof-of-print Artwork approved by Cardiome, Basilea shall bear all costs of replacement or correction.

 

    	 	24	 

    CONFIDENTIAL

    

 

		(e)	Basilea shall provide Cardiome with the estimated Third Party costs for the secondary packaging
and related required quality activities no later than one hundred (100) days prior to the Delivery date. Cardiome shall confirm
acceptance of the estimated secondary packaging costs. If no confirmation is provided by Cardiome within five (5) days, the secondary
packaging costs are considered to be approved. Basilea shall charge Cardiome on a pass-through basis for the costs of preparation
of Finished Product. If in any calendar year the pass through cost of secondary packaging, including labelling, for all of the
countries combined, exceeds [...***...] of net sales for the relevant period, then the Parties shall discuss in good faith if any
adjustment can be made to production planning or otherwise to reduce costs.

 

ARTICLE 6
MANUFACTURING STANDARDS AND QUALITY ASSURANCE

 

		6.1	Quality Agreements. The Parties shall discuss in good faith and agree a Quality Agreement
within thirty (30) days of the Effective Date or prior to the first Purchase Order, whichever occurs first, such Quality Agreement
to cover the period of time during which Basilea supplies Cardiome and Basilea continues to hold the Marketing Authorisation in
any country or countries in the Territory (the “First Quality Agreement”). The Parties shall subsequently discuss in
good faith and agree a second Quality Agreement no later than the transfer date of the first Marketing Authorization to cover the
period of time during which Basilea supplies Cardiome and Cardiome holds the Marketing Authorisation in any country or countries
in the Territory (the “Second Quality Agreement”). Together the First Quality Agreement and the Second Quality Agreement
shall be deemed the “Quality Agreements.” In the event of a conflict between the terms of the Quality Agreements and
the terms of this Agreement with respect to quality issues, the terms of the Quality Agreements shall prevail. In the event of
a conflict between the terms of the Quality Agreements and the terms of this Agreement with respect to non-quality issues, the
terms of the Agreement shall prevail.

 

		6.2	Manufacturing Standards. Basilea shall have manufactured and supply the Product strictly
in accordance with the Specifications, Applicable Law, the requirements of the Dossier, and the Quality Agreement.

 

		6.3	Maintenance and Retention of Records. Both Parties shall maintain detailed Records with
respect to the Product in accordance with the Quality Agreement and Applicable Law.

 

		6.4	Audits. Upon reasonable prior notice and the pre-agreement of the affected Facility, Cardiome
may request that it or its approved Third Party Licensees be able to physically audit all Facilities (in which case Basilea may
decide in its sole discretion to join such audit), or to join routine visits of Basilea to its Facilities. Cardiome shall bear
all of its own and any Third Party costs of audits that it solely requests, and shall bear all of its own costs to join any routine
visit of Basilea to a Facility. Conduct of periodic quality audits will be described in the Quality Agreement. In the event of
Product Recall or an emergency, each Party shall provide necessary access as soon as practicably possible upon the other Party’s
request.

 

    	 	25	 

    CONFIDENTIAL

    

 

		6.5	Inspections. If inspections are requested by a Regulatory Authority, each Party shall grant
to the other Party reasonable access on reasonable prior notice during normal business hours to its sites or (as feasible) to the
sites of its Third Party Licensees and Third Party Distributors to allow that Party to prepare for such Regulatory Authority inspection
or to allow that representatives of any Regulatory Authority inspect and take copies of all material documentation as may be required
by the Regulatory Authority. Cardiome shall bear all of its own and Third Party costs of pre-inspection visits that it requests.

 

		6.6	Quality Tests and Checks. Basilea shall provide Product in accordance with the Specifications
and shall conduct and document tests and test results (including but not limited to all bulk holding stability, manufacturing trials,
validation (including, but not limited to, method, process and equipment cleaning validation), raw material, in-process, bulk finished
product and stability (chemical and/or microbial) tests or checks required to assure the quality of the Product) in compliance
with the Specifications, the approved Dossier, the Quality Agreement and Applicable Law.

 

		6.7	Transportation, Storage and Distribution of Product. Cardiome shall transport, store and
distribute the Product in accordance with: (i) applicable good distribution practice (GDP) principles and/or good manufacturing
practice (GMP); (ii) associated guidelines; (iii) the approved Specifications in the Territory; and (iv) all Applicable Law.

 

		6.8	Compliance with Basilea Instructions. Cardiome shall adhere to Basilea’s express instructions
regarding storage and transport conditions for the Product (including but not limited to the temperature, humidity and safety data
sheet) of which Basilea shall provide notice from time to time. If an excursion from the storage and transport conditions specified
by Basilea occurs during Cardiome’s transport or storage of the Product, then Cardiome may request from Basilea, and Basilea
shall provide, such data and information as is necessary for Cardiome to evaluate such excursion.

 

		6.9	Inspection. Cardiome shall, within ten (10) business days following Delivery of Product,
carry out an inspection and shall promptly notify Basilea in writing in sufficient detail of any visible nonconformity or nonconformity
identified related to the certificate of conformance together with reasonable supporting documentation to evidence such nonconformity.
If Cardiome does not notify Basilea in writing of rejection of such Delivery within such five (5) business days, the Delivery of
Product shall be deemed to have been accepted by Cardiome.

 

		6.10	Latent Defects.  In case of an alleged Latent Defect found within the Product’s shelf
life, Cardiome shall promptly upon discovery notify Basilea in writing in sufficient detail of the alleged Latent Defect together
with reasonable supporting documentation to evidence such alleged Latent Defect.

 

    	 	26	 

    CONFIDENTIAL

    

 

		6.11	Return Authorisation.

 

		(a)	Within ten (10) days of receipt by Basilea of a notice of nonconformity from Cardiome in accordance
with Section 6.9 or a notice of alleged Latent Defect in accordance with Section 6.10, Basilea shall indicate in writing to Cardiome
whether Basilea will issue a return authorisation. In the event that Basilea issues a return authorisation, Cardiome shall return
to Basilea the allegedly nonconforming or defective Product within ten (10) days of such notice at Basilea’s cost and Basilea
shall free of charge replace such Product by conforming or non-defective Product as soon as reasonably practicable thereafter and
shall bear the associated shipping costs.

 

		(b)	After receipt of a nonconformity notice from Cardiome pursuant to Section 6.9 or a notice of alleged
Latent Defect in accordance with Section 6.10, if Basilea does not issue a return authorisation under Section 6.11(a), Basilea
shall analyse any batch of Product rejected by Cardiome for alleged nonconformity or Latent Defect within sixty (60) days of receipt
of such notice, and present its findings with respect to such Product to Cardiome.

 

		(i)	If such tests confirm nonconformity or a Latent Defect, Basilea shall supply to Cardiome conforming
or non-defective Product in the same quantity as the rejected Product free of charge within a time: a) not exceeding ninety (90)
days in the case of non-conforming Product; or b) in case of a Latent Defect, within a reasonable time for Basilea to address the
Latent Defect and supply non-defective Product.

 

		(ii)	If such tests do not confirm nonconformity or a Latent Defect (meaning if Basilea’s tests
confirm conformity and no Latent Defect), but if Cardiome does not accept Basilea’s findings and the Parties cannot agree
on whether the Product in question is non-conforming or has a Latent Defect, an independent qualified laboratory shall analyse
both Cardiome’s and Basilea’s samples of Product in question. The definitive results of such laboratory analysis shall
be binding on the Parties as follows:

 

		(A)	the Party who is found to be responsible for nonconformity or Latent Defect by the laboratory shall
bear the cost of the laboratory and the testing;

 

		(B)	if the Product in question is determined to be non-conforming or having a Latent Defect, it shall
be held for Basilea’s disposition, or shall be returned to Basilea at Basilea’s cost and expense, as directed by Basilea
and Basilea shall replace each non-conforming Product, or the portion of non-conforming Product, with conforming Product free of
charge and bear the costs and expenses of shipment, as soon as reasonably practical after receipt of notice thereof; and

 

		(C)	if the Product in question is determined to be conforming or not having a Latent Defect, such Product
shall remain with Cardiome or be returned to Cardiome at Cardiome’s cost and expense.

 

    	 	27	 

    CONFIDENTIAL

    

 

		6.12	Product Recall. The Parties shall comply with the Quality Agreement, particularly regarding
Product Recalls, as amended from time to time. Cardiome shall prepare and implement standard operating procedures for the Recall
of Product in the Territory that complies with the requirements of this Agreement and the Quality Agreement.

 

		6.13	Decisions on Product Recall.

 

		(a)	Decisions to globally recall Product shall be made by Basilea at its discretion, to the extent
permitted under Applicable Law.

 

		(b)	Decisions to recall Product in the Territory where Cardiome is marketing authorization holder shall
be made by Cardiome at its discretion. To the extent permitted under Applicable Law; however, Cardiome shall provide Basilea with
as much advance notice of such decisions as possible and shall discuss any planned or ongoing recall with Basilea and accept Basilea’s
reasonable input regarding such recall.

 

		(c)	Both Parties shall cooperate with the other party with regard to any recall and shall comply with
the procedures set forth in the Quality Agreement.

 

		(d)	Basilea shall reimburse Cardiome’s reasonable costs of complying with this Section 6.13 (including
expenses related to communications and meetings with all required Regulatory Authorities, reimbursement of the Assumed Transfer
Price or Actual Transfer Price actually paid by Cardiome to Basilea for any recalled Product, expenses relating to the replacement
of the recalled Product, the cost of notifying Customers and shipping costs associated with the Recall), provided that the Recall
was: (i) the result of a Recall outside the Territory or a global recall; or (ii) the result of out of Specification Product; or
(iii) was not caused directly or indirectly as a result of the breach of this Agreement, the Safety Data Exchange Agreement or
the Quality Agreement by, or any negligence or willful act or omission on the part of Cardiome, its Affiliates, Third Party Distributors,
Third Party Licensees, Wholesalers or subcontractors. If the Recall occurs directly or indirectly as a result of the breach of
this Agreement, the Safety Data Exchange Agreement or the Quality Agreement by, or any negligence or willful act or omission on
the part of, Cardiome, its Affiliates, Third Party Distributors, Third Party Licensees, Wholesalers or subcontractors, then Cardiome
shall bear its own costs of the Recall and a fair portion of Basilea’s costs associated with the Recall.

 

		6.14	Customer Inquiries. Cardiome shall handle all Customer inquiries in the Territory relating
to the Product. Each Party shall promptly report in writing to the other Party all suspected Product defects or other problems
relating to the use of the Product in the Territory and the Parties shall keep each other reasonably informed of Customer complaints
concerning such defects or problems as further defined in Quality Agreements. If Cardiome receives any request or inquiry related
to sales of the Product outside of the Territory, Cardiome shall inform Basilea of such requests or inquiries within five (5) business
days.

 

    	 	28	 

    CONFIDENTIAL

    

 

ARTICLE 7
ASSUMED AND ACTUAL TRANSFER PRICE; PAYMENT TERMS

 

		7.1	Cardiome shall pay the price for each Bulk Vial of Product purchased from Basilea in accordance
with this Article 7.

 

		7.2	The Assumed Transfer Price (in Swiss Francs) for Bulk Vials of the Product in each country of the
Territory until the completion of the first four (4) calendar quarters following the Effective Date is provided in Schedule 8.
The Assumed Transfer Price will be agreed upon between the Parties on an annual basis at least thirty (30) days prior to the beginning
of each relevant period, provided that if the Parties are unable to agree, the Assumed Transfer Price for a subsequent period shall
be equivalent to the Actual Transfer Price in the previous four calendar quarters.

 

		7.3	Actual Transfer Price and Minimum Transfer Price

 

		(a)	The Actual Transfer Price for Bulk Vials of the Product in the Territory shall be calculated as
follows:

 

		(i)	[...***...] of Net Sales until completion of the first four (4) full calendar years following the
Effective Date;

 

		(ii)	[...***...] of Net Sales starting from the fifth (5th) calendar year until the end of the eighth
(8th) year;

 

		(iii)	[...***...] of Net Sales starting from the ninth (9th) calendar year until the end of the Term.

 

		(b)	Notwithstanding the above, in no event shall the Actual Transfer Price paid by Cardiome to Basilea
be less than the Minimum Transfer Price, however the following (i) and (ii) apply:

 

		(i)	[...***...]

 

		(ii)	[...***...]

 

		(c)	If the situation in (b)(ii)(a) has occurred in two sequential calendar quarters, then the Parties
shall hold good faith discussions of the situation to try to find solutions.

 

		7.4	Basilea shall invoice Cardiome for each Delivery of Product contained in such Delivery, based on
the Assumed Transfer Price in Swiss Francs. Such invoice will include value added taxes, if applicable. Cardiome shall pay by bank
transfer the relevant invoice within forty-five (45) days of receipt of such invoice. If Cardiome is overdue with any payment hereunder,
then without prejudice to Basilea’s other rights or remedies, Cardiome shall be liable to pay interest on the overdue amount
at the annual rate of three percent above the three (3) month London Interbank Rate, which interest shall accrue on a daily basis
from the date payment becomes overdue until Basilea has received full payment of the overdue amount together with all interest
that has accrued, and shall be payable within ten (10) calendar days of the date of Basilea’s invoice in respect of the same.

 

    	 	29	 

    CONFIDENTIAL

    

 

		7.5	Within fifteen (15) days following (i) the end of each calendar quarter and (ii) the expiration
or earlier termination of this Agreement, Cardiome shall provide Basilea with a Net Sales report including detailed itemized (in
accordance with Section 1.57) calculations of the Net Sales on a country-by-country level (in local currency and in Swiss Francs)
and including the number of vials of Product sold in the Territory during such calendar quarter. All amounts which require conversion
from local currencies into Swiss Francs shall be converted based on the quarterly average rates published on http://www.oanda.com/currency/average
for the respective currency and for the respective calendar quarter. Cardiome shall include such currency rates used to convert
local currencies to Swiss Francs in the Net Sales report.

 

		7.6	Basilea shall promptly calculate the Actual Transfer Price per vial of Product on a country by
country basis in Swiss Francs based on the reported Net Sales and compare the Assumed Transfer Price per vial invoiced to Cardiome
during such calendar quarter against the Actual Transfer Price per vial calculated for that calendar quarter. If the result of
such comparison is that the Actual Transfer Price per vial is greater than the Assumed Transfer Price per vial, Basilea shall invoice
Cardiome for the difference (calculated by multiplying the difference between the Actual Transfer Price per vial and the Assumed
Transfer Price per vial by the number of vials sold to Cardiome during such calendar quarter), such invoice being payable by Cardiome
within thirty (30) days of its date. If the result of such comparison is that the Assumed Transfer Price is greater than the Actual
Transfer Price, Basilea shall at Cardiome’s sole option either refund back to Cardiome the calculated amount within thirty
(30) days or credit to Cardiome in subsequent invoices such calculated difference until all such credits are finally settled. In
no circumstances shall the Actual Transfer Price be less than the respective Minimum Transfer Price, unless otherwise agreed by
Basilea in writing.

 

		7.7	Clawback/Payback/ Managed Entry Requirements Report.

 

		(a)	No later than thirty (30) days after the end of each calendar year on a country-by-country basis,
Cardiome shall provide Basilea with a report (“Clawback/Payback/ Managed Entry Requirements Report”) showing a detailed
calculation of any Paybacks, Clawbacks or Managed Entry Requirements imposed on Cardiome by a competent Regulatory Authority based
on Applicable Law during the preceding calendar year.

 

		(b)	Based on each Clawback/Payback Managed Entry Requirements Report, Basilea shall promptly, and on
a cumulative yearly basis of the preceding calendar year, calculate any changes to the Actual Transfer Price per vial of Product
previously calculated by Basilea (the “Adjusted Actual Transfer Price”).

 

		(c)	If the calculation in (b) shows that the Actual Transfer Price for the total preceding calendar
year is greater than the yearly cumulated total Adjusted Actual Transfer Price for the preceding calendar year, Basilea shall inform
Cardiome of such, and thereafter, if the Adjusted Actual Transfer Price per vial is higher than the Minimum Purchase Price, shall
refund to Cardiome the difference between the Adjusted Actual Transfer Price and the Actual Transfer Price, such refund to be paid
by Basilea within thirty (30) days from Basilea’s receipt of Cardiome’s request for such refund.

 

    	 	30	 

    CONFIDENTIAL

    

 

		(d)	If the calculation in (b) shows that the Adjusted Actual Transfer Price per vial is lower than
the Minimum Transfer Price, the applicable Minimum Purchase Price for the relevant period and country will be reduced by [...***...]
of the difference between the Actual Transfer Price and the Adjusted Actual Transfer Price (“Adjusted Minimum Transfer Price”),
and Basilea shall refund to Cardiome the difference between the Adjusted Actual Transfer Price and the Actual Transfer Price, such
refund to be paid by Basilea within thirty (30) days from Basilea’s receipt of Cardiome’s request for such refund.
For the avoidance of doubt, in no event shall the payment made by Cardiome to Basilea be less than the Adjusted Minimum Purchase
Price per Bulk Vial of Product for the relevant period and country.

 

		(e)	As an example, [...***...]

 

		(f)	The conversion of the difference between the Adjusted Actual Transfer Price and the Actual Transfer
Price from local currency into Swiss Francs for each SKU will be done on a country-by-country basis using the average yearly rates
published on http://www.oanda.com/currency/average for the respective currency.

 

		(g)	For the avoidance of doubt, Basilea will be responsible for any and all Clawback/Payback payments,
(including payments due to AIFA) that have been incurred prior to the Effective Date. Any Clawback/Payback payments which relate
to a time period before prior to and after the Effective Date shall be borne by each Party on a prorated basis and Cardiome will
be responsible for any portion that is related to the time period starting on and continuing after the Effective Date.

 

		7.8	Any and all expenses, costs and charges incurred by Cardiome in the performance of its obligations
under this Agreement shall be paid by Cardiome, unless otherwise agreed in writing with Basilea.

 

		7.9	Each Party shall pay all sums payable by it under this Agreement free and clear of all deductions
or withholdings unless the Applicable Law require a deduction or withholding to be made.

 

		7.10	Cardiome and Basilea will cooperate with respect to all documentation required by any tax authority,
or reasonably requested by Cardiome or Basilea related to any payment or other obligations under this Agreement to ensure that
Cardiome and Basilea can submit any tax filings in line with local regulations and requirements.

 

    	 	31	 

    CONFIDENTIAL

    

 

ARTICLE
8 EXECUTION PAYMENT; REGULATORY PAYMENTS; MILESTONE PAYMENTS

 

		8.1	Execution Payment. Upon execution of this Agreement, Cardiome will pay to Basilea an execution
payment of CHF 5,000,000 (five million Swiss Francs) (“Execution Payment”).

 

		8.2	Milestone Payments.

 

		(a)	Sales Milestone Payments. When aggregate annual Net Sales in the Territory in any calendar
year reach the following thresholds for the first time, Cardiome will make the following one-time milestone payments to Basilea
within thirty (30) days of the respective thresholds being reached:

 

	Threshold in EUROs (aggregate annual

    Net Sales in the Territory in any calendar 

    year)	 	Milestone payments in EUROs
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]

 

For the avoidance of doubt, in
the event more than one threshold as listed above is reached in any calendar year for the first time, Cardiome shall make all one-time
milestone payments achieved to Basilea (no matter whether more than one is achieved during a single calendar year).

 

		(b)	Regulatory Milestone Payment. When the Product is approved with an indication for bacteremia
in all five (5) of the countries, Germany, France, Italy, Spain, and the UK, Cardiome will make a one-time milestone payment [...***...]
to Basilea within thirty (30) days of the milestone being met.

 

ARTICLE 9
REPRESENTATIONS AND WARRANTIES

 

		9.1	Mutual Warranties.  Each Party represents, warrants and covenants to the other Party that:

 

		(a)	it has full corporate power and authority to enter into the Agreement and to carry out its obligations
hereunder;

 

    	 	32	 

    CONFIDENTIAL

    

 

		(b)	it is duly authorised to execute and deliver the Agreement and to perform its obligations under
the Agreement. The person executing the Agreement on the Party’s behalf has been duly authorised to do so by the Party’s
articles of association or requisite corporate action;

 

		(c)	this Agreement is legally binding and enforceable in accordance with its terms. The execution,
delivery and performance of the Agreement by a Party will not be prevented or impaired by any agreement, instrument or understanding,
oral or written, to which that Party is a Party or by which that Party may be bound, nor violate any Applicable Law; and

 

		(d)	it is aware of no action, legal proceedings or inquiry or investigation instituted by any governmental
or regulatory agency or by any other person or company that might question or threaten the validity of the Agreement.

 

		9.2	Warranties of Basilea. Basilea represents warrants and undertakes to Cardiome that:

 

		(a)	Basilea or one of its Affiliates Controls or is the legal and beneficial owner or applicant for
registration of each of the Trade Marks, Domains and Patents;

 

		(b)	the details of the Trade Marks, Domains and Patents are correct in all material respects;

 

		(c)	with respect to its activities related to the Product in the Territory under this Agreement, it
shall not, and shall procure that each of its employees, directors, officers, Affiliates, Third Party Distributors, Third Party
Licensees, Wholesalers, subcontractors, agents, representatives and other involved Third Parties shall not (i) offer, promise or
give an advantage to another person, or (ii) request, agree to receive or accept a financial or other advantage in violation of
any anti-corruption laws, rules, regulations and decrees applicable to the respective Party (collectively, “Anti-Corruption
Legislation”), including but not limited to the United States Foreign Corrupt Practices Act, as amended (the “FCPA”),
the United Kingdom Bribery Act 2010 (the “Bribery Act”) and any implementing legislation under the OECD Convention
Against the Bribery of Foreign Government Officials in International Business Transactions (“OECD Convention”). It
is Basilea’s responsibility to be familiar with, and comply with, the provisions of the applicable Anti-Corruption Legislation;

 

		(d)	all actions required to be taken to prosecute and maintain the Trade Marks, Domains and Patents
(including payment of all applicable annuities due and payable) have been and will be taken or paid during the Term;

 

		(e)	all documents provided in the dataroom for Cardiome’s review are owned or under the Control
of Basilea and can be provided to Cardiome as needed for it to undertake its obligations under this Agreement, and Basilea and
its Affiliates have not, to its best knowledge, withheld from Cardiome any material information in the possession of Basilea or
its Affiliates related to the safety, toxicity, quality or efficacy of the Product that a biopharmaceutical company would reasonably
consider to be material for a Regulatory Authority’s evaluation of the safety, toxicity, quality and/or efficacy of the Product;

 

    	 	33	 

    CONFIDENTIAL

    

 

		(f)	Basilea has not received any material written communications alleging that the conduct of the Parties’
responsibilities as currently proposed under this Agreement would violate any of the intellectual property rights of a Third Party,
and Basilea is not aware of any fact that is likely to give rise to such allegation from any Third Party;

 

		(g)	with respect to its activities related to the Product in the Territory under this Agreement, it
shall ensure compliance with any applicable sanctions, prohibitions or restrictions under United Nations resolutions or the trade
or economic sanctions, laws or regulations of the European Union, United Kingdom or United States of America;

 

		(h)	Basilea and its Affiliates have not, to its best knowledge, withheld from any Regulatory Authority
any material information in the possession of Basilea or its Affiliates related to the safety, toxicity, quality or efficacy of
the Product that a biopharmaceutical company would reasonably consider to be material for a Regulatory Authority’s evaluation
of the safety, toxicity, quality and/or efficacy of the Product;

 

		(i)	none of Basilea or its Affiliates is engaged in any proceedings in any court, arbitration, administrative
or other tribunal anywhere in the world which affects or relates to the Product (including but not limited to claims relating to
product liability);

 

		(j)	Basilea is not aware of any Patents of any Third Party that covers the composition of matter of
Drug Substance, or the use of Drug Substance or Product for the Subject Indication and that would be infringed by the manufacture,
Development or Commercialization or the use of the Drug Substance or Product in the Territory;

 

		(k)	there are no pending proceedings in any court, arbitration, patent office, or administrative or
other tribunal which are concerned with the ownership of any of the Basilea IP and to the best knowledge of Basilea and its Affiliates,
as of the Effective Date, there are no pending proceedings in any court, arbitration, patent office, administrative or other tribunal
which are concerned with the validity of any of the Basilea IP (other than any pending Trade Mark, Domain or the Patent applications
or registration proceedings);

 

		(l)	Basilea will Deliver the Product to Cardiome which has been manufactured in compliance with the
manufacturing standards in Section 6.2, and Basilea will comply with all Applicable Laws and good manufacturing practice (cGMP)
and good distribution practice (GDP) relating to the manufacturing and supply of the Product under this Agreement; and

 

    	 	34	 

    CONFIDENTIAL

    

 

		(m)	Basilea confirms that it is not aware of any Product recalls or Product defect notices that may
impact patient safety, quality or efficacy of the Product, and that it is not aware of any Regulatory Authority inspection findings
or proceedings that will impact Basilea’s ability to supply Product in accordance with this Agreement.

 

		9.3	Warranties of Cardiome. Cardiome represents, warrants and undertakes to Basilea that:

 

		(a)	it shall, and shall procure that each of its employees, directors, officers, Affiliates, Third
Party Distributors, Third Party Licensees, Wholesalers, subcontractors, agents and representatives shall fulfil any and all of
its obligations hereunder in accordance with all Applicable Law related to, including but not limited to, the registration, approval,
marketing, promotion, storage, distribution and sale of the Product, including good manufacturing practice (cGMP), good distribution
practice (GDP) and all applicable local pharmaceutical industry marketing and promotion codes and guidelines;

 

		(b)	it shall not, and shall procure that each of its employees, directors, officers, Affiliates, Third
Party Distributors, Third Party Licensees, Wholesalers, subcontractors, agents, representatives and other involved Third Parties
shall not (i) offer, promise or give an advantage to another person, or (ii) request, agree to receive or accept a financial or
other advantage in violation of any anti-corruption laws, rules, regulations and decrees applicable to the respective Party (collectively,
“Anti-Corruption Legislation”), including but not limited to the United States Foreign Corrupt Practices Act, as amended
(the “FCPA”), the United Kingdom Bribery Act 2010 (the “Bribery Act”) and any implementing legislation
under the OECD Convention Against the Bribery of Foreign Government Officials in International Business Transactions (“OECD
Convention”). It is Cardiome’s responsibility to be familiar with, and comply with, the provisions of the applicable
Anti-Corruption Legislation;

 

		(c)	it shall ensure compliance with any applicable sanctions, prohibitions or restrictions under United
Nations resolutions or the trade or economic sanctions, laws or regulations of the European Union, United Kingdom or United States
of America. Basilea is exempt from fulfilling its obligations under this Agreement to the extent that the fulfilment of such obligation
would expose Basilea to any damages or claims under United Nations resolutions or the trade or economic sanctions, laws or regulations
of the European Union, United Kingdom or United States of America; and

 

		(d)	from time to time, at the reasonable request of Basilea, it shall confirm in writing that it has
complied with its undertakings under this Section 9.3 and shall provide any information reasonably requested by Basilea to demonstrate
such compliance.

 

    	 	35	 

    CONFIDENTIAL

    

 

ARTICLE 10
INTELLECTUAL PROPERTY

 

		10.1	Ownership and Maintenance. Basilea shall at its sole cost and expense retain full and exclusive
rights, title and interest to, and maintain the registration (as applicable) for all Basilea IP licensed to Cardiome in the Territory
that Basilea or its Affiliates own or Control during the Term.

 

		10.2	Alternative Marks. If it is not permissible or advisable for regulatory, legal or other
reasons in a country in the Territory to use the Trade Marks as the brand name of the Product, an alternative trademark that is
available and that can be registered will be used as the brand name of the Product in the Territory. Such alternative trademarks
will be determined by Cardiome after good-faith discussion with Basilea and Basilea shall own and maintain such trademark in the
Territory. To the extent permitted under Applicable Law, Basilea’s name shall be included on packaging of Product.

 

		10.3	Notification of Infringements.

 

		(a)	If Cardiome becomes aware of any actual, threatened or suspected infringement by a Third Party
of any Patents, Know-how, Basilea Information or Trade Marks relating to the Product in the Territory, it shall promptly inform
Basilea in writing and vice versa. Basilea shall have the first right, but not the obligation, to bring, defend, or maintain any
suit or action or to control the conduct thereof against any actual, threatened or suspected infringement and Cardiome shall upon
reasonable request from Basilea assist and cooperate with Basilea in any such enforcement or defence (with Basilea to reimburse
Cardiome for all its reasonable out of pocket costs and expenses, if any, relating to such enforcement or defence). If Basilea
requests Cardiome to join Basilea in such suit or action, Cardiome (including any Affiliate of Cardiome) shall execute all papers
and perform such other acts as may be reasonably required, in which case Basilea shall reimburse Cardiome for all its reasonable
out of pocket costs and expenses, if any. If Basilea (or its designated Basilea Affiliate) lack standing to bring any such action,
then Basilea may ask Cardiome to do so, in which case Basilea shall reimburse Cardiome for its reasonable out of pocket costs and
expenses in connection therewith, if any, and Cardiome shall conduct such action in accordance with Basilea’s instructions.
Any recoveries obtained by Basilea as a result of any proceeding against a Third Party infringer shall be allocated as follows:

 

		(i)	Such recovery shall first be used to reimburse each Party for all reasonable litigation costs in
connection with such litigation paid by that Party (other than those already reimbursed to Cardiome under Section 10.3(a));

 

		(ii)	such recovery shall then be used to compensate each Party for the respective damages suffered from
the infringement of the respective Patents, Know-how, Basilea Information, Domains or Trade Marks relating to the Product in the
Territory, provided that in the event the remaining portion of the recovery is not sufficient to compensate each Party’s
damages, such compensation shall be paid on a pro-rata share based on the respective damages suffered, provided, however, if such
respective damages suffered cannot be reasonably ascertained, the recovery shall be equally shared between the Parties; and

 

    	 	36	 

    CONFIDENTIAL

    

 

		(iii)	the remaining portion of such recovery, if any, shall be shared between the Parties in accordance
with their respective share of payments under (ii).

 

		(b)	If Basilea chooses not to take any action, after the expiration of a three (3) months period after
notification by Cardiome of actual infringement, to obtain a discontinuance of infringement of the respective Patents, Know-how,
Basilea Information or Trade Marks relating to the Product in the Territory, nor to file a suit against any such Third Party infringer,
then Cardiome shall have the right, but not the obligation, to take action or bring suit against such Third Party infringer.

 

		(c)	The enforcing Party has the right at any time and at its sole discretion to enter into any settlement
or compromise of any Claim or Proceeding in relation to the Product.

 

		10.4	No Challenge. Cardiome shall not contest or challenge the validity or ownership of, or aid
or assist others to contest or challenge the validity or ownership of, any Patents, Trade Marks, regulatory applications, Know-how,
Domains or other Basilea Information in or relating to the Product. Basilea may terminate this Agreement in whole or in part in
accordance with Section 14.4(f) should Cardiome breach this Section 10.4.

 

		10.5	No Transfer of Goodwill. To the extent necessary to conduct Commercialization, Cardiome
and its Affiliates shall have an exclusive non-assignable right and license to use the Trade Marks and Domains for Commercializing
the Product in the Territory during the Term in accordance with this Agreement. The use by Cardiome and its Affiliates of the Trade
Marks shall not constitute or imply any assignment or transfer of the Trade Marks or any goodwill associated with it. Whatever
use Cardiome makes of the Trade Marks shall inure to the sole and exclusive benefit of the Product in accordance with this Agreement.

 

		10.6	Use of Corporate Name. Neither Party shall use the other Party’s corporate name, or
use any trade marks (other than the Trade Marks and Domains and only in accordance with the terms and conditions of this Agreement)
in connection with any publication or promotion without the other Party’s prior written consent which shall not be unreasonably
withheld. The above restriction will not apply to representations that Cardiome is the exclusive licensee and exclusive distributor
of Basilea for the Product in the Territory.

 

		10.7	No Survival. Upon the expiration or termination of this Agreement for any reason, except
with respect to any remaining stock of the Product, Cardiome agrees to immediately discontinue all use of the Trade Marks and Domains
and shall immediately discontinue any and all representations, direct or implied that it is a distributor or licensee of Basilea.

 

    	 	37	 

    CONFIDENTIAL

    

 

ARTICLE 11
INDEMNIFICATION AND LIABILITY

 

		11.1	Indemnification.

 

		(a)	Cardiome shall defend, indemnify and hold Basilea, its Affiliates and their directors, officers,
employees and agents (collectively, “Basilea Indemnitees”), harmless from and against any Losses arising out of or
in relation to Third Party claims, actions, suits or other proceedings, or demands (“Third Party Claims”) based on
Cardiome’s and its Affiliates (i) breach of any of the provisions of this Agreement, the Quality Agreement or the Safety
Data Exchange Agreement; (ii) breach of its warranties under this Agreement; (iii) violation of Applicable Law; or Third Party
Claims relating to this Agreement caused by the intent (willful act) or negligence of Cardiome and its Affiliates.

 

		(b)	Basilea shall defend, indemnify and hold Cardiome, its Affiliates and their directors, officers,
employees and agents (collectively, “Cardiome Indemnitees”) harmless from and against any Losses arising out of or
in relation to Third Party claims, actions, suits or other proceedings, or demands (“Third Party Claims”) based on
(a) Basilea’s and its Affiliates (i) breach of any of the provisions of this Agreement, the Quality Agreement or the Safety
Data Exchange Agreement; (ii) breach of its warranties under this Agreement; (iii) violation of Applicable Law; or Third Party
Claims relating to this Agreement caused by the intent (willful act) or negligence of Basilea and its Affiliates, (b) any assertion
by a Third Party that its intellectual property rights are or will be infringed or misappropriated by Commercializing of Product,
except to the extent that such alleged infringement or misappropriation is attributable to (i) the use of any information or materials
other than those provided by Basilea to Cardiome or (ii) the use of such marks, logos or design, other than the Trade Marks, as
determined by Cardiome in its sole judgement in Commercializing of Product, (c) for death, personal injury or property damage arising
out of, or in connection with, any defective Product which was Delivered by Basilea to Cardiome, except to the extent that the
defect is attributable to the acts or omissions of Cardiome Indemnitees.

 

		(c)	The indemnity obligations of each Party under this Article 11 shall be conditioned upon the following:

 

		(i)	the indemnified Party giving a prompt notice of a Third Party Claim no later than thirty (30) days
of the indemnified Party’s receipt of such Third Party Claim;

 

		(ii)	the indemnified Party providing reasonable cooperation with the indemnifying Party in the defence
of such Third Party Claim: and

 

		(iii)	the indemnified Party’s agreement not to settle such Third Party Claims without the indemnifying
Party’s prior written consent, such consent not to be unreasonably withheld or delayed.

 

    	 	38	 

    CONFIDENTIAL

    

 

		(d)	Nothing in this Agreement shall be deemed to exclude or limit the liability of either Party for
any form of liability that may not be excluded or limited by Applicable Law.

 

		11.2	Limit on Liability. Neither Party, its Affiliates or their respective officers, directors,
employees, agents and representatives shall be liable to the other, its Affiliates or their respective officers, directors, employees,
agents and representatives whether in contract, tort (including negligence) or for breach of statutory duty or misrepresentation,
or otherwise, for any:

 

		(i)	loss of profits;

 

		(ii)	loss of contracts or opportunity; or

 

		(iii)	indirect, special, incidental or consequential damages suffered by any person under or in connection
with this Agreement.

 

ARTICLE 12
INSURANCE

 

		12.1	During the Term of this Agreement and for a period of three (3) years thereafter, Basilea, its
Affiliates and subcontractors shall procure and maintain a minimum of general liability insurance (which shall include product
liability) under ordinary terms and conditions standard in the pharmaceutical industry, with limits of not less than the equivalent
of USD [...***...] per occurrence and in aggregate with insurers who are reputable and financially sound.

 

		12.2	During the Term of this Agreement and for a period of three (3) years thereafter, Cardiome, its
Affiliates and subcontractors shall procure and maintain a minimum of general liability insurance for all countries in the Territory
(which shall include product liability) under ordinary terms and conditions standard in the pharmaceutical industry, with limits
of not less than the equivalent of USD [...***...] per occurrence and in aggregate with insurers who are reputable and
financially sound.

 

		12.3	In addition, upon request, both Parties will provide the other with written evidence of such cover
with insurers who are reputable and financially sound.

 

		12.4	Each Party shall bear the costs for any deductibles/retentions for its insurance policy.

 

    	 	39	 

    CONFIDENTIAL

    

 

ARTICLE 13
CONFIDENTIAL INFORMATION

 

		13.1	For the purpose of this Article 13 only, any reference to a Party shall also be understood to include
all of its Affiliates which either receive or provide Confidential Information. Each Party shall further procure that any Third
Party to whom it provides Confidential Information (whether Third Party Distributors, Third Party Licensees, Wholesalers, or any
other Third Party) is bound to protect such information under terms at least as onerous as those contained herein. A Party receiving
Confidential Information from the other Party shall (i) maintain in confidence such Confidential Information to the same extent
such Party maintains its own Confidential Information; (ii) not disclose such Confidential Information to any Third Party without
prior written consent of the other Party; and (iii) not use such Confidential Information for any purpose except as permitted by
this Agreement. “Confidential Information” shall mean (i) any and all information including any proprietary data, inventions,
ideas, discoveries and materials (whether or not patentable or protectable as a trade secret) (whether or not it falls within the
Basilea Information or Know-how) not generally known to the public regarding a Party’s technology, products, business or
objectives, in each case, which are disclosed or made available by a Party (such Party being referred to as the “Disclosing
Party”) to the other Party (such Party being referred to as the “Receiving Party”) in connection with this Agreement,
(ii) all information developed during the course of performing the obligations set out in this Agreement, which shall be the Confidential
Information of the relevant Party (if developed by that Party alone) or of the Parties jointly (if developed by the Parties jointly)
and (iii) the fact that the Parties entered into this Agreement, the Quality Agreement and the Safety Data Exchange Agreement,
and the content of this Agreement, the Quality Agreement and the Safety Data Exchange Agreement. The obligations under this Article
13 shall remain in force until the expiration of five (5) years after Cardiome stops Commercializing the Product in the Territory.

 

		13.2	The obligations set forth in this Article 13 shall not apply with respect to any portion of such
Confidential Information which:

 

		(a)	is publicly disclosed by the Disclosing Party, either before or after it becomes known to the Receiving
Party; or

 

		(b)	was known to the Receiving Party, without obligation to keep it confidential, prior to when it
was received from the Disclosing Party; or

 

		(c)	is subsequently disclosed to the Receiving Party by a Third Party lawfully in possession thereof
without obligation to keep it confidential; or

 

		(d)	has been published by a Third Party or otherwise enters the public domain through no fault of the
Receiving Party in breach of this Agreement; or

 

		(e)	has been independently developed or acquired by the Receiving Party without the aid, application
or use of Confidential Information received from the Disclosing Party.

 

		13.3	The Receiving Party shall have the right to disclose any Confidential Information provided hereunder
if, in the reasonable opinion of the Receiving Party’s legal counsel, such disclosure is necessary to comply with the terms
of this Agreement, or the requirements of any Applicable Law, but only to the extent of such necessity or requirements; and no
such disclosure shall cause any such information to cease to be Confidential Information hereunder, except to the extent such disclosure
results in a public disclosure of such information. Where reasonably possible under the requirements of any Applicable Law, the
Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent to make such disclosure of Confidential
Information as soon as reasonably practicable prior to making such disclosure so as to allow the Disclosing Party adequate time
to take whatever action the Disclosing Party may deem appropriate to protect the confidentiality of the information.

 

    	 	40	 

    CONFIDENTIAL

    

 

		13.4	Each Party agrees that it shall provide or permit access to Confidential Information received from
the other Party only to the Receiving Party’s Affiliates, employees, officers, directors, consultants, advisors, and other
permitted (actual and potential) subcontractors, Third Parties, (hereafter “Permitted Persons”), who have a need to
know such Confidential Information to assist the Receiving Party with the activities contemplated or required of it by this Agreement,
the Quality Agreement and/or the Safety Data Exchange Agreement and who are subject to obligations of confidentiality and non-use
with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the Receiving
Party pursuant to this Article 13; provided, that each Party shall remain responsible for any failure by any of its Permitted Persons
to treat such Confidential Information as is required by this Article 13.

 

		13.5	If this Agreement terminates or expires pursuant to Article 14, each Party shall promptly upon
written request from the other Party, but no later than within thirty (30) days after such request, destroy or return at its own
cost, all Confidential Information received from the other Party, and any copies thereof as well as notes, summaries or drawings
containing Confidential Information (collectively the “Documentation”), shall cease any use of such Confidential Information
except one copy of the Documentation may be retained solely for compliance purposes or for archive purposes, and shall make sure
that any person or entity to whom Confidential Information has been disclosed or distributed by it or on its behalf does the same.
In addition, each Party shall, upon the other Party’s request, confirm in writing that it does not retain and/or has destroyed
all Documentation and has ceased to use the Confidential Information in any manner pursuant to this Section 13.5, except as permitted
under this Agreement.

 

		13.6	With Basilea’s prior approval, Cardiome may make scientific publications relating to the
Product. Cardiome shall provide the proposed publication, presentation or other material intended for publication to Basilea in
English, or, if the material is not in English, shall provide it in the original language together with an English summary forty-five
(45) days prior to proposed submission for publication or presentation at conferences for Basilea’s review. Basilea shall
advise Cardiome within twenty (20) days of receipt of such proposed material of its approval or any comments to such proposed publication
and Cardiome shall comply with Basilea’s request to delete any references to Confidential Information supplied by Basilea,
or shall withhold any presentation or publication for an additional period of time in order to permit Basilea to obtain patent
protection prior to publication if Basilea deems it necessary.

 

		13.7	It is understood and agreed that all “Confidential Information” under the Confidentiality
Agreements entered between the Parties dated November 30, 2016 shall be deemed Confidential Information under this Agreement and
be subject to this Article 13.

 

    	 	41	 

    CONFIDENTIAL

    

 

ARTICLE 14
TERM; TERMINATION

 

		14.1	Term of Agreement. The Agreement shall commence on the Effective Date and shall continue
to be in force for [...***...] from the Effective Date.

 

		14.2	Termination for Cause. Either Party may terminate this Agreement immediately upon written
notice to the other Party in the event of a material breach by the other Party of any term of this Agreement, which breach remains
uncured for sixty (60) calendar days following written notice (the “Cure Period”). Notwithstanding the foregoing, if
such material breach, by its nature, cannot be cured, the non-breaching Party may terminate this Agreement immediately upon written
notice to the breaching Party.

 

		14.3	Termination in Event of Insolvency. In the event that either Party (i) becomes insolvent,
or institutes or has instituted against it a petition for bankruptcy or is adjudicated bankrupt; or (ii) executes a bill of sale,
deed of trust, or a general assignment for the benefit of creditors; or (iii) is dissolved or transfers a substantial portion of
its assets to a Third Party; or (iv) a receiver is appointed for the benefit of its creditors, or a receiver is appointed on account
of insolvency (in any of (i)-(iv), such Party is the “Insolvent Party”), then the Insolvent Party shall immediately
notify the other Party of such event and such other Party shall be entitled to: (a) terminate this Agreement for cause immediately
upon written notice to the Insolvent Party; or (b) request that the Insolvent Party or its successor provide adequate assurances
of continued and future performance in form and substance acceptable to such other Party, which shall be provided by the Insolvent
Party within ten (10) calendar days of such request, and the other Party may terminate this Agreement for cause immediately upon
written notice to the Insolvent Party in the event that the Insolvent Party fails to provide such assurances acceptable to the
other Party within such ten (10) day period. For the sake of clarity, any asset transfer as a result of a Third Party acquiring
Cardiome’s assets via a merger or acquisition, or the transfer of the Product to an entity acquired by Cardiome, shall not
be considered an event with a Termination right.

 

		14.4	Other Termination. This Agreement may be terminated on a country-by-country basis after
the Cure Period as follows:

 

		(a)	by either Party pursuant to Section 17.5 (continuing force majeure);

 

		(b)	by Basilea pursuant to Section 2.6 (Non-compete);

 

		(c)	by Basilea pursuant to Section 10.4 (no challenge to IP);

 

		(d)	by Basilea if the First Commercial Sale Date in Italy, France, Germany and UK does not occur within
the later of i) three months from the end of the Initial Transition Period or ii) six months from the Effective Date; or in the
case of Spain, if the First Commercial Sale Date does not occur within nine months of the Effective Date. This Section 14.4 (d)
shall not be applicable to the extent and for so long as the delay of the First Commercial Sale Date is due to causes which do
not constitute force majeure but which are beyond Cardiome’s reasonable control and not due to its acts or omissions;

 

    	 	42	 

    CONFIDENTIAL

    

 

		(e)	by Basilea if Cardiome ceases the majority of Commercialization activities for the Product after
launch of the Product;

 

		(f)	by Basilea if Cardiome fails to achieve the Minimum Purchase Quantities for two consecutive calendar
years; or

 

		(g)	by Cardiome in a particular country, if the Marketing Authorisation for the Product in that country
is withdrawn, suspended or terminated.

 

For the avoidance of doubt, where
the Agreement is only terminated on a country basis, the Parties’ rights and responsibilities shall only terminate in relation
to such country and the provisions of the Agreement shall continue to apply in full force to all other countries.

 

		14.5	Effect of Termination.

 

		(a)	Expiration or termination of the Agreement (including on a country basis) for whatever reason and
regardless of the Party terminating shall result in:

 

		(i)	the Parties shall within thirty (30) days agree a transition plan including the operational details
of the transition of activities from Cardiome to Basilea, (including continued supply to the end of any existing bid and tender
agreements for up to one year after termination, it being understood that, if Cardiome has entered any such agreements with terms
lasting more than one year, the Parties shall discuss in good faith how such obligations shall be met), after a reasonable transition
period, to be agreed by the Parties, but in no event less than six (6) months;

 

		(ii)	Cardiome shall cooperate with Basilea to take necessary steps to transfer and assign all Authorisations,
Know-how and Information related to the Product either to Basilea or its designee;

 

		(iii)	at the end of the transition period, all rights granted by Basilea to Cardiome under the Agreement
shall terminate and revert to Basilea, all unconfirmed orders and supply obligations of Basilea shall terminate, Cardiome shall
supply to Basilea all remaining stocks of any advertising and Cardiome Core Materials in connection with Commercialization of Product
in the Territory, and Cardiome shall cease all use of the Dossier, Know-how and other Basilea Information supplied by Basilea hereunder.

 

		(b)	Cardiome shall notify Basilea of the amount of stock of Product held by it at the time of termination
or expiration, and the amount subject to Customer orders. Basilea shall have the option (exercisable by written notice to Cardiome
to be given not more than thirty (30) days after expiration or termination), either: (i) to inspect and repurchase from Cardiome
at the Actual Transfer Price all of or any of stocks of the Product held by Cardiome which are not subject to orders from Customers
and are in good and saleable condition; or (ii) permit Cardiome to Commercialize such stocks of Product, in accordance with all
Applicable Law for a maximum period of six (6) months following the date of expiration or termination.

 

    	 	43	 

    CONFIDENTIAL

    

 

		(c)	Termination of the Agreement shall be without prejudice to any rights that shall have accrued to
the benefit of either Party before such termination.

 

		(d)	The termination or expiration of this Agreement shall not affect the survival and continuing validity
of Article 9 (Representations and Warranties), Article 10 (Intellectual Property), Article 11 (Indemnification and Liability),
Article 12 (Insurance), Article 15 (Records and Audits), Article 16 (Notices), Article 17 (Miscellaneous), or of any other provision
which is expressly or by implication intended to continue in force after such termination or expiration.

 

ARTICLE 15
RECORDS AND AUDITS

 

		15.1	Both Parties shall maintain complete and accurate Records of all matters relating to their performance
that enable the other Party to demonstrate compliance with its obligations under this Agreement. Cardiome shall keep Records including
normal business accounts which must be complete, accurate and in conformity with generally accepted accounting procedures (US GAAP
or IAS) and that include a record of the sales or other disposition of the Product, any amounts paid to Basilea, and any amounts
referenced in this Agreement. Both Parties’ Records shall be retained for no less than a six (6) year period following the
year in which any such sale, distribution or payment occurred. Either Party may audit the other Party’s Records by an independent
accountant nominated by and at auditing Party’s expense. The audited Party shall reasonably cooperate with such an accountant.
Any audit shall be limited to the verification and determination of the correctness of the Records relating to the use or Commercialization
of the Product or any amounts paid under this Agreement. All Records reviewed by the independent accountant shall be treated as
Confidential Information. The audited Party shall be provided a copy of the audit within five (5) days of its conclusion. If the
audit shows a sum is payable by one Party to the other, then this sum shall be paid within thirty (30) days. If the audit shows
that the auditing Party has overpaid the audited Party, that Party shall apply this as a credit against future sums owing to it.
This Article 15 shall survive the expiration or any termination of this Agreement for a period of two (2) years.

 

		15.2	Provided reasonable notice has been given to the audited Party, the auditing Party may appoint
qualified delegates to undertake an audit during normal working hours of the locations where the audited Party (or its Affiliates
or authorised representatives) stores or has stored the Product, stock rotation, inventory and storage systems.

 

ARTICLE 16
NOTICES

 

		16.1	Any notice required to be given hereunder shall be in writing and shall be deemed to have been
sufficiently given: (i) when delivered in person, (ii) on the fifth business day after mailing by registered or certified mail,
postage prepaid, return receipt requested, (iii) on the next business day after mailing by overnight courier service, or (iv) when
delivered via facsimile with the original delivered via one of the preceding methods on or prior to the fifth business day after
transmission of the facsimile, to the addresses specified below. Each notice shall specify the name and date of and Parties to
this Agreement:

 

    	 	44	 

    CONFIDENTIAL

    

 

If to Cardiome:

 

Correvio International Sàrl

Rue des Alpes 21

Case postale 1674

1201 Geneva, Switzerland

Attention: General Counsel

 

with a copy to:

 

Cardiome Pharma Corp.

1441 Creekside Drive

Floor Six

Vancouver, BC V6J4S7

Canada

Attention: General Counsel

 

If to Basilea:

 

Basilea Pharmaceutica International
Ltd

Grenzacherstrasse 487, CH-4058,

Basel, Switzerland

Attention: Chief Commercial Officer

 

with a copy to:

 

Basilea Pharmaceutica International
Ltd

Grenzacherstrasse 487, CH-4058,

Basel, Switzerland

Attention: Legal Department

 

		16.2	Either Party may, by notice to the other Party, change the addresses and names given in Section
16.1.

 

ARTICLE 17
MISCELLANEOUS

 

		17.1	Publicity.

 

		(a)	Neither Party shall issue any press release or other publicity materials, or make any presentation
with respect to the existence of this Agreement or the terms and conditions hereof without the prior written consent of the other
Party in each instance, unless such disclosures only repeats information disclosed previously following mutual written consents.
This restriction shall not, however, apply to the extent that any such disclosures are required by Applicable Law, including as
may be required in connection with any filings required to be made by the disclosure policies of a major stock exchange and a Party’s
requirements to provide general guidance to financial analysts and investors related to the terms of the Agreement and Cardiome’s
performance under this Agreement.

 

    	 	45	 

    CONFIDENTIAL

    

 

		(b)	The Parties shall agree on a press release to be published upon the execution of this Agreement.

 

		(c)	Cardiome shall have no right to publish any papers, abstracts, summaries, materials for scientific
communication or any other publications or make any presentation related to or based on information derived from performance under
this Agreement without Basilea’s prior approval.

 

		17.2	Choice of Law and Dispute Resolution by Arbitration.

 

		(a)	Choice of Law. This agreement shall be governed by, and construed in accordance with, the
laws of Switzerland, without giving effect to its conflict of law provisions.

 

		(b)	Arbitration. The Parties recognize that disputes as to certain matters may from time to
time arise during the Term that relate to the Party’s respective rights and/or obligations hereunder, including the validity,
invalidity, or termination of this Agreement (“Dispute”). The Parties shall initially attempt in good faith to resolve
any Dispute arising out of or relating to this Agreement by holding discussions between its executives. If no resolution is reached
within thirty (30) days of the start of such discussion, then any Dispute, controversy or claim arising out of, or in relation
to, this contract, including the validity, invalidity, breach, or termination thereof, shall be resolved by arbitration in accordance
with the Swiss Rules of International Arbitration of the Swiss Chambers’ Arbitration Institution in force on the date on
which the Notice of Arbitration is submitted in accordance with these Rules.

 

		(i)	The number of arbitrators shall be three.

 

		(ii)	The seat of the arbitration shall be Zurich, Switzerland.

 

		(iii)	The arbitral proceedings shall be conducted in English.

 

		(c)	This Section 17.2 shall be without prejudice to the right of either Party to seek injunctive or
other preliminary judicial relief in any court of proper jurisdiction without attempting to resolve such Disputes as provided in
this Section 17.2, if in a Party’s judgment such action is necessary to avoid irreparable harm. Further, the requirement
to attempt in good faith to resolve Disputes in accordance with this Section 17.2 does not affect a Party’s right to terminate
this Agreement as provided for herein, and neither Party shall be required to follow these procedures prior to terminating this
Agreement, as the case may be.

 

		17.3	Relationship of the Parties. The relationship hereby established between the Parties is
solely that of independent contractors. Neither Party has any authority to act or make any agreements or representations on behalf
of the other Party or its Affiliates. This Agreement is not intended to create, and shall not be construed as creating, between
Basilea and Cardiome, the relationship of principal and agent, employer and employee, joint venturers, co-partners, or any other
such relationship, the existence of which is expressly denied. No employee or agent engaged by one Party shall be, or shall be
deemed to be, an employee or agent of the other Party and no such employee shall be entitled to any benefits that the other Party
provides to its own employees.

 

    	 	46	 

    CONFIDENTIAL

    

 

		17.4	Assignment; Binding Effect; and Performance by Affiliates.

 

		(a)	Assignment by Cardiome. Cardiome shall have the right to assign this Agreement in whole
to an Affiliate or to any successor to all of the business and assets of Cardiome, whether in a merger, consolidation, sale of
stock, sale of assets or other similar transaction. Cardiome shall inform Basilea about such assignment as soon as reasonably possible.
Apart from that Cardiome shall not assign, novate or otherwise transfer its rights or obligations hereunder without the prior written
consent of Basilea, such consent not to be unreasonably withheld.

 

		(b)	Assignment by Basilea. Basilea shall have the right to assign this Agreement in whole or
in part to an Affiliate or to any successor to all or substantially all of the business and assets of Basilea relevant to this
Agreement, whether in a merger, consolidation, sale of stock, sale of assets or other similar transaction. Basilea shall inform
Cardiome about such assignment as soon as reasonably possible. Basilea shall further have the right to assign this Agreement in
whole or in part to a purchaser of the Product.

 

		(c)	Binding Effect of Delegation. Any delegation or subcontracting consented to by the other
Party shall not relieve the subcontracting Party of its responsibilities and liabilities hereunder and the subcontracting Party
shall remain liable to the other Party for the conduct and performance of each permitted delegate and subcontractor hereunder.
This Agreement shall apply to, inure to the benefit of and be binding upon the Parties hereto and their respective successors and
permitted assigns. The Parties agree that this Agreement is not intended by any Party to give any benefits, rights, privileges,
actions or remedies to any person or entity, partnership, firm or corporation as a Third Party beneficiary or otherwise under any
theory of law.

 

		(d)	Performance by Affiliates. Each Party may discharge any obligations and exercise any right
hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations
under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.
Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach
by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such
Party’s Affiliate.

 

    	 	47	 

    CONFIDENTIAL

    

 

		17.5	Force Majeure. No Party shall be liable for any failure to perform or any delays in performance,
and no Party shall be deemed to be in breach or default of its obligations set forth in this Agreement, if, to the extent and for
so long as, such failure or delay is due to any causes that are beyond its reasonable control and not to its acts or omissions,
including, without limitation, such causes as acts of God, natural disasters, fire, flood, severe storm, earthquake, civil disturbance,
lockout, riot, order of any court or administrative body, embargo, acts of government, war (whether or not declared), acts of terrorism,
or other similar causes (each, a “Force Majeure Event”). For clarity, raw material price increases, unavailability
of raw materials, and labor disputes shall not be deemed a Force Majeure Event. In the event of a Force Majeure Event, the Party
prevented from or delayed in performing shall promptly give notice to the other Party and avoid or minimize the delay. In the event
that the delay continues for a period of at least six (6) months, the Party affected by the other Party’s delay may elect
to: (a) suspend performance and extend the time for performance for the duration of the Force Majeure Event, or (b) cancel the
unperformed part of this Agreement and/or any Purchase Orders.

 

		17.6	Severability. If and solely to the extent that any court or tribunal of competent jurisdiction
holds any provision of this Agreement to be unenforceable in a final non-appealable order, such unenforceable provision shall be
stricken and the remainder of this Agreement shall not be affected thereby. In such event, the Parties shall in good faith attempt
to replace any unenforceable provision of this Agreement with a provision that is enforceable and that comes as close as possible
to expressing the intention of the original provision.

 

		17.7	Non-Waiver; Remedies. A waiver by any Party of any term or condition of this Agreement in
any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach
thereof. All remedies specified in this Agreement shall be cumulative and in addition to any other remedies provided at law or
in equity.

 

		17.8	Further Documents. Each Party hereto agrees to execute such further documents and take such
further steps as may be reasonably necessary or desirable to effectuate the purposes of this Agreement.

 

		17.9	Forms. The Parties recognize that, during the Term of this Agreement, a purchase order acknowledgment
form or similar routine document (collectively, “Forms”) may be used to implement or administer provisions of this
Agreement. The Parties agree that the terms of this Agreement shall prevail in the event of any conflict between terms of this
Agreement and the terms of such Forms, and any additional or different terms contained in such Forms shall not apply to this Agreement.

 

		17.10	Headings. Headings of Sections or other parts of this Agreement are included herein for
convenience of reference only and shall not constitute a part of this Agreement or change the meaning of this Agreement.

 

    	 	48	 

    CONFIDENTIAL

    

 

		17.11	Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall constitute an original and all of which together shall constitute one and the same agreement and shall become effective when
signed by each of the Parties hereto and delivered to the other Party in accordance with the means set forth in Article 16 or by
reliable electronic means (with receipt electronically confirmed), followed by a prompt delivery of a signed counterpart.

 

		17.12	Entire Agreement; Amendments. This Agreement, together with any attachments and amendments,
constitutes the entire agreement of the Parties with respect to its subject matter and merges and supersedes all prior discussions
and writings with respect to thereto. No modification or alteration of this Agreement shall be binding upon the Parties unless
contained in writing signed by a duly authorized agent for each respective Party and specifically referring hereto or thereto.
No representation, undertaking or promise shall be taken to have been given or be implied from anything said or written in negotiations
between the Parties prior to this Agreement except as expressly stated in this Agreement. Neither Party shall have any remedy in
respect of any untrue statement made by the other upon which that Party relied in entering into this Agreement (unless such untrue
statement was made fraudulently) and that Party’s only remedies shall be for breach of contract as provided in this Agreement.

 

[Signatures on the next page]

 

    	 	49	 

    CONFIDENTIAL

    

 

IN WITNESS WHEREOF, the Parties hereto
have caused this Agreement to be duly executed and delivered as of the date first written above.

 

	Basilea Pharmaceutica International Ltd.	 	Correvio International Sàrl
	 	 	 
	By	/s/ Ronald Scott	 	By	/s/ David D. McMasters
	Name: Ronald Scott	 	Name: David D. McMasters
	Title: Chief Executive Officer	 	Title:   Director
	Place/Date: Basel, 	 	Place/Date:
	 	 	 	 	 

	Basilea Pharmaceutica International Ltd.	 	Correvio International Sàrl
	 	 	 
	By:	/s/ Donato Spota 	 	By
	Name: Donato Spota	 	Name: 
	Title: Chief Financial Officer	 	Title:  Director
	Place/Date: Basel	 	Place/Date:
	 	 	 	 

    	 	50Exhibit 4.2

 

Execution Version

 

 

 

SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT

 

dated as of

 

May 15, 2018

 

between

 

CORREVIO PHARMA CORP. 

as Borrower,

 

The Subsidiary Guarantors from Time to Time
Party Hereto,

 

The Lenders from Time to Time Party Hereto,

 

and

 

CRG SERVICING LLC

as Administrative and Collateral Agent

 

U.S. $50,000,000

 

 

 

    	i

     

    

 

TABLE OF CONTENTS

 

	 	Page
	 	 
	SECTION 1 DEFINITIONS	1
	1.01	Certain Defined Terms	1
	1.02	Accounting Terms and Principles	24
	1.03	Interpretation	24
	1.04	Quebec Interpretation Clause	24
	1.05	Changes to GAAP	25
	 	 
	SECTION 2 THE COMMITMENT	26
	2.01	Commitments	26
	2.02	Borrowing Procedures	26
	2.03	Fees	26
	2.04	Use of Proceeds	26
	2.05	Defaulting Lenders	27
	2.06	Substitution of Lenders	28
	2.07	Prior Borrowings	29
	 	 
	SECTION 3 PAYMENTS OF PRINCIPAL AND INTEREST	29
	3.01	Repayment	29
	3.02	Interest	29
	3.03	Prepayments	30
	 	 
	SECTION 4 PAYMENTS, ETC.	33
	4.01	Payments	33
	4.02	Computations	33
	4.03	Notices	33
	4.04	Set-Off	33
	4.05	Pro Rata Treatment	34
	 	 
	SECTION 5 YIELD PROTECTION, ETC.	35
	5.01	Additional Costs	35
	5.02	Illegality	36
	5.03	Taxes	36
	 	 
	SECTION 6 CONDITIONS PRECEDENT	39
	6.01	The First Borrowing	39
	6.02	Conditions to Second Borrowing	43
	6.03	Conditions to Third Borrowing	44
	6.04	Conditions to Fourth Borrowing	45
	6.05	Conditions to Each Borrowing	45
	6.06	Conditions to the effectiveness of this Agreement	46

 

    	ii

     

    

 

TABLE OF CONTENTS

(continued)

 

	 	Page
	 	 
	SECTION 7 REPRESENTATIONS AND WARRANTIES	49
	7.01	Power and Authority	49
	7.02	Authorization; Enforceability	49
	7.03	Governmental and Other Approvals; No Conflicts	49
	7.04	Financial Statements; Material Adverse Change	50
	7.05	Properties	50
	7.06	No Actions or Proceedings	53
	7.07	Compliance with Laws and Agreements	53
	7.08	Taxes	54
	7.09	Full Disclosure	54
	7.10	Regulation	54
	7.11	Solvency	54
	7.12	Subsidiaries	54
	7.13	Indebtedness and Liens	54
	7.14	Material Agreements	55
	7.15	Restrictive Agreements	55
	7.16	Real Property	55
	7.17	Pension Matters	56
	7.18	Collateral; Security Interest	56
	7.19	Regulatory Approvals	56
	7.20	Canadian Pension or Benefit Plans	56
	7.21	Series A Shares	56
	7.22	The Toronto-Dominion Bank Account	56
	 	 
	SECTION 8 AFFIRMATIVE COVENANTS	57
	8.01	Financial Statements and Other Information	57
	8.02	Notices of Material Events	58
	8.03	Existence; Conduct of Business	60
	8.04	Payment of Taxes and Other Claims	60
	8.05	Insurance	60
	8.06	Books and Records; Inspection Rights	61
	8.07	Compliance with Laws and Other Obligations	61
	8.08	Maintenance of Properties, Etc.	61
	8.09	Licenses	61
	8.10	Action under Environmental Laws	62
	8.11	Use of Proceeds	62
	8.12	Certain Obligations Respecting Subsidiaries; Further Assurances	62
	8.13	Termination of Non-Permitted Liens	63
	8.14	Intellectual Property	64

 

    	iii

     

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	Page
	 	 	 
	8.15	Owned Real Property	64
	8.16	Update of Schedules	64
	8.17	Post-Closing Items	64
	8.18	Swiss Guarantors	64
	8.19	Loan Proceeds	65
	8.20	Cipher Transaction Proceeds	65
	 	 
	SECTION 9 NEGATIVE COVENANTS	65
	9.01	Indebtedness	65
	9.02	Liens	66
	9.03	Fundamental Changes and Acquisitions	67
	9.04	Lines of Business	68
	9.05	Investments	68
	9.06	Restricted Payments	69
	9.07	Payments of Indebtedness	69
	9.08	Change in Fiscal Year	69
	9.09	Sales of Assets, Etc.	69
	9.10	Transactions with Affiliates	70
	9.11	Restrictive Agreements	70
	9.12	Amendments to Material Agreements	70
	9.13	Operating Leases	70
	9.14	Sales and Leasebacks	71
	9.15	Hazardous Material	71
	9.16	Accounting Changes	71
	9.17	Compliance with ERISA	71
	9.18	Canadian Benefit Plans	71
	9.19	[Reserved.]	71
	9.20	Series A Shares	71
	9.21	Swiss Indebtedness	71
	 	 
	SECTION 10 FINANCIAL COVENANTS	72
	10.01	Minimum Liquidity	72
	10.02	Minimum Revenue	72
	10.03	Cure Right	72
	 	 
	SECTION 11 EVENTS OF DEFAULT	73
	11.01 	Events of Default	73
	11.02	Remedies	76

 

    	iv

     

    

 

TABLE OF CONTENTS

(continued)

 

	 	Page
	 	 
	SECTION 12 ADMINISTRATIVE AGENT	77
	12.01	Appointment and Duties	77
	12.02	Duties as Collateral and Disbursing Agent	79
	12.03	Binding Effect	79
	12.04	Use of Discretion	79
	12.05	Delegation of Rights and Duties	80
	12.06	Reliance and Liability	80
	12.07	Administrative Agent Individually	81
	12.08	Lender Credit Decision	81
	12.09	Expenses; Indemnities	81
	12.10	Resignation of Administrative Agent	82
	12.11	Release of Collateral or Guarantors	82
	12.12	Additional Secured Parties	83
	12.13	Quebec Security	83
	12.14	French Security	84
	 	 
	SECTION 13 MISCELLANEOUS	84
	13.01	No Waiver	84
	13.02	Notices	85
	13.03	Expenses, Indemnification, Etc.	85
	13.04	Amendments, Etc.	86
	13.05	Successors and Assigns	87
	13.06	Survival	88
	13.07	Captions	88
	13.08	Counterparts	89
	13.09	Governing Law	89
	13.10	Jurisdiction, Service of Process and Venue	89
	13.11	Waiver of Jury Trial	90
	13.12	Waiver of Immunity	90
	13.13	Entire Agreement	90
	13.14	Severability	90
	13.15	No Fiduciary Relationship	90
	13.16	Confidentiality	90
	13.17	USA PATRIOT Act	91
	13.18	Maximum Rate of Interest	91
	13.19	Certain Waivers	92
	13.20	Judgment Currency	93
	13.21	Limitations	93
	13.22	Permitted Liens	93

 

    	v

     

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	Page
	 	 	 
	13.23	Amendment and Restatement of the First A&R Agreement	93
	13.24	English Guarantee and Security Confirmation	94
	 	 
	SECTION 14 GUARANTEE	95
	14.01	The Guarantee	95
	14.02	Obligations Unconditional	95
	14.03	Reinstatement	96
	14.04	Subrogation	96
	14.05	Remedies	96
	14.06	Instrument for the Payment of Money	96
	14.07	Continuing Guarantee	96
	14.08	Rights of Contribution	96
	14.09	General Limitation on Guarantee Obligations	97
	14.10	Joint and Several Obligations	97
	14.11	Restricted Obligations – Switzerland	97
	14.12	Restricted Obligations – Germany	99
	14.13	Restricted Obligations – France	101
	14.14	English Obligors	102

 

SCHEDULES AND EXHIBITS

 

	Schedule 1	 	 
	Schedule 6.06	 	 
	Schedule 7.05(b)(i)	 	 
	Schedule 7.05(b)(ii)	 	 
	Schedule 7.05(c)	 	 
	Schedule 7.06	 	 
	Schedule 7.08	 	 
	Schedule 7.12	 	 
	Schedule 7.13(a)	 	 
	Schedule 7.13(b)	 	 
	Schedule 7.14	 	 
	Schedule 7.15	 	 
	Schedule 7.16	 	 
	Schedule 7.17	 	 
	Schedule 9.05	 	 
	Schedule 9.10	 	 
	Schedule 9.14	 	 
	 	 	 
	Exhibit A	 	 
	Exhibit B	 	 
	Exhibit C	 	 
	Exhibit D	 	 

 

    	vi

     

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	Page

 

	Exhibit E	 	 
	Exhibit F	 	 
	Exhibit G	 	 

 

    	vii

     

    

 

SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT,
dated as of May 15, 2018 (this “Agreement”), among CORREVIO PHARMA CORP., a corporation incorporated
pursuant to the federal laws of Canada (“Borrower”), the Subsidiary Guarantors from time to time party
hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, a Delaware limited liability company (“CRG
Servicing”), as administrative and collateral agent for the Lenders (in such capacities, together with its successors
and assigns, “Administrative Agent”).

 

WITNESSETH:

 

Cardiome Pharma Corp., a corporation incorporated
pursuant to the federal laws of Canada (“Original Borrower”), the Subsidiary Guarantors and the Administrative
Agent were parties to that certain term loan agreement dated as of June 13, 2016 (the “Original Agreement”),
pursuant to which the Lenders made available certain loan facilities to the Original Borrower;

 

Original Borrower, the
Subsidiary Guarantors and the Administrative Agent are parties to that certain amended and restated term loan agreement dated as
of May 11, 2017 as amended by a first amending agreement dated as of March 27, 2018 (the “First A&R Agreement”),
pursuant to which the Original Agreement was amended and restated in its entirety to allow for additional loans to be made available
to the Original Borrower pursuant to the terms thereof;

 

Original Borrower, Borrower, the Subsidiary
Guarantors and the Administrative Agent entered into that certain Assignment, Assumption and Confirmation Agreement dated as of
the Closing Date (the “Assignment Agreement”), pursuant to which the Original Borrower assigned to the
Borrower all of its rights and obligations under the First A&R Agreement and the other Loan Documents to which the Original
Borrower was party, and the Borrower assumed all of the rights and obligations of the Original Borrower under the First A&R
Agreement and the other Loan Documents to which the Original Borrower was a Party, and the Subsidiary Guarantors confirmed their
respective obligations under the First A&R Agreement and each of the other Loan Documents to which each such Subsidiary Guarantor
was a party; and

 

Borrower has requested that the First A&R
Agreement be amended and restated in its entirety pursuant to the terms hereof, and the Lenders are prepared to amend and restate
the Original Agreement on and subject to the terms and conditions hereof (it being agreed that this Agreement shall not constitute
a novation of the obligations and liabilities of the parties under the First A&R Agreement or be deemed to evidence or constitute
full repayment of such obligations and liabilities, but that this Agreement amends and restates in its entirety the First A&R
Agreement and re-evidences the obligations and liabilities of the Borrower outstanding thereunder, which shall be payable in accordance
with the terms hereof).

 

Accordingly, the parties agree as follows:

 

SECTION 1

DEFINITIONS

 

1.01      Certain Defined Terms. As used herein,
the following terms have the following respective meanings:

 

    	 	1	 

     

    

 

“10-Non-Qualifying Bank Creditor
Rule” means the rule that the aggregate number of creditors (other than Qualifying Bank Creditors) of the Swiss Guarantors
under the Loan Documents must not exceed ten (10).

 

“20-Non-Qualifying Bank Creditor
Rule” means the rule that the aggregate number of creditors (including the Lenders and the Participants), other than
Qualifying Bank Creditors and related entities (provided that, the annual accounts of such related entities are fully consolidated
at the level of the group as per recognized accounting standards) of a Swiss Guarantor, under all outstanding debts relevant for
classification by the Swiss Federal Tax Administration as debenture (Kassenobligation), such as facilities and/or private
placements (including with respect to the proceeds of the Loans that are on-lent to such Swiss Guarantor from time to time) must
not at any time exceed twenty (20).

 

“Accounting Change Notice”
has the meaning set forth in Section 1.05(a).

 

“Act” has the meaning
set forth in Section 13.17.

 

“Acquisition”
means any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a take-over
bid, tender offer, amalgamation, merger, purchase of assets, or similar transaction having the same effect as any of the foregoing,
(a) acquires any business or product, or all or substantially all of the assets of any Person engaged in any business, (b) acquires
control of securities of a Person engaged in a business representing more than 50% of the ordinary voting power for the election
of directors or other governing body if the business affairs of such Person are managed by a board of directors or other governing
body, or (c) acquires control of more than 50% of the ownership interest in any Person engaged in any business that is not managed
by a board of directors or other governing body.

 

“Affected Lender”
has the meaning set forth in Section 2.06(a).

 

“Affiliate” means,
with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or
is Controlled by or is under common Control with the Person specified.

 

“Agreement” has the
meaning set forth in the introduction hereto.

 

“Asset Sale” has the
meaning set forth in Section 9.09.

 

“Asset Sale Net Proceeds”
means the aggregate amount of the cash proceeds received from any Asset Sale, net of any bona fide costs incurred in connection
with such Asset Sale, plus, with respect to any non-cash proceeds of an Asset Sale, the fair market value of such non cash proceeds
as determined by the Majority Lenders, acting reasonably.

 

“Assignment
Agreement” has the meaning set forth in the introduction hereto.

 

“Assignment and Assumption”
means an assignment and assumption entered into by a Lender and an assignee of such Lender.

 

“Backend
Facility Fee” has the meaning given to such term in the Fee Letter.

 

    	 	2	 

     

    

 

“Bankruptcy Code”
means Title II of the United States Code entitled “Bankruptcy.”

 

“Benefit Plan” means
any employee benefit plan as defined in Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise)
to which any Obligor or Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise.

 

“Borrower” has the
meaning set forth in the introduction hereto.

 

“Borrower Facility”
means the premises located at Suite 600, 6th floor, 1441 Creekside Drive, Vancouver, British Columbia, which are leased
by Borrower pursuant to the Borrower Lease.

 

“Borrower Landlord”
means Central 1 Credit Union.

 

“Borrower Lease”
means the office lease dated July 23, 2014 by and between the Original Borrower (and subsequently assigned to the Borrower) and
Borrower Landlord in respect of the Borrower Facility.

 

“Borrower Party” has
the meaning set forth in Section 13.03(b).

 

“Borrowing” means
a borrowing consisting of Loans made on the same day by the Lenders according to their respective Commitments (including, without
limitation, a borrowing of a PIK Loan).

 

“Borrowing Date” means
the date of a Borrowing including, for certainty, the initial Borrowing made on June 14, 2016, the second Borrowing made on May
11, 2017 and the third Borrowing made on August 8, 2017.

 

“Borrowing
Notice Date” means, (a) in the case of the second Borrowing, a date that is at least twelve Business Days prior to
the Borrowing Date of such Borrowing and, (b) in the case of a subsequent Borrowing, a date that is at least twenty Business Days
prior to the Borrowing Date of such Borrowing.

 

“Business Day” means
a day (other than a Saturday or Sunday) on which commercial banks are not authorized or required to close in New York City or Vancouver,
British Columbia.

 

“Canadian Benefit Plans”
means all Canadian (including without limitation any Canadian provincial or territorial) plans, arrangements, agreements, programs,
policies, practices or undertakings, whether oral or written, formal or informal, funded or unfunded, insured or uninsured, registered
or unregistered, subject to the laws of Canada or any province or territory thereof to which an Obligor or any of its Subsidiaries
is a party or bound or in which their employees participate or under which an Obligor or any of its Subsidiaries has, or will have,
any liability or contingent liability, or pursuant to which payments are made, or benefits are provided to, or an entitlement to
payments or benefits may arise with respect to, any of their employees or former employees, their directors or officers, individuals
working on contract with an Obligor or any of its Subsidiaries or other individuals providing services to an Obligor or any of
its Subsidiaries of a kind normally provided by employees (or any spouses, dependents, survivors or beneficiaries of any such persons).

 

    	 	3	 

     

    

 

“Canadian Insolvency Legislation”
means the Bankruptcy and Insolvency Act (Canada), the Companies’ Creditors Arrangement Act (Canada), the Winding-up
and Restructuring Act (Canada) or any other bankruptcy, insolvency or analogous law of Canada.

 

“Canadian Pension Plans”
means all Canadian Benefit Plans which are required to be registered under Canadian provincial, territorial or federal pension
benefits standards legislation.

 

“Canadian Security
Agreement” means the Amended and Restated Canadian Security Agreement, dated as of the Closing Date, among the Borrower,
the other grantors from time to time party thereto and Administrative Agent.

 

“Canadian Security Documents”
means the Canadian Security Agreement, each Canadian Short-Form IP Security Agreement, the Landlord Consent and any other agreement
governed by Canadian law that creates or purports to create security and that is entered into by a Canadian Obligor pursuant to
this Agreement (as such agreement may be amended, restated, replaced, supplemented or otherwise modified from time to time).

 

“Canadian Short-Form IP Security
Agreement” means the amended and restated (if applicable) short-form copyright, patent or trademark (as the case
may be) security agreements governed by the laws of any province or territory of Canada, dated as of the Original Closing Date
or the Closing Date, as the case may be, entered into by one or more Obligors in favor of the Secured Parties, each in form and
substance satisfactory to the Majority Lenders (as such agreement may be amended, restated, replaced, supplemented or otherwise
modified from time to time).

 

“Capital Lease Obligations”
means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying
the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital
lease on a balance sheet of such Person under GAAP and, for purposes of this Agreement, the amount of such obligations shall be
the capitalized amount thereof, determined in accordance with GAAP.

 

“Change of Control”
means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person or group of Persons acting
jointly or otherwise in concert of capital stock representing (i) in the case of the Borrower, more than 30% of the aggregate ordinary
voting power represented by the issued and outstanding capital stock of the Borrower or (ii) in the case of a Subsidiary Guarantor,
any of the ordinary voting power represented by the issued and outstanding capital stock of such Subsidiary Guarantor, (b) during
any period of twelve (12) consecutive calendar months, the occupation of a majority of the seats (other than vacant seats) on the
board of directors of the Borrower or any Subsidiary Guarantor by Persons who were neither (i) nominated by the board of directors
of the Borrower or any Subsidiary Guarantor, as applicable, nor (ii) appointed by directors so nominated, or (c) the acquisition
of direct or indirect Control of the Borrower or any Subsidiary Guarantor, as applicable, by any Person or group of Persons acting
jointly or otherwise in concert; in each case whether as a result of a tender or exchange offer, open market purchases, privately
negotiated purchases or otherwise.

 

    	 	4	 

     

    

 

“Cipher Transaction”
means the purchase of all the outstanding shares of the Original Borrower pursuant to and on the terms and conditions of the arrangement
agreement dated as of March 19, 2018 among Cipher Pharmaceuticals Inc., the Original Borrower and the Borrower.

 

“Claims” means any
claims, demands, complaints, grievances, actions, applications, suits, causes of action, orders, charges, indictments, prosecutions,
informations (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments.

 

“Closing Date” means
May 15, 2018.

 

“Code” means the Internal
Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder from time to time.

 

“Collateral” means
any Property in which a Lien is purported to be granted under any of the Security Documents (or all such Property, as the context
may require).

 

“Commitment” means,
with respect to each Lender, the obligation of such Lender to make Loans to Borrower in accordance with the terms and conditions
of this Agreement, which commitment is in the amount set forth opposite such Lender’s name on Schedule 1 under the
caption “Commitment”, as such Schedule may be amended from time to time. The aggregate Commitments on the date hereof
equal $50,000,000. For purposes of clarification, the amount of any PIK Loans shall not reduce the amount of the available Commitment.

 

“Commitment Period”
means the period from and including the Original Closing Date and through and including March 31, 2018 or such later date as the
Administrative Agent agrees to in writing in its sole discretion.

 

“Commodity Account”
has the meaning set forth in the U.S. Security Agreement.

 

“Compliance Certificate”
has the meaning given to such term in Section 8.01(d).

 

“Contracts” means
contracts, licenses, leases, agreements, obligations, promises, undertakings, understandings, arrangements, documents, commitments,
entitlements or engagements under which a Person has, or will have, any liability or contingent liability (in each case, whether
written or oral, express or implied).

 

“Control” means, in
respect of a particular Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management
or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling”
and “Controlled” have meanings correlative thereto.

 

“Copyright” has the
meaning set forth in the Canadian Security Agreement.

 

“Cure Amount” has
the meaning set forth in Section 10.03(a).

 

“Cure Right” has the
meaning set forth in Section 10.03(a).

 

“Default” means any
Event of Default and any event that, upon the giving of notice, the lapse of time or both, would constitute an Event of Default.

 

    	 	5	 

     

    

 

“Default Rate” has
the meaning set forth in Section 3.02(b).

 

“Defaulting Lender”
means, subject to Section 2.05, any Lender that (a) has failed to perform any of its funding obligations hereunder, including
in respect of its Loans, within three (3) Business Days of the date required to be funded by it hereunder, (b) has notified Borrower
or any Lender that it does not intend to comply with its funding obligations or has made a public statement to that effect with
respect to its funding obligations hereunder or under other agreements in which it commits to extend credit, or (c) has, or has
a direct or indirect parent company that has, (i) become the subject of an Insolvency Proceeding, (ii) had a receiver, conservator,
trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of
its business or a custodian appointed for it, or (iii) taken any action in furtherance of, or indicated its consent to, approval
of or acquiescence in any such proceeding or appointment; provided that a Lender shall not be a Defaulting Lender solely by virtue
of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental
Authority.

 

“Deposit Account”
is defined in the Canadian Security Agreement.

 

“Dollars” and “$”
means lawful money of the United States of America.

 

“Domestic Subsidiary”
means any Subsidiary that is a corporation, limited liability company, unlimited liability company, partnership or similar business
entity incorporated, formed or organized under the laws of the United States, any state of the United States, the District of Columbia,
the laws of Canada or any province or territory of Canada.

 

“Eligible Transferee”
means and includes a commercial bank, an insurance company, a finance company, a financial institution, any investment fund that
invests in loans or any other “accredited investor” (as defined in Regulation D of the Securities Act) that is principally
in the business of managing investments or holding assets for investment purposes, provided that each Eligible Transferee shall
either (i) be a Qualifying Bank Creditor or (ii) not cause the number of existing Lenders and Participants (directly or indirectly)
hereunder which are not, in each case, Qualifying Bank Creditors to exceed in aggregate ten (10).

 

“English Debenture”
means the composite debenture between the English Obligors and the Administrative Agent dated the date of the Original Agreement.

 

“English Guarantee”
means the composite guarantee between the English Obligors and the Administrative Agent dated the date of the Original Agreement.

 

“English Obligors”
means Cardiome UK Limited (company number 06304464) and Correvio (UK) Ltd. (company number 06481819) both having their registered
addresses at Lakeside House, 1 Furzeground Way, Stockley Park, Uxbridge, Middlesex, England UB11 1BD.

 

“English Security Documents” means the English Debenture, the English Share Charges and any other agreement governed by English law that creates or
purports to create security and that is entered into by either of the English Obligors pursuant to this Agreement (as any such
agreement may be amended, restated, replaced, supplemented or otherwise modified from time to time).

 

    	 	6	 

     

    

 

“English Share Charges”
means each of:

 

1. the share charge between Cardiome International
SA and the Administrative Agent over the shares in Correvio (UK) Ltd. dated the Closing Date; and

 

2. the share charge between the Borrower and
the Administrative Agent over the shares in Cardiome UK Limited dated the Closing Date.

 

“Environmental Law”
means any federal, state, provincial, territorial or local governmental law, rule, regulation, order, writ, judgment, injunction
or decree relating to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release
or handling of hazardous materials, and all local laws and regulations related to environmental matters and any specific agreements
entered into with any competent authorities which include commitments related to environmental matters.

 

“Equity Cure Right”
has the meaning set forth in Section 10.03(a).

 

“Equity Interest”
means, with respect to any Person, any and all shares, interests, participations or other equivalents, including membership interests
(however designated, whether voting or nonvoting), of equity of such Person, including, if such Person is a partnership, partnership
interests (whether general or limited) and any other interest or participation that confers on a Person the right to receive a
share of the profits and losses of, or distributions of property of, such partnership, but excluding debt securities convertible
or exchangeable into such equity.

 

“Equivalent Amount”
means, with respect to an amount denominated in one currency, the amount in another currency that could be purchased by the amount
in the first currency determined by reference to the Exchange Rate at the time of determination.

 

“ERISA” means the
United States Employee Retirement Income Security Act of 1974, as amended.

 

“ERISA Affiliate”
means, collectively, any Obligor, Subsidiary thereof, and any Person under common control, or treated as a single employer, with
any Obligor or Subsidiary thereof, within the meaning of Section 414(b), (c), (m) or (o) of the Code.

 

    	 	7	 

     

    

 

“ERISA Event”
means (a) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such events
as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within 30 days of
the occurrence of such event; (b) the applicability of the requirements of Section 4043(b) of ERISA with respect to a contributing
sponsor, as defined in Section 4001(a)(13) of ERISA, to any Title IV Plan where an event described in paragraph (9), (10), (11),
(12) or (13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such plan within the following 30 days;
(c) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the termination of any Title IV Plan resulting
in liability under Sections 4063 or 4064 of ERISA; (d) the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete
or partial withdrawal (within the meaning of Section 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential
liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it
is in reorganization or insolvency pursuant to Section 4241 or 4245 of ERISA; (e) the filing of a notice of intent to terminate,
the treatment of a plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by
the PBGC to terminate a Title IV Plan or Multiemployer Plan; (f) the imposition of liability on any Obligor or any ERISA Affiliate
thereof pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (g) the failure
by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Plan, or the failure to meet the minimum funding
standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c)
of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with respect to any Title
IV Plan or the failure to make any required contribution to a Multiemployer Plan; (h) the determination that any Title IV Plan
is considered an at-risk plan or a plan in endangered to critical status within the meaning of Sections 430, 431 and 432 of the
Code or Sections 303, 304 and 305 of ERISA; (i) an event or condition which is reasonably likely to constitute grounds under Section
4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Title IV Plan or Multiemployer Plan; (x)
the imposition of any liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under Section
4007 of ERISA, upon any Obligor or any ERISA Affiliate thereof; (j) an application for a funding waiver under Section 303 of ERISA
or an extension of any amortization period pursuant to Section 412 of the Code with respect to any Title IV Plan; (k) the occurrence
of a non-exempt prohibited transaction under Sections 406 or 407 of ERISA for which any Obligor or any Subsidiary thereof may be
directly or indirectly liable; (l) a violation of the applicable requirements of Section 404 or 405 of ERISA or the exclusive benefit
rule under Section 401(a) of the Code by any fiduciary or disqualified person for which any Obligor or any ERISA Affiliate thereof
may be directly or indirectly liable; (m) the occurrence of an act or omission which could give rise to the imposition on any Obligor
or any ERISA Affiliate thereof of fines, penalties, taxes or related charges under Chapter 43 of the Code or under Sections 409,
502(c), (i) or (1) or 4071 of ERISA; (n) the assertion of a material claim (other than routine claims for benefits) against any
Plan or the assets thereof, or against any Obligor or any Subsidiary thereof in connection with any such plan; (o) receipt from
the IRS of notice of the failure of any Qualified Plan to qualify under Section 401(a) of the Code, or the failure of any trust
forming part of any Qualified Plan to fail to qualify for exemption from taxation under Section 501(a) of the Code; (p) the imposition
of any lien (or the fulfillment of the conditions for the imposition of any lien) on any of the rights, properties or assets of
any Obligor or any ERISA Affiliate thereof, in either case pursuant to Title I or IV, including Section 302(f) or 303(k) of ERISA
or to Section 401(a)(29) or 430(k) of the Code; or (q) the establishment or amendment by any Obligor or any Subsidiary thereof
of any “welfare plan”, as such term is defined in Section 3(1) of ERISA, that provides post-employment welfare benefits
in a manner that would materially increase the liability of any Obligor.

 

“ERISA Funding Rules”
means the rules regarding minimum required contributions (including any installment payment thereof) to Title IV Plans, as set
forth in Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA.

 

“Escrow Account”
means the “Escrow Fund” (as defined in the Murk Stock and Asset Purchase Agreement) established pursuant to the terms
and conditions of the Murk Stock and Asset Purchase Agreement which includes an obligation of Borrower to maintain a minimum balance
of $1,000,000 in such “Escrow Fund” at all times.

 

    	 	8	 

     

    

 

“Event of Default”
has the meaning set forth in Section 11.01.

 

“Exchange Rate” means
the rate at which any currency (the “Pre-Exchange Currency”) may be exchanged into another currency (the
“Post-Exchange Currency”), as set forth on such date on the relevant Reuters screen at or about 11:00
a.m. (Central time) on such date. In the event that such rate does not appear on the Reuters screen, the “Exchange Rate”
with respect to exchanging such Pre-Exchange Currency into such Post-Exchange Currency shall be determined by reference to such
other publicly available service for displaying exchange rates as may be agreed upon by Borrower and Administrative Agent or, in
the absence of such agreement, such Exchange Rate shall instead be determined by Administrative Agent by any reasonable method
as they deem applicable to determine such rate, and such determination shall be conclusive absent manifest error.

 

“Excluded Taxes” means
any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a
Recipient: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in each
case imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of
any Lender, its applicable lending office located in, the jurisdiction imposing such Tax, (b) Other Connection Taxes, (c) United
States federal withholding Taxes that are imposed on amounts payable to a Lender to the extent that the obligation to withhold
amounts existed on the date that such Lender became a “Lender” under this Agreement, except in each case to the extent
such Lender is a direct or indirect assignee of any other Lender that was entitled, at the time the assignment of such other Lender
became effective, to receive additional amounts under Section 5.03, (d) any Taxes imposed in connection with FATCA, (e)
any Canadian federal withholding Taxes imposed on the payment as a result of having been made to a Recipient that, at the time
of making such payment, (i) is a person with which an Obligor does not deal at arm’s length (for the purposes of the Income
Tax Act (Canada)), or (ii) is a “specified shareholder” (as defined in subsection 18(5) of the Income Tax Act
(Canada)) of an Obligor or does not deal at arm’s length (for the purposes of the Income Tax Act (Canada)) with
such a “specified shareholder” (other than where the non-arm’s length relationship arises, or where the Recipient
is a “specified shareholder” or does not deal at arm’s length with a “specified shareholder”, in
connection with or as a result of the Recipient having become a party to, received or perfected a security interest under or received
or enforced any rights under, a Loan Document), and (f) Taxes attributable to such Recipient’s failure to comply with Section
5.03(e).

 

“FATCA” means Sections
1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable
and not more onerous to comply with), any regulations or official interpretations thereof and any agreements entered into pursuant
to Section 1471(b)(1) of the Code.

 

“Federal Funds Effective Rate”
means, for any day, the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve
System arranged by federal funds brokers, as published on the next succeeding Business Day by the Federal Reserve Bank of New York,
or, if such rate is not so published for any day that is a Business Day, the average of the quotations for the day of such transactions
received by Administrative Agent from three federal funds brokers of recognized standing selected by it.

 

    	 	9	 

     

    

 

“Fee Letter” means
the second amended and restated fee letter agreement dated as of the date hereof between Borrower and Administrative Agent.

 

“First Amendment”
means the First Amending Agreement to the First A&R Agreement dated as of March 27, 2018.

 

“First A&R Agreement”
has the meaning set forth in the introduction hereto.

 

“First Restatement Date” means May 11, 2017.

 

“Foreign Lender” means
a Lender that is not a U.S. Person.

 

“Foreign Subsidiary”
means a Subsidiary of Borrower that is not a Domestic Subsidiary.

 

“Fourth Borrowing Milestone” has the
meaning set forth in Section 6.04(c).

 

“French Security Documents”
has the meaning given to such term in Section 12.14.

 

“French Subsidiary Guarantor”
means any Subsidiary Guarantor incorporated or established in France.

 

“GAAP” means generally
accepted accounting principles in the United States of America, as in effect from time to time, set forth in the opinions and pronouncements
of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements
of the Financial Accounting Standards Board and in such other statements by such other entity as may be in general use by significant
segments of the accounting profession that are applicable to the circumstances as of the date of determination. Subject to Section
1.02, all references to “GAAP” shall be to GAAP applied consistently with the principles used in the preparation
of the financial statements described in Section 7.04(a).

 

“German Account Pledge Agreements”
means (i) the German law governed account Pledge Agreement dated as of the date of the Original Agreement and (ii) the German law
governed confirmation and junior ranking account pledge agreement dated on or around the date of this Agreement, in each case entered
into between, among others, Correvio GmbH as pledgor and the Administrative Agent.

 

“German Confirmation Agreement
– First Restatement” means the German law governed confirmation agreement dated on or around the First Restatement
Date and relating to (i) the German Security Assignment Agreement and (ii) the German Security Trust Agreement.

 

“German Confirmation
Agreement – Second Restatement” means the German law governed confirmation agreement dated on or around the
Closing Date and relating to (i) the German Security Assignment Agreement and (ii) the German Security Trust Agreement.

 

“German Security Documents”
means the German Share Pledge Agreements, the German Security Assignment Agreement, the German Account Pledge Agreements, the German
Confirmation Agreement – First Restatement, the German Confirmation Agreement – Second Restatement and any other agreement
governed by German law that creates or purports to create security and that is entered into by a German Obligor pursuant to this
Agreement.

 

    	 	10	 

     

    

 

“German Security Assignment Agreement”
means the German law governed security assignment agreement dated the date of the Original Agreement entered into between, among
others, Correvio GmbH as assignor and the Administrative Agent as collateral agent (as such agreement may be amended, restated,
replaced, supplemented or otherwise modified from time to time).

 

“German Security Trust Agreement”
means the German law governed security trust agreement dated the date of the Original Agreement entered into between, among others,
Correvio GmbH and Correvio International Sàrl as security grantors and the Administrative Agent, under which the Administrative
Agent has been granted certain rights and has assumed certain obligations in relation to the German Security Documents (as such
agreement may be amended, restated, replaced, supplemented or otherwise modified from time to time).

 

“German Share Pledge Agreements”
means (i) the German law governed share pledge agreement dated the date of the Original Agreement and (ii) the German law governed
junior ranking share pledge agreement dated on or around the First Restatement Date, in each case entered into between, among others,
Correvio International Sàrl as pledgor and the Administrative Agent.

 

“Governmental Approval”
means any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing
or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.

 

“Governmental Authority”
means any nation, government, branch of power (whether executive, legislative or judicial), state, province, territory or municipality
or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative
functions of or pertaining to government, including without limitation regulatory authorities, governmental departments, agencies,
commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law-, rule-
or regulation-making organizations or entities of any state, province, territory, county, city or other political subdivision of
the United States or Canada.

 

“Guarantee” of
or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the guarantor
guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the
“primary obligor”) in any manner, whether directly or indirectly, and including any obligation of
the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such
Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the
payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such
Indebtedness or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other
financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such
Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued
to support such Indebtedness or obligation; provided, that the term Guarantee shall not include endorsements for collection
or deposit in the ordinary course of business.

 

“Guarantee Assumption Agreement”
means a Guarantee Assumption Agreement substantially in the form of Exhibit A by an entity that, pursuant to Section
8.12(a), is required to become a “Subsidiary Guarantor” hereunder.

 

    	 	11	 

     

    

 

“Guaranteed Obligations”
has the meaning set forth in Section 14.01.

 

“Hazardous Material”
means any substance, element, chemical, compound, product, solid, gas, liquid, waste, by- product, pollutant, contaminant or material
which is hazardous or toxic, and includes, without limitation, (a) asbestos, polychlorinated biphenyls and petroleum (including
crude oil or any fraction thereof) and (b) any material classified or regulated as “hazardous” or “toxic”
or words of like import pursuant to an Environmental Law.

 

“Hedging Agreement”
means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other
interest or currency exchange rate or commodity price hedging arrangement.

 

“Indebtedness” of
any Person means, without duplication, (a) all obligations of such Person for borrowed money or obligations of such Person with
respect to deposits or advances of any kind by third parties, (b) all obligations of such Person evidenced by bonds, debentures,
notes or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid, (d) all obligations
of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all
obligations of such Person in respect of the deferred purchase price of property or services (excluding current accounts payable
incurred in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness
has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether
or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h) all
Capital Lease Obligations of such Person, (i) all obligations, contingent or otherwise, of such Person as an account party in respect
of letters of credit and letters of guaranty, (j) obligations under any Hedging Agreement, currency swaps, forwards, futures or
derivatives transactions, (k) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances,
(l) all obligations of such Person under license or other agreements containing a guaranteed minimum payment or purchase by such
Person, and (m) all Equity Interests of such Person subject to repurchase or redemption rights or obligations (excluding repurchases
or redemptions at the sole option of such Person). The Indebtedness of any Person shall include the Indebtedness of any other entity
(including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result
of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness
provide that such Person is not liable therefor.

 

“Indemnified Party”
has the meaning set forth in Section 13.03(b).

 

“Indemnified Taxes”
means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any Obligation and
(b) to the extent not otherwise described in clause (a), Other Taxes.

 

“Insolvency Proceeding”
means (a) any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy, reorganization,
insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, including any proceeding under applicable
Canadian federal or provincial corporate law seeking an arrangement or compromise of some or all of the debts of a Person or a
stay of proceedings to enforce some or all claims of creditors against a Person, or (b) any general assignment for the benefit
of creditors, composition, marshaling of assets for creditors, or other, similar arrangement in respect of any Person’s creditors
generally or any substantial portion of such Person’s creditors, in each case undertaken under Canadian federal law, Canadian
provincial or territorial law, United States federal law, U.S. state law, or foreign law, including the Bankruptcy Code and the
Canadian Insolvency Legislation.

 

    	 	12	 

     

    

 

“Intellectual Property”
means all Patents, Trademarks, Copyrights, and Technical Information, whether registered or not, domestic and foreign. Intellectual
Property shall include all:

 

(a)          applications
or registrations relating to such Intellectual Property;

 

(b)          rights
and privileges arising under applicable Laws with respect to such Intellectual Property;

 

(c)          rights
to sue for past, present or future infringements of such Intellectual Property; and

 

(d)          rights
of the same or similar effect or nature in any jurisdiction corresponding to such Intellectual Property throughout the world.

 

“Interest-Only Period”
means the period from and including the first Borrowing Date and through and including the sixteenth (16th)
Payment Date following the first Borrowing Date unless the “Interest-Only Period” has been extended in accordance with
Section 3.02(e).

 

“Interest Period”
means, with respect to each Borrowing, (a) initially, the period commencing on and including the Borrowing Date thereof and ending
on and excluding the next Payment Date, and, (b) thereafter, each period beginning on and including the last day of the immediately
preceding Interest Period and ending on and excluding the next succeeding Payment Date.

 

“Invention” means
any novel, inventive and useful art, apparatus, method, process, machine (including article or device), manufacture or composition
of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device),
manufacture or composition of matter.

 

“Investment” means,
for any Person: (a) the acquisition (whether for cash, property, services or securities or otherwise) of capital stock, bonds,
notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any
such acquisition (including any “short sale” or any sale of any securities at a time when such securities are not owned
by the Person entering into such sale); (b) the making of any deposit with, or advance, loan or other extension of credit to, any
other Person (including the purchase of property from another Person subject to an understanding or agreement, contingent or otherwise,
to resell such property to such Person), but excluding any such advance, loan or extension of credit having a term not exceeding
90 days arising in connection with the sale of inventory or supplies by such Person in the ordinary course of business; (c) the
entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any other
Person and (without duplication) any amount committed to be advanced, lent or extended to such Person; or (d) the entering into
of any Hedging Agreement.

 

    	 	13	 

     

    

 

“IRS” means the U.S.
Internal Revenue Service or any successor agency, and to the extent relevant, the U.S. Department of the Treasury.

 

“Italian Account”
means an account, with a balance not to exceed $2,000,000 at any time, that is used as collateral against which Credit Suisse issues
bid and performance bonds to Italian government regions for tenders of the Products.

 

“Italian Civil Code”
means the Italian civil code, enacted by Royal Decree No. 262 of 16 March 1942, as subsequently amended and supplemented.

 

“Knowledge” means,
with respect to any Person, the actual knowledge of any Responsible Officer of such Person and, in the case of Borrower, so long
as he or she is employed by Borrower or its Subsidiaries, the actual knowledge of the chief executive officer or the chief financial
officer, so long as such Person is an officer of Borrower.

 

“Landlord Consent”
means a Landlord Consent substantially in the form of Exhibit F.

 

“Laws” means, collectively,
all international, foreign, federal, state, provincial, territorial, municipal and local statutes, treaties, rules, guidelines,
regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration
thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable
administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental
Authority, in each case whether or not having the force of law.

 

“Lender” means each
Person listed as a “Lender” on a signature page hereto, together with its successors, and each assignee of a Lender
pursuant to Section 13.05(b).

 

“Lien” means any
mortgage, lien, hypothec, pledge, charge, assignment or other security interest, or any lease, title retention agreement, mortgage,
restriction, easement, right-of-way, option or adverse claim (of ownership or possession) or other encumbrance of any kind or
character whatsoever or any preferential arrangement that has the practical effect of creating a security interest.

 

“Liquidity” means
the balance of unencumbered (other than by Liens securing the Obligations) cash and Permitted Cash Equivalent Investments (which
for greater certainty shall not include any undrawn credit lines), in each case, to the extent held in an account over which the
Secured Parties have a first priority perfected security interest and have received an executed deposit account control agreement,
blocked account agreement or similar agreement, in form and substance satisfactory to the Administrative Agent, with respect to
each such account.

 

“Loan” means (a) each
loan advanced by a Lender pursuant to Section 2.01 and (b) each PIK Loan deemed to have been advanced by a Lender pursuant
to Section 3.02(d). For purposes of clarification, any calculation of the aggregate outstanding principal amount of Loans on any
date of determination shall include both the aggregate principal amount of loans advanced pursuant to Section 2.01 and not
yet repaid, and all PIK Loans deemed to have been advanced and not yet repaid, on or prior to such date of determination.

 

    	 	14	 

     

    

 

“Loan Documents” means,
collectively, this Agreement, the Fee Letter, the Assignment Agreement, the Security Documents, each Warrant, the English Guarantee,
the German Security Trust Agreement, the Swiss Share Pledge Transfer Agreement, any other subordination agreement or any intercreditor
agreement entered into by Administrative Agent (on behalf of the Lenders) with any other creditors of Obligors or any agent acting
on behalf of such creditors, and any other present or future document, instrument, agreement or certificate executed by Obligors
and delivered to Administrative Agent or any Secured Party in connection with or pursuant to this Agreement or any of the other
Loan Documents, all as amended, restated, supplemented or otherwise modified.

 

“Loss” means judgments,
debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or
unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees
and disbursements of legal counsel on a full indemnity basis, and all costs incurred in investigating or pursuing any Claim or
any proceeding relating to any Claim.

 

“Majority Lenders”
means, at any time, Lenders having at such time in excess of 50% of the aggregate Commitments (or, if such Commitments are terminated,
the outstanding principal amount of the Loans) then in effect, ignoring, in such calculation, the Commitments of and outstanding
Loans owing to any Defaulting Lender.

 

“Margin Stock” means
“margin stock” within the meaning of Regulation U.

 

“Market
Capitalization” means, as of the date of determination, the product of (a) the sum of (i) the number of shares
of Borrower’s common shares outstanding as of such date of determination and (ii) the number of shares (not included in
clause (i)) of Borrower’s common shares that would be outstanding if all outstanding in-the-money stock options,
warrants and convertible securities were exercised for, or converted into, as applicable, common shares and (b) the closing
price of Borrower’s common shares on the Toronto Stock Exchange on such date of determination.

 

“Material Adverse Change”
and “Material Adverse Effect” mean a material adverse change in or effect on (a) the business, condition
(financial or otherwise), operations, performance, Property or prospects of Borrower and the other Obligors taken as a whole, (b)
the ability of any Obligor to perform its obligations under the Loan Documents, or (c) the legality, validity, binding effect or
enforceability of the Loan Documents or the rights and remedies of Administrative Agent or any Lender under any of the Loan Documents.

 

“Material Agreements”
means (a) the agreements which are listed in Schedule 7.14 (as updated by Borrower from time to time in accordance with
Section 8.16 to list all such agreements that meet the description set forth in clause (b) of this definition) and (b) all
other agreements held by the Obligors from time to time, the absence or termination of any of which would reasonably be expected
to result in a Material Adverse Effect; provided, however, that “Material Agreements” exclude all: (i) licenses
implied by the sale of a product; and (ii) paid-up licenses for commonly available software programs under which an Obligor is
the licensee. “Material Agreement” means any one such agreement.

 

    	 	15	 

     

    

 

“Material Indebtedness”
means, at any time, any Indebtedness of any Obligor, the outstanding principal amount of which, individually or in the aggregate,
exceeds $500,000 (or the Equivalent Amount in other currencies).

 

“Material Intellectual Property”
means, the Obligor Intellectual Property described in Schedule 7.05(c) and any other Obligor Intellectual Property after
the date hereof the loss of which could reasonably be expected to have a Material Adverse Effect.

 

“Maturity Date” means
the earlier to occur of (a) the Stated Maturity Date, and (b) the date on which the Loans are accelerated pursuant to Section
11.02.

 

“Maximum Rate” has
the meaning set forth in Section 13.18(a).

 

“MidCap” means MidCap Financial
Trust.

 

“Minimum Required Revenue”
has the meaning set forth in Section in 10.02.

 

“Multiemployer Plan”
means any multiemployer plan, as defined in Section 400l(a)(3) of ERISA, to which any ERISA Affiliate incurs or otherwise has any
obligation or liability, contingent or otherwise.

 

“Murk Stock and Asset Purchase Agreement”
means the stock and asset purchase agreement dated as of November 18, 2013 between the Original Borrower (and subsequently assigned
to the Borrower), Cardiome International SA, Murk Acquisition Sub, Inc., Correvio LLC and CarCor Investment Holdings LLC.

 

“Non-Consenting Lender”
has the meaning set forth in Section 2.06(a).

 

“Non-Disclosure Agreement”
has the meaning set forth in Section 13.16.

 

“Non-Qualifying Bank Creditor Rules”
means the 10-Non-Qualifying Bank Creditor Rule and the 20-Non-Qualifying Bank Creditor Rule.

 

“Notice of Borrowing”
has the meaning set forth in Section 2.02.

 

“Obligations”
means, with respect to any Obligor, all amounts, obligations, liabilities, covenants and duties of every type and description
owing by such Obligor to any Lender, any other indemnitee hereunder or any participant, arising out of, under, or in
connection with, any Loan Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or
contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and
whether or not evidenced by any instrument or for the payment of money, including, without duplication, (a) if such Obligor
is Borrower, all Loans, (b) all interest, whether or not accruing after the filing of any petition in bankruptcy or after the
commencement of any insolvency, reorganization or similar proceeding, and whether or not a claim for post-filing or
post-petition interest is allowed in any such proceeding, and (c) all other fees, expenses (including fees, charges and
disbursement of counsel), interest, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid
and other sums chargeable to such Obligor under any Loan Document.

 

    	 	16	 

     

    

 

“Obligor Intellectual Property”
means Intellectual Property owned by or licensed to any of the Obligors other than immaterial Intellectual Property owned by any
Obligor in a jurisdiction which such Obligor does not have assets or revenue with a fair market value greater than $1,000,000 in
aggregate.

 

“Obligors” means,
collectively, Borrower and the Subsidiary Guarantors and their respective successors and permitted assigns.

 

“Original Agreement”
has the meaning set forth in the introduction hereto.

 

“Original Borrower”
has the meaning set forth in the introduction hereto.

 

“Original Closing Date”
means June 13, 2016.

 

“Other Connection Taxes”
means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the
jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to,
performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other
transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).

 

“Other Taxes” means
all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made
under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security
interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed
with respect to an assignment (other than an assignment made pursuant to Section 5.03(g)).

 

“Participant” has
the meaning set forth in Section 13.05(e).

 

“Patents” has the
meaning set forth in the Canadian Security Agreement.

 

“Payment Date” means
each March 31, June 30, September 30, December 31 and the Maturity Date, commencing on the first such date to occur following the
first Borrowing Date; provided that, if any such date shall occur on a day that is not a Business Day, the applicable Payment
Date shall be the immediately preceding Business Day.

 

“PBGC” means the United
States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions.

 

“Permitted
Acquisition” means any acquisition by Borrower or any of its wholly-owned Subsidiaries, whether by purchase, merger,
amalgamation or otherwise, of all or substantially all of the assets of, all of the Equity Interests of, or a business line or
unit or a division of, any Person; provided that:

 

(a)          immediately prior to, and after giving effect
thereto, no Default or Event of Default shall have occurred and be continuing or would result therefrom;

 

    	 	17	 

     

    

 

(b)          all transactions in
connection therewith shall be consummated, in all material respects, in accordance with all applicable Laws and in conformity with
all applicable Governmental Approvals;

 

(c)          in the case of the
acquisition of all of the Equity Interests of such Person, all of the Equity Interests acquired, or otherwise issued by such Person
or any newly formed Subsidiary of Borrower in connection with such acquisition, shall be owned 100% by an Obligor or any other
Subsidiary, and Borrower shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of Borrower,
each of the actions set forth in Section 8.12, if applicable;

 

(d)          Borrower and its Subsidiaries
shall be in compliance with the financial covenants set forth in Section 10.01 and Section 10.02 on a pro forma
basis after giving effect to such acquisition;

 

(e)          such Person (in the
case of an acquisition of Equity Interests) or assets (in the case of an acquisition of assets or a division) (i) shall be engaged
or used, as the case may be, in the same business or lines of business in which Borrower and/or its Subsidiaries are engaged or
(ii) shall have a similar customer base as Borrower and/or its Subsidiaries; and

 

(f)           such Person has not
at any time in the past or present established or been associated with any Canadian Pension Plans or any Canadian Benefit Plans.

 

“Permitted
Cash Equivalent Investments” means investments made in accordance with the Borrower’s investment policy in
existence as of the date of this Agreement provided that all such investments remain liquid at all times.

 

“Permitted Credit Card Indebtedness”
means all Indebtedness owing by the Obligors in respect of Visa, Mastercard or other credit or charge card.

 

“Permitted Cure Debt”
means Indebtedness incurred in connection with the exercise of the Subordinated Debt Cure Right and (a) that is governed by documentation
containing representations, warranties, covenants and events of default no more burdensome or restrictive than those contained
in the Loan Documents, (b) that has a maturity date at least six (6) months later than the Maturity Date, (c) in respect of which
no cash payments of principal or interest are required prior to the Maturity Date, and (d) in respect of which the holders have
agreed in favor of Borrower, Administrative Agent and Lenders (i) that prior to the date on which the Commitments have expired
or been terminated and all Obligations have been paid in full indefeasibly in cash, such holders will not exercise any remedies
available to them in respect of such Indebtedness, (ii) that such Indebtedness is unsecured, and (iii) to terms of subordination
in an agreement in form and substance satisfactory to the Majority Lenders.

 

“Permitted Indebtedness”
means any Indebtedness permitted under Section 9.01.

 

“Permitted Liens”
means any Liens permitted under Section 9.02.

 

    	 	18	 

     

    

 

“Permitted
Priority Liens” means (a) Liens permitted under Section 9.02(c), (d), (f), (g), (h), (i), (l), (m) and (o),
and (b) Liens permitted under Section 9.02(b) provided that such Liens are also of the type described in Section 9.02(c),
(d), (f), (g), (h), (i), (l), (m) and (o).

 

“Permitted Refinancing”
means, with respect to any Indebtedness, any extensions, renewals and replacements of such Indebtedness; provided that such
extension, renewal or replacement (a) shall not increase the outstanding principal amount of such Indebtedness, (b) contains terms
relating to outstanding principal amount, amortization, maturity, collateral (if any) and subordination (if any), and other material
terms taken as a whole no less favorable in any material respect to Borrower and its Subsidiaries or the Secured Parties than the
terms of any agreement or instrument governing such existing Indebtedness, (c) shall have an applicable interest rate which does
not exceed the rate of interest of the Indebtedness being replaced, and (d) shall not contain any
new requirement to grant any lien or security or to give any guarantee that was not an existing requirement of such Indebtedness.

 

“Person” means any
individual, corporation, company, voluntary association, partnership, limited liability company, unlimited liability company, joint
venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature.

 

“PIK Loan” has the
meaning set forth in Section 3.02(d).

 

“PIK Period” means
the period beginning on the First Restatement Date through and including the earlier to occur of (a) March 31, 2020, and (b) the
date on which any Default shall have occurred (provided that if such Default shall have been cured or waived, the PIK Period
shall resume until the earlier to occur of the next Default and March 31, 2020); provided, however, that upon the Borrower achieving
the Revenue Milestone the PIK Period shall be extended to the Maturity Date.

 

“Plan” means any employee
pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code
or Section 302 of ERISA, and in respect of which Borrower or any ERISA Affiliate is (or, if such plan were terminated, would under
Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA.

 

“PPSA” shall mean
the Personal Property Security Act (Ontario), the Civil Code of Québec or any other applicable Canadian federal,
provincial or territorial statute pertaining to the granting, perfecting, priority or ranking of security interests, liens, hypothecs
on personal property, and any successor statues, together with any regulations thereunder or Ministerial orders in respect thereof,
in each case as in effect from time to time. References to sections of the PPSA and the Civil Code of Québec shall
be construed to also refer to any successor sections.

 

“Prepayment Premium”
has the meaning set forth in Section 3.03(a).

 

“Product” means Aggrastat,
Brinavess, Esmolol, Trevyent, Dalbavancin, Impavido and other products to be acquired or in-licensed, and each of their respective
successors.

 

“Property” of any
Person means any property or assets, or interest therein, of such Person.

 

    	 	19	 

     

    

 

“Proportionate Share”
means, with respect to any Lender, the percentage obtained by dividing (a) the sum of the Commitment (or, if the Commitments are
terminated, the outstanding principal amount of the Loans) of such Lender then in effect by (b) the sum of the Commitments (or,
if the Commitments are terminated, the outstanding principal amount of the Loans) of all Lenders then in effect.

 

“Qualified Plan” means
an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (a) that is or was at any time maintained
or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has ever made,
or was ever obligated to make, contributions, and (b) that is intended to be tax qualified under Section 401(a) of the Code.

 

“Qualifying Bank Creditor”
means any entity which effectively conducts true banking activities as its principal purpose with its own infrastructure and staff,
premises, communication devices of its own and the authority of decision making, and which is recognised as a bank by the banking
laws in force in the jurisdiction of its incorporation.

 

“Recipient” means
Administrative Agent, any Lender or any other recipient of any payment to be made by or on account of any Obligation.

 

“Redemption Date”
has the meaning set forth in Section 3.03(a).

 

“Redemption Price”
has the meaning set forth in Section 3.03(a).

 

“Register” has the
meaning set forth in Section 13.05(d).

 

“Regulation T” means
Regulation T of the Board of Governors of the Federal Reserve System, as amended.

 

“Regulation U” means
Regulation U of the Board of Governors of the Federal Reserve System, as amended.

 

“Regulation X” means
Regulation X of the Board of Governors of the Federal Reserve System, as amended.

 

“Regulatory Approvals”
means any registrations, licenses, authorizations, permits or approvals issued by any Governmental Authority and applications or
submissions related to any of the foregoing.

 

“Related Person” means,
with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees,
administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates.

 

“Requirement of Law”
means, as to any Person, any statute, law, treaty, rule or regulation or determination, order, injunction or judgment of an arbitrator
or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its Properties or
revenues.

 

“Responsible Officer”
of any Person means each of the president, chief executive officer, and chief financial officer of such Person.

 

    	 	20	 

     

    

 

“Restricted Payment”
means any dividend or other distribution (whether in cash, securities or other property) with respect to any Equity Interest of
Borrower or any of its Subsidiaries, or any payment (whether in cash, securities or other property), including any sinking fund
or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such shares
of capital stock of Borrower or any of its Subsidiaries or any option, warrant or other right to acquire any such shares of capital
stock of Borrower or any of its Subsidiaries.

 

“Restrictive Agreement”
has the meaning set forth in Section 7.15.

 

“Revenue” of a Person
means all revenue properly recognized under GAAP, consistently applied, less all rebates, discounts and other price allowances.

 

“Revenue Milestone”
has the meaning set forth in Section 3.2(d).

 

“Secured Parties”
means the Lenders, Administrative Agent, each other Indemnified Party and any other holder of any Obligation.

 

“Security Documents”
means, collectively, the Canadian Security Documents, the U.S. Security Documents, the English Security Documents, the French Security
Documents, the German Security Documents, the Swiss Security Documents and each other security document, control agreement or other
agreement that creates or purports to create Liens in favor of the Secured Parties, as such agreements may be amended, restated,
replaced, supplemented or otherwise modified from time to time.

 

“Securities Account”
has the meaning set forth in the Canadian Security Agreement.

 

“Series A Shares”
has the meaning given to such term in the Borrower’s articles of amalgamation.

 

“Short-Form IP Security Agreements”
means the Canadian Short-Form IP Security Agreements and the U.S. Short-Form IP Security Agreements.

 

“Solvent” means, with
respect to any Person at any time, that (a) the fair saleable value of the Property of such Person is greater than the total amount
of liabilities (including contingent liabilities) of such Person, (b) the present fair saleable value of the Property of such Person
is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute
and matured, (c) such Person has not incurred and does not intend to, and does not believe that it will, incur debts or liabilities
beyond such Person’s ability to pay as such debts and liabilities mature, and (d) such Person is not an “insolvent
person” within the meaning of the Bankruptcy and Insolvency Act (Canada).

 

“Specified Financial Covenants”
has the meaning set forth in Section 10.03(a).

 

“Stated Maturity Date”
means the twenty-fourth (24th) Payment Date following the first Borrowing Date.

 

“Subordinated Debt Cure Right”
has the meaning set forth in Section 10.03(a).

 

    	 	21	 

     

    

 

“Subsidiary” means,
with respect to any Person (the “parent ”) at any date, any corporation, limited liability company, unlimited
liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent
in the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of
such date, as well as any other corporation, limited liability company, unlimited liability company, partnership, association or
other entity (a) of which securities or other ownership interests representing more than 50% of the equity or more than 50% of
the ordinary voting power or, in the case of a partnership, more than 50% of the general partnership interests are, as of such
date, owned, controlled or held, or (b) that is, as of such date, otherwise Controlled, by the parent or one or more subsidiaries
of the parent or by the parent and one or more subsidiaries of the parent.

 

“Subsidiary Guarantors”
means each of the Subsidiaries of Borrower identified under the caption “SUBSIDIARY GUARANTORS” on the signature pages
hereto and each Subsidiary of Borrower that becomes a “Subsidiary Guarantor” after the date hereof pursuant to Section
8.12(a) or (b) after having satisfied the requirements of such Sections, as applicable.

 

“Substitute Lender”
has the meaning set forth in Section 2.06(a).

 

“Swiss Federal Tax Administration”
means the Swiss Federal tax administration (Eidgenössische Steuerverwaltung).

 

“Swiss Guarantor”
means any of Cardiome International SA, Correvio International Sàrl and each other Subsidiary Guarantor party hereto, from
time to time, organized under the laws of Switzerland.

 

“Swiss Share Pledge Transfer Agreement”
has the meaning set forth in Section 6.06(iv)(D).

 

“Swiss Security Documents”
means collectively, (a) security agreements executed by each of the Swiss Guarantors in favor of the Administrative Agent on behalf
of the Secured Parties creating a first ranking security interest over certain of the Swiss Guarantor’s present and future
(i) bank account claims, (ii) intellectual property rights and royalty claims, and (iii) trade, intra-group and insurance receivables;
(b) share/quota pledge agreements executed by all of the shareholders or each of the Swiss Guarantors in favor of the Administrative
Agent on behalf of the Secured Parties creating a first ranking security interest over all of the shares/quota in the capital of
each of the Swiss Guarantors; and (c) any other agreement that creates or purports to create security and that is entered into
by a Swiss Guarantor, all governed by the laws of Switzerland (as any such agreement may be amended, restated, replaced, supplemented
or otherwise modified from time to time).

 

“Swiss Witholding Tax”
means any withholding tax imposed under the Swiss Withholding Tax Act.

 

“Swiss Withholding
Tax Act ” means the Swiss Federal Act on Anticipatory Tax of October 13, 1965 (Bundesgesetz über die Verrechnungssteuer)
with related regulations and guidelines, all as amended and applicable from time to time.

 

    	 	22	 

     

    

 

“Taxes” means all
present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or
other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Technical Information”
means all trade secrets and other proprietary or confidential information, public information, non-proprietary know-how, any information
of a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations,
discoveries, Invention disclosures, all documented research, developmental, demonstration or engineering work and all other information,
data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, know-how, technical information,
systems, methodologies, computer programs, information technology and any other information.

 

“Third Borrowing Milestone”
has the meaning set forth in Section 6.03(c).

 

“Title IV Plan” means
an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was within the past
six (6) years maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate
thereof is or was obligated to make within the past six (6) years, contributions, and (ii) that is or was subject to Section 412
of the Code, Section 302 of ERISA or Title IV of ERISA.

 

“Trademarks” is defined
in the Canadian Security Agreement.

 

“Transactions”
means the execution, delivery and performance by each Obligor of this Agreement and the other Loan Documents to which such Obligor
is intended to be a party and the Borrowings (and the use of the proceeds of the Loans).

 

“U.S. Person” means
a “United States Person” within the meaning of Section 7701(a)(30) of the Code.

 

“U.S. Security Agreement”
means the Amended and Restated U.S. Security Agreement, dated as of the Closing Date, among Cardiome, Inc., Artesian Therapeutics,
Inc., Murk Acquisition Sub, Inc., Correvio LLC, the Borrower and Administrative Agent, granting a security interest in each of
such Obligor’s personal Property in favor of the Secured Parties (as such agreement may be amended, restated, replaced, supplemented
or otherwise modified from time to time).

 

“U.S. Security Documents”
means the U.S. Security Agreement, each U.S. Short-Form IP Security Agreement and any other agreement governed by U.S. law that
creates or purports to create security and that is entered into by a U.S. Obligor pursuant to this Agreement.

 

“U.S. Short-Form IP Security Agreement”
means the amended and restated (if applicable) short-form copyright, patent or trademark (as the case may be) security agreements
governed by the laws of any state or political subdivision of the United States of America, dated as of the Original Closing Date
or the Closing Date, as the case may be, entered into by one or more Obligors in favor of the Secured Parties, each in form and
substance satisfactory to the Majority Lenders (as such agreement may be amended, restated, replaced, supplemented or otherwise
modified from time to time)).

 

    	 	23	 

     

    

 

“U.S. Tax Compliance Certificate”
has the meaning set forth in Section 5.03(e)(ii)(B)(3).

 

“Warrants” means the
warrants to purchase Equity Interests of Borrower, issued by Borrower to the Lender as to replace the warrants previously issued
by the Original Borrower as an inducement for the Lenders to agree to the amendments to the Original Agreement and to the First
Amendment.

 

“Withdrawal Liability”
means, at any time, any liability incurred (whether or not assessed) by any ERISA Affiliate and not yet satisfied or paid in full
at such time with respect to any Multiemployer Plan pursuant to Section 4201 of ERISA.

 

1.02       Accounting
Terms and Principles. All accounting determinations required to be made pursuant hereto shall, unless expressly otherwise provided
herein, be made in accordance with GAAP. All components of financial calculations made to determine compliance with this Agreement,
including Section 10, shall be adjusted to include or exclude, as the case may be, without duplication, such components
of such calculations attributable to any Acquisition consummated after the first day of the applicable period of determination
and prior to the end of such period, as determined in good faith by Borrower based on assumptions expressed therein and that were
reasonable based on the information available to Borrower at the time of preparation of the Compliance Certificate setting forth
such calculations.

 

1.03       Interpretation.
For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires,
(a) the terms defined in this Agreement include the plural as well as the singular and vice versa; (b) words importing gender include
all genders; (c) any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to,
this Agreement; (d) any reference to “this Agreement” refers to this Agreement, including all Annexes, Schedules and
Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its
Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision;
(e) references to days, months and years refer to calendar days, months and years, respectively; (f) all references herein to “include”
or “including” shall be deemed to be followed by the words “without limitation”; (g) the word “from”
when used in connection with a period of time means “from and including” and the word “until” means “to
but not including”; and (h) accounting terms not specifically defined herein shall be construed in accordance with GAAP (except
for the term “property” , which shall be interpreted as broadly as possible, including, in any case, cash, securities,
other assets, rights under contractual obligations and permits and any right or interest in any property, except where otherwise
noted). Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents)
and other contractual instruments shall be deemed to include all permitted subsequent amendments, restatements, extensions, supplements
and other modifications thereto.

 

    	 	24	 

     

    

 

1.04       Quebec
Interpretation Clause. For purposes of any assets, liabilities or entities located in the Province of Québec and for
all other purposes pursuant to which the interpretation or construction of this Agreement may be subject to the laws of the Province
of Québec or a court or tribunal exercising jurisdiction in the Province of Québec, (i) “personal property”
shall be deemed to include “movable property”, (ii) “real property” shall be deemed to include “immovable
property”, (iii) “tangible property” shall be deemed to include “corporeal property”, (iv) “intangible
property” shall be deemed to include “incorporeal property”, (v) “security interest”, “mortgage”
and “lien” shall be deemed to include a “hypothec”, “prior claim”, “reservation of ownership”
and a “resolutory clause”, (vi) all references to filing, registering or recording under the Uniform Commercial Code
or the Personal Property Security Act shall be deemed to include publication under the Civil Code of Québec, (vii) all references
to “perfection” of or “perfected” liens or security interest shall be deemed to include a reference to
an “opposable” or “set up” hypothec as against third parties, (viii) any “right of offset”,
“right of setoff” or similar expression shall be deemed to include a “right of compensation”, (ix) “goods”
shall be deemed to include “corporeal movable property” other than chattel paper, documents of title, instruments,
money and securities, (x) an “agent” shall be deemed to include a “mandatary”, (xi) “construction
liens” shall be deemed to include “legal hypothecs in favour of persons having taken part in the construction or renovation
of an immovable”; (xii) “joint and several” shall be deemed to include “solidary”; (xiii) “gross
negligence or willful misconduct” shall be deemed to be “intentional or gross fault”; (xiv) “beneficial
ownership” shall be deemed to include “ownership”; (xv) “legal title” shall be deemed to include
“holding title on behalf of an owner as mandatary or prête-nom”; (xvi) “easement” shall be deemed
to include “servitude”; (xvii) “priority” shall be deemed to include “rank” or “prior
claim”, as applicable; (xviii) “survey” shall be deemed to include “certificate of location and plan”;
(xix) “state” shall be deemed to include “province”; (xx) “fee simple title” shall be deemed
to include “ownership” (including ownership under a right of superficies); (xi) “ground lease” shall be
deemed to include “emphyteusis” or a “lease with a right of superficies”, as applicable; (xii) “leasehold
interest” shall be deemed to include “a valid lease”; (xiii) “lease” shall be deemed to include a
“contract of leasing (crédit-bail)” and (xiv) “deposit account” shall include a “financial
account” as defined in Article 2713.6 of the Civil Code of Québec.

 

1.05       Changes
to GAAP. If, after the date hereof, any change occurs in GAAP or in the application thereof and such change would cause any
amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant to Section 8,
9 or 10 to be materially different than the amount that would be determined prior to such change, then:

 

(a)          Borrower
will provide a detailed notice of such change (an “Accounting Change Notice”) to Administrative Agent
within 30 days of such change;

 

(b)          either
Borrower or the Majority Lenders may indicate within 90 days following the date of the Accounting Change Notice that they wish
to revise the method of calculating such financial covenants or amend any such amount, in which case the parties will in good faith
attempt to agree upon a revised method for calculating the financial covenants;

 

(c)          until
Borrower and the Majority Lenders have reached agreement on such revisions, (i) such financial covenants or amounts will be determined
without giving effect to such change and (ii) all financial statements, Compliance Certificates and similar documents provided
hereunder shall be provided together with a reconciliation between the calculations and amounts set forth therein before and after
giving effect to such change in GAAP;

 

(d)          if
no party elects to revise the method of calculating the financial covenants or amounts, then the financial covenants or amounts
will not be revised and will be determined in accordance with GAAP without giving effect to such change; and

 

    	 	25	 

     

    

 

(e) any Event of Default arising as a result
of such change which is cured by operation of this Section 1.04 shall be deemed to be of no effect ab initio.

 

SECTION 2

THE COMMITMENT

 

2.01       Commitments.
Each Lender agrees severally, on and subject to the terms and conditions of this Agreement (including Section 6), to
make up to four term loans (provided that PIK Loans shall be deemed not to constitute “term loans” for purposes of
this Section 2.01) to Borrower, each on a Business Day during the Commitment Period in Dollars in an aggregate principal
amount for such Lender not to exceed such Lender’s Commitment; provided, however, that at no time shall any
Lender be obligated to make a Loan in excess of such Lender’s Proportionate Share of the amount by which the then effective
Commitments exceeds the aggregate principal amount of Loans outstanding at such time. Amounts of Loans repaid may not be reborrowed.

 

2.02       Borrowing
Procedures. Subject to the terms and conditions of this Agreement (including Section 6), each Borrowing (other than
a Borrowing of PIK Loans) shall be made on written notice in the form of Exhibit B given by Borrower to Administrative Agent
not later than 11:00 a.m. (Central time) on the Borrowing Notice Date (a “Notice of Borrowing”).

 

2.03       Fees.
Borrower shall pay to Administrative Agent and/or the Lenders, as applicable, such fees as described in the Fee Letter.

 

2.04       Use
of Proceeds.

 

(a)          Borrower
shall use the proceeds of the Loans for general working capital purposes and corporate purposes, to pay fees, costs and expenses
incurred in connection with the Transactions and, only with respect to the first Borrowing, to pay existing Indebtedness owing
to MidCap as set out in Section 6.01(g)(xiv), but in no event shall the proceeds of the Loans be deposited or held in any
account in which the Secured Parties do not have a first priority perfected security interest and in which the Administrative Agent
has not received an executed deposit account control agreement, blocked account agreement or similar agreement, in form and substance
satisfactory to the Administrative Agent; provided that the Lenders shall have no responsibility as to the use of any proceeds
of Loans.

 

(b)          Notwithstanding
the generality of Section 2.04(a) above:

 

(i)           the
Borrower shall be permitted to receive the proceeds of the Loans in an account domiciled in Canada opened on behalf of and for
the sole benefit of the Borrower despite such account not being subject to an executed deposit account control agreement, blocked
account agreement or similar agreement as of the date of this Agreement; provided that the Borrower shall provide the Administrative
Agent an executed deposit account control agreement, blocked account agreement or similar agreement, in form and substance satisfactory
to the Administrative Agent, in accordance with the terms of Schedule 8.17; and

 

(ii)          the
Borrower shall be permitted to provide proceeds of the Loans to deposit accounts held by and for the sole benefit of a Subsidiary
Guarantor despite such account not being subject to an executed deposit account control agreement, blocked account agreement or
similar agreement provided that at no time shall the aggregate account balance of all such accounts exceed $1,000,000.

 

    	 	26	 

     

    

 

(c)          No
proceeds of the Loans shall be, directly or indirectly, extended, on-lent or otherwise advanced to any Swiss Guarantor (not including
however a contribution of proceeds of the Loans into the equity of such Swiss Guarantor, which shall be permissible at all times)
until such Swiss Guarantor has delivered to the Administrative Agent an officer’s certificate certifying that such Swiss
Guarantor has obtained a confirmation (reasonably satisfactory as to content to the Administrative Agent) from the Swiss Federal
Tax Administration (a copy of such confirmation to be attached to the officer’s certificate) which either (i) confirms that
the entities that are a party to this Agreement as Lenders as of the date hereof are each eligible to qualify as one sole lender
for the purpose of the 10-Non-Qualifying Bank Creditor Rule or (ii) otherwise confirms that no Swiss Withholding Tax will be imposed
in respect of any payments of interest or in respect of any other payments related to the Loans.

 

2.05       Defaulting
Lenders.

 

(a)          Adjustments.
Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such
time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable law:

 

(i)           Waivers
and Amendments. Such Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect
to this Agreement shall be restricted as set forth in Section 13.04.

 

(ii)          Reallocation
of Payments. Any payment of principal, interest, fees or other amounts received by the Lenders for the account of such Defaulting
Lender (whether voluntary or mandatory, at maturity, pursuant to Section 11 or otherwise), shall be applied at such time
or times as follows: first, as Borrower may request (so long as no Default exists), to the funding of any Loan in respect of which
such Defaulting Lender has failed to fund its portion thereof as required by this Agreement; second, if so determined by the Majority
Lenders and Borrower, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of such
Defaulting Lender to fund Loans under this Agreement; third, to the payment of any amounts owing to the Lenders as a result of
any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of such Defaulting
Lender’s breach of its obligations under this Agreement; fourth, so long as no Default exists, to the payment of any amounts
owing to Borrower as a result of any judgment of a court of competent jurisdiction obtained by Borrower against such Defaulting
Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and fifth, to such Defaulting
Lender or as otherwise directed by a court of competent jurisdiction; provided that if (A) such payment is a payment of the principal
amount of any Loans in respect of which such Defaulting Lender has not fully funded its appropriate share and (B) such Loans were
made at a time when the conditions set forth in Section 6 were satisfied or waived, such payment shall be applied solely
to pay the Loans of all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of
such Defaulting Lender. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or
held) to pay amounts owed by a Defaulting Lender pursuant to this Section 2.05(a)(ii) shall be deemed paid to and redirected
by such Defaulting Lender, and each Lender irrevocably consents hereto.

 

    	 	27	 

     

    

 

(b)          Defaulting
Lender Cure. If Borrower and the Majority Lenders agree in writing in their sole discretion that a Defaulting Lender should
no longer be deemed to be a Defaulting Lender, that Lender will, to the extent applicable, purchase that portion of outstanding
Loans of the other Lenders or take such other actions as necessary to cause the Loans to be held on a pro rata basis by
the Lenders in accordance with their Proportionate Share, whereupon that Lender will cease to be a Defaulting Lender; provided
that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of Borrower while
that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected
parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder
arising from that Lender’s having been a Defaulting Lender.

 

2.06       Substitution
of Lenders.

 

(a)          Substitution
Right. If any Lender (an “Affected Lender”), (i) becomes a Defaulting Lender or (ii) does not consent
to any amendment, waiver or consent to any Loan Document for which the consent of the Majority Lenders is obtained but that requires
the consent of other Lenders (a “Non-Consenting Lender”), then (x) Borrower may elect to pay in full
such Affected Lender with respect to all Obligations due to such Affected Lender or (y) either Borrower or Administrative Agent
shall identify any willing Lender or Affiliate of any Lender or Eligible Transferee (in each case, a “Substitute Lender”)
to substitute for such Affected Lender; provided that any substitution of a Non-Consenting Lender shall occur only with
the consent of Administrative Agent.

 

(b)          Procedure.
To substitute such Affected Lender or pay in full all Obligations owed to such Affected Lender, Borrower shall deliver a notice
to such Affected Lender. The effectiveness of such payment or substitution shall be subject to the delivery by Borrower (or, as
may be applicable in the case of a substitution, by the Substitute Lender) of (i) payment for the account of such Affected Lender,
of, to the extent accrued through, and outstanding on, the effective date for such payment or substitution, all Obligations owing
to such Affected Lender (which for the avoidance of doubt, shall not include any Prepayment Premium) and (ii) in the case of a
substitution, an Assignment and Assumption executed by the Substitute Lender, which shall thereunder, among other things, agree
to be bound by the terms of the Loan Documents.

 

(c)          Effectiveness.
Upon satisfaction of the conditions set forth in Sections 2.06(a) and (b), Administrative Agent shall record
such substitution or payment in the Register, whereupon (i) in the case of any payment in full of an Affected Lender, such
Affected Lender’s Commitments shall be terminated and (ii) in the case of any substitution of an Affected Lender, (A)
such Affected Lender shall sell and be relieved of, and the Substitute Lender shall purchase and assume, all rights and
claims of such Affected Lender under the Loan Documents, except that the Affected Lender shall retain such rights under the
Loan Documents that expressly provide that they survive the repayment of the Obligations and the termination of the
Commitments, (B) such Affected Lender shall no longer constitute a “Lender” hereunder and such Substitute Lender
shall become a “Lender” hereunder and (C) such Affected Lender shall execute and deliver an Assignment and
Assumption to evidence such substitution; provided, however, that the failure of any Affected Lender to execute
any such Assignment and Assumption shall not render such sale and purchase (or the corresponding assignment) invalid.

 

    	 	28	 

     

    

 

2.07       Prior
Borrowings. The Borrower hereby acknowledges (x) that the Original Borrower made (i) the first Borrowing on June 14, 2016 in
an amount of $20,000,000, (ii) the second Borrowing on May 11, 2017 in an amount of $10,000,000 and (iii) the third Borrowing on
August 8, 2017 in an amount of $10,000,000, each of which remain outstanding as of the date hereof and (y) receipt of the proceeds
of each such Borrowing pursuant to the terms of the Assignment Agreement.

 

SECTION 3

PAYMENTS OF PRINCIPAL AND INTEREST

 

3.01       Repayment.

 

(a)          Repayment.
During the Interest-Only Period, no payments of principal of the Loans shall be due. Borrower agrees to repay to the Lenders the
outstanding principal amount of the Loans, on each Payment Date occurring after the Interest-Only Period, in equal installments.
The amounts of such installments shall be calculated by dividing (i) the sum of the aggregate principal amount of the Loans outstanding
on the first day following the end of the Interest-Only Period, by (ii) the number of Payment Dates remaining prior to and including
the Stated Maturity Date.

 

(b)          Application.
Any optional or mandatory prepayment of the Loans shall be applied to the installments thereof under Section 3.01(a) in
the inverse order of maturity. To the extent not previously paid, the principal amount of the Loans, together with all other outstanding
Obligations, shall be due and payable on the Maturity Date.

 

3.02       Interest.

 

(a)          Interest
Generally. Subject to Section 3.02(d), Borrower agrees to pay to the Lenders interest on the unpaid principal amount
of the Loans and the amount of all other outstanding Obligations, in the case of the Loans, for the period from the applicable
Borrowing Date, and in the case of any other Obligation, from the date such other Obligation is due and payable, in each case,
until paid in full, at a rate per annum equal to (i) on and after the First Restatement Date, thirteen percent (13%), and
(ii) from the Original Closing Date to the date immediately preceding the First Restatement Date, fourteen percent (14%).

 

(b)          Default
Interest. Notwithstanding the foregoing, upon the occurrence and during the continuance of any Event of Default, the interest
payable pursuant to Section 3.02(a) shall, subject to applicable laws, increase automatically by 4.00% per annum
(such aggregate increased rate, the “Default Rate”). Notwithstanding any other provision herein, interest
required to be paid at the Default Rate shall be paid entirely in cash. If any Obligation is not paid when due under the applicable
Loan Document, the amount thereof shall, subject to applicable laws, accrue interest at a rate equal to 4.00% per annum
(without duplication of interest payable at the Default Rate). Each Obligor acknowledges that interest payable under this Agreement
at the Default Rate represents a genuine pre-estimate of damages to the Lenders and shall not be construed as a penalty.

 

(c)          Interest
Payment Dates. Subject to Section 3.02(d), accrued interest on the Loans shall be payable in arrears on each Payment
Date with respect to the most recently completed Interest Period in cash, and upon the payment or prepayment of the Loans (on the
principal amount being so paid or prepaid); provided that interest payable at the Default Rate shall be payable from time
to time on demand.

 

    	 	29	 

     

    

 

(d)          Paid
In-Kind Interest. Notwithstanding Section 3.01(a), at any time during the PIK Period, Borrower may, on notice to the
Administrative Agent, elect at the time that the Borrower makes the applicable interest payment to pay the interest on the outstanding
principal amount of the Loans payable pursuant to Section 3.01 as follows: (i) only 9.00% of the 13.00% per annum interest
in cash and (ii) 4.00% of the 13.00% per annum interest as compounded interest, which will be added to the aggregate principal
amount of the Loans (the amount of any such compounded interest being a “PIK Loan”). The principal amount
of each PIK Loan shall accrue interest in accordance with the provisions of this Agreement applicable to the Loans.

 

(e)          Interest-Only
Period. The Interest-Only Period may be extended to the twenty-third (23rd)
Payment Date if (a) the Borrower’s Revenue resulting from the sale of the Products meets or exceeds $80,000,000 during any
consecutive twelve (12) month period on or prior to the twenty-third (23rd) Payment
Date (the “Revenue Milestone”), (b) the Borrower has requested such extension of the Interest-Only Period in
writing to the Administrative Agent, (c) the Administrative Agent has received evidence, in form and substance satisfactory to
the Administrative Agent in its sole discretion, of the Revenue Milestone, (d) no Default or Event of Default has occurred and
is continuing, and (e) the Administrative Agent has provided written confirmation (which for certainty may be in the form of electronic
communication) of such extension of the Interest-Only Period, which for certainty shall be provided if conditions (c) and (d)
of this Section 3.02(e) have been satisfied.

 

(f)          Interest
Act (Canada). For the purposes of this Agreement, whenever interest is calculated on the basis of a period which is less
than the actual number of days in a calendar year (a “deemed year”), each rate of interest determined pursuant
to such calculation shall, for the purposes of the Interest Act (Canada), be expressed as a yearly rate by multiplying such
rate of interest for the deemed year by the actual number of days in the calendar year in which such rate is to be ascertained
and dividing the product thereof by the number of days in the deemed year. The Borrower confirms that it and each of the Subsidiary
Guarantors understand and is able to calculate the rate of interest applicable to the Loans based on the methodology for calculating
per annum rates provided in this Agreement. The Borrower and each Subsidiary Guarantor agree not to plead or assert, whether by
way of defence or otherwise, in any proceeding relating to this Agreement or any other Loan Document, that the interest payable
under this Agreement or any other Loan Document and the calculation thereof has not been adequately disclosed to the Borrower or
the Subsidiary Guarantors as required pursuant to section 4 of the Interest Act (Canada) or any other applicable law.

 

3.03       Prepayments.

 

(a)          Optional
Prepayments. Borrower shall have the right to optionally prepay in whole or in part the outstanding principal amount of the
Loans on any Payment Date (a “Redemption Date”) for an amount equal to the aggregate principal amount
of the Loans being prepaid plus the Prepayment Premium plus any accrued but unpaid interest and any fees then due and owing (such
aggregate amount, the “Redemption Price”). The applicable “Prepayment Premium”
shall be an amount calculated pursuant to Section 3.03(a)(i).

 

    	 	30	 

     

    

 

(i)           If
the Redemption Date occurs:

 

(A)         on
or prior to the fourth (4th) Payment Date, the Prepayment Premium shall be an amount equal to five percent (5%) of the
aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date plus the Backend Facility Fee related
to such Loans;

 

(B)         after
the fourth (4th) Payment Date, but on or prior to the eighth (8th ) Payment Date, the Prepayment Premium
shall be an amount equal to four percent (4%) of the aggregate outstanding principal amount of the Loans being prepaid on such
Redemption Date plus the Backend Facility Fee related to such Loans;

 

(C)          after
the eighth (8th) Payment Date, but on or prior to the twelfth (12th) Payment Date, the Prepayment Premium
shall be an amount equal to three percent (3%) of the aggregate outstanding principal amount of the Loans being prepaid on such
Redemption Date plus the Backend Facility Fee related to such Loans;

 

(D)         
after the twelfth (12th) Payment Date, but on or prior to the sixteenth (16th) Payment Date, the Prepayment
Premium shall be an amount equal to two percent (2%) of the aggregate outstanding principal amount of the Loans being prepaid on
such Redemption Date plus the Backend Facility Fee related to such Loans;

 

(E)          after
the sixteenth (16th) Payment Date, but on or prior to the twentieth (20th) Payment Date, the Prepayment Premium
shall be an amount equal to one percent (1%) of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption
Date plus the Backend Facility Fee related to such Loans;

 

(F)          after
the twentieth (20th) Payment Date, the Prepayment Premium shall be an amount equal to 0.00% of the aggregate outstanding
principal amount of the Loans being prepaid on such Redemption Date plus the Backend Facility Fee related to such Loans.

 

(ii)          To
determine the aggregate outstanding principal amount of the Loans, and how many Payment Dates have occurred, as of any Redemption
Date for purposes of  Section 3.03(a):

 

(A)         if,
as of such Redemption Date, Borrower shall have made only one Borrowing, the number of Payment Dates shall be deemed to be the
number of Payment Dates that shall have occurred following the first Borrowing Date;

 

(B)          if,
as of such Redemption Date, Borrower shall have made more than one Borrowing, then the Redemption Price shall equal the sum of
multiple Redemption Prices calculated with respect to the Loans of each Borrowing, each of which Redemption Prices shall be calculated
based on solely the aggregate outstanding principal amount of the Loans borrowed in such Borrowing, as though the applicable number
of Payment Dates equals the number of Payment Dates that shall have occurred following the applicable Borrowing Date. In the case
of any partial prepayment, the amount of such prepayment shall be allocated to Loans made in the various Borrowings in the order
in which such Borrowings were made;

 

    	 	31	 

     

    

 

(iii)         No
partial prepayment shall be made under this Section 3.03(a) in connection with any event described in Section 3.03(b).

 

(iv)         Borrower
shall deliver to the Administrative Agent a notice of optional repayment in accordance with Section 4.03(a) in respect of
all prepayments permitted under Section 3.03(a).

 

(b)          Mandatory
Prepayments.

 

(i)           Asset
Sales. In the event of any contemplated Asset Sale or series of Asset Sales (other than any Asset Sale permitted under Section
9.09(a), (b), (d) or (e)) yielding Asset Sale Net Proceeds in excess of $1,000,000 in the aggregate, Borrower
shall provide 30 days’ prior written notice of such Asset Sale to Administrative Agent and, if within such notice period
Majority Lenders or Administrative Agent advise Borrower that the Majority Lenders require a prepayment pursuant to this Section
3.03(b)(i), Borrower shall: (x) if the assets sold represent substantially all of the assets or revenues of Borrower, or represent
any specific line of business which either on its own or together with other lines of business sold over the term of this Agreement
account for revenue generated by such lines of business exceeding 10% of the revenue of Borrower in the immediately preceding year,
prepay the aggregate outstanding principal amount of the Loans in an amount equal to the Redemption Price applicable on the date
of such Asset Sale in accordance with Section 3.03(a), and (y) in the case of all other Asset Sales not described in the
foregoing clause (x), prepay the Loans in an amount equal to the entire amount of the Asset Sale Net Proceeds of such Asset
Sale, plus any accrued but unpaid interest and any fees then due and owing (including for certainty the Backend Facility Fee),
credited in the following order:

 

(A)         first,
in reduction of Borrower’s obligation to pay any unpaid interest and any fees then due and owing;

 

(B)          second,
in reduction of Borrower’s obligation to pay any Claims or Losses referred to in Section 13.03 then due and owing;

 

(C)          third,
in reduction of Borrower’s obligation to pay any amounts due and owing on account of the unpaid principal amount of the Loans;

 

(D)          fourth,
in reduction of any other Obligation then due and owing;

 

and

 

(E)          fifth,
to Borrower or such other Persons as may lawfully be entitled to or directed by Borrower to receive the remainder.

 

(ii)          Change
of Control. In the event of a Change of Control, Borrower shall immediately provide notice of such Change of Control to Administrative
Agent and, if within ten (10) days of receipt of such notice the Majority Lenders or Administrative Agent advise Borrower that
the Majority Lenders require a prepayment pursuant to this Section 3.03(b)(ii), Borrower shall prepay the aggregate outstanding
principal amount of the Loans in an amount equal to the Redemption Price applicable on the date of such Change of Control in accordance
with Section 3.03(a). The Majority Lenders shall use commercially reasonable efforts to review and approve any mergers,
amalgamations or other reorganizations resulting from acquisitions which lead to a Change of Control
but are materially beneficial to both the Borrower and the Lender’s security interests and rights to the Borrower’s
assets, property, rights and interests.

 

    	 	32	 

     

    

 

SECTION 4

PAYMENTS, ETC.

 

4.01       Payments.

 

(a)          Payments
Generally. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any other
Loan Document shall be made in Dollars, in immediately available funds, without deduction, set off or counterclaim, to an account
to be designated by Administrative Agent by notice to Borrower, not later than 4:00 p.m. (Central time) on the date on which such
payment shall become due (each such payment made after such time on such due date to be deemed to have been made on the next succeeding
Business Day).

 

(b)          Application
of Payments. Each Obligor shall, at the time of making each payment under this Agreement or any other Loan Document, specify
to Administrative Agent the amounts payable by such Obligor hereunder to which such payment is to be applied (and in the event
that Obligors fail to so specify, or if an Event of Default has occurred and is continuing, the Lenders may apply such payment
in the manner they determine to be appropriate).

 

(c)          Non-Business
Days. If the due date of any payment under this Agreement (other than of principal of or interest on the Loans) would otherwise
fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of
any payment accruing interest, interest thereon shall be payable for the period of such extension.

 

4.02       Computations.
All computations of interest and fees hereunder shall be computed on the basis of a year of 360 days and actual days elapsed
during the period for which payable.

 

4.03       Notices.
Each notice of optional prepayment shall be effective only if received by Administrative Agent not later than 4:00 p.m. (Central
time) on the date one Business Day prior to the date of prepayment. Each notice of optional prepayment shall specify the amount
to be prepaid and the date of prepayment.

 

4.04       Set-Off.

 

(a)          Set-Off
Generally. Upon the occurrence and during the continuance of any Event of Default, each of Administrative Agent, each Lender
and each of their Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to
set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness
at any time owing by Administrative Agent, any Lender and any of their Affiliates to or for the credit or the account of any Obligor
against any and all of the Obligations, whether or not such Person shall have made any demand and although such obligations may
be unmatured. Administrative Agent and each Lender agree promptly to notify Borrower after any such set-off and application, provided
that the failure to give such notice shall not affect the validity of such set-off and application. The rights of Administrative
Agent, each Lender and each of their Affiliates under this Section 4.04 are in addition to other rights and remedies (including
other rights of set-off) that such Persons may have.

 

    	 	33	 

     

    

 

(b)          Exercise
of Rights Not Required. Nothing contained herein shall require Administrative Agent, any Lender or any of their respective
Affiliates to exercise any such right or shall affect the right of such Person to exercise, and retain the benefits of exercising,
any such right with respect to any other indebtedness or obligation of any Obligor.

 

4.05       Pro
Rata Treatment.

 

(a)          Unless
Administrative Agent shall have been notified in writing by any Lender prior to the proposed date of any Borrowing that such Lender
will not make the amount that would constitute its share of such Borrowing available to Administrative Agent, Administrative Agent
may assume that such Lender has made such amount available to Administrative Agent on such date in accordance with Section 2,
and Administrative Agent may, in reliance upon such assumption, make available to Borrower a corresponding amount. If such amount
is not in fact made available to Administrative Agent by the required time on the applicable Borrowing Date therefor, such Lender
and Borrower severally agree to pay to Administrative Agent forthwith, on demand, such corresponding amount with interest thereon,
for each day from and including the date on which such amount is made available to Borrower but excluding the date of payment to
Administrative Agent, at (i) in the case of a payment to be made by such Lender, a rate equal to the greater of (A) the Federal
Funds Effective Rate and (B) a rate reasonably determined by Administrative Agent in accordance with banking industry rules on
interbank compensation. If Borrower and such Lender shall pay such interest to Administrative Agent for the same or an overlapping
period, Administrative Agent shall promptly remit to Borrower the amount of such interest paid by Borrower for such period. If
such Lender pays its share of the applicable borrowing to Administrative Agent, then the amount so paid shall constitute such Lender’s
Loan included in such borrowing. Any payment by Borrower shall be without prejudice to any claim Borrower may have against a Lender
that shall have failed to make such payment to Administrative Agent.

 

(b)          Unless
Administrative Agent shall have received notice from Borrower prior to the date on which any payment is due to Administrative Agent
for the account of the Lenders hereunder that Borrower will not make such payment, Administrative Agent may assume that Borrower
has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders
the amount due. In such event, if Borrower has not in fact made such payment, then each of the Lenders severally agrees to repay
to Administrative Agent forthwith on demand the amount so distributed to such Lender, with interest thereon, for each day from
and including the date such amount is distributed to it to but excluding the date of payment to Administrative Agent, at the greater
of the Federal Funds Effective Rate and a rate determined by Administrative Agent in accordance with banking industry rules on
interbank compensation. Nothing herein shall be deemed to limit the rights of Administrative Agent or any Lender against any Obligor.

 

    	 	34	 

     

    

 

(c)          If
any Lender shall obtain any payment (whether voluntary, involuntary, through the exercise of any right of set-off, or
otherwise) on account of the principal of or interest on any Loan made by it or other obligations hereunder, as applicable
(other than pursuant to a provision hereof providing for non-pro rata treatment), in excess of its Proportionate Share, of
such payment on account of the Loans, such Lender shall (i) notify Administrative Agent of the receipt of such payment, and
(ii) within five (5) Business Days of such receipt purchase (for cash at face value) from the other Lenders, as applicable
(directly or through Administrative Agent), without recourse, such participations in the Loans made by them or make such
other adjustments as shall be equitable, as shall be necessary to cause such purchasing Lender to share the excess payment
ratably with each of the other Lenders in accordance with their respective Proportionate Shares, as applicable; provided,
however, that (A) if any such participations are purchased and all or any portion of the payment giving rise thereto is
recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without
interest and (B) the provisions of this paragraph shall not be construed to apply to (x) any payment made by Borrower
pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the
existence of a Defaulting Lender) or (y) any payment obtained by a Lender as consideration for the assignment or sale of a
participation in any of its Loans to any assignee or participant, other than to Borrower or any of its Affiliates (as to
which the provisions of this paragraph shall apply). Borrower agrees that any Lender so purchasing a participation from
another Lender pursuant to this Section 4.05(c) may exercise all its rights of payment (including the right of
set-off) with respect to such participation as fully as if such Lender were the direct creditor of Borrower in the amount of
such participation. No documentation other than notices and the like referred to in this Section 4.05(c) shall be
required to implement the terms of this Section 4.05(c). Administrative Agent shall keep records (which shall be
conclusive and binding in the absence of manifest error) of participations purchased pursuant to this Section 4.05(c)
and shall in each case notify the Lenders following any such purchase. Borrower consents on behalf of itself and each other
Obligor to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a
participation pursuant to the foregoing arrangements may exercise against each Obligor rights of setoff and counterclaim with
respect to such participation as fully as if such Lender were a direct creditor of each Obligor in the amount of such
participation.

 

SECTION 5

YIELD PROTECTION, ETC.

 

5.01       Additional
Costs.

 

(a)          Change
in Requirements of Law Generally. If, on or after the date hereof, the adoption of any Requirement of Law, or any change in
any Requirement of Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority
charged with the interpretation or administration thereof, or compliance by any of the Lenders (or its lending office) with any
request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem
applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve System), special
deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof,
against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending office) or shall impose
on a Lender (or its lending office) any other condition affecting the Loans or the Commitment, and the result of any of the foregoing
is to increase the cost to such Lender of making or maintaining the Loans (other than (i) Indemnified Taxes and (ii) Taxes described
in clause (c), (d) or (f) of the definition of “Excluded Taxes”), or to reduce the amount of any
sum received or receivable by such Lender under this Agreement or any other Loan Document, by an amount deemed by such Lender to
be material, then Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender
for such increased cost or reduction.

 

    	 	35	 

     

    

 

(b)          Change
in Capital Requirements. If a Lender shall have determined that, on or after the date hereof, the adoption of any Requirement
of Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any
Governmental Authority charged with the interpretation or administration thereof, or any request or directive regarding capital
adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after
the date hereof, has or would have the effect of reducing the rate of return on capital of a Lender (or its parent) as a consequence
of a Lender’s obligations hereunder or the Loans to a level below that which a Lender (or its parent) could have achieved
but for such adoption, change, request or directive by an amount reasonably deemed by it to be material, then Borrower shall pay
to such Lender on demand such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.

 

(c)          Notification
by Lender. Each Lender (directly or through Administrative Agent) will promptly notify Borrower of any event of which it has
knowledge, occurring after the date hereof, which will entitle such Lender to compensation pursuant to this Section 5.01.
Before giving any such notice pursuant to this Section 5.01(c) such Lender shall designate a different lending office if
such designation (x) will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation
and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to such Lender. A certificate of the
Lender claiming compensation under this Section 5.01, setting forth the additional amount or amounts to be paid to it hereunder,
shall be conclusive and binding on Borrower in the absence of manifest error.

 

(d)          Notwithstanding
anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines
or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by
the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the
United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute
a change in Requirements of Law for all purposes of this Section 5.01, regardless of the date enacted, adopted or issued.

 

5.02       Illegality.
Notwithstanding any other provision of this Agreement, in the event that on or after the date hereof the adoption of or any
change in any Requirement of Law or in the interpretation or application thereof by any competent Governmental Authority shall
make it unlawful for a Lender or its lending office to make or maintain the Loans (and, in the opinion of such Lender, the designation
of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such Lender), then such Lender
shall promptly notify Borrower thereof following which (a) the Lender’s Commitment shall be suspended until such time as
such Lender may again make and maintain the Loans hereunder and (b) if such Requirement of Law shall so mandate, the Loans shall
be prepaid by Borrower on or before such date as shall be mandated by such Requirement of Law in an amount equal to the Redemption
Price applicable on the date of such prepayment in accordance with Section 3.03(a).

 

5.03       Taxes.

 

(a)          Payments
Free of Taxes. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for any
Taxes, except as required by applicable law. If any applicable law requires the deduction or withholding of any Tax from any such
payment by an Obligor, then such Obligor shall be entitled to make such deduction or withholding and shall timely pay the full
amount deducted or withheld to the relevant Governmental Authority in accordance with applicable
law and, if such Tax is an Indemnified Tax, then the sum payable by such Obligor shall be increased as necessary so that after
such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under
this Section 5) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction
or withholding been made.

 

    	 	36	 

     

    

 

(b)          Payment
of Other Taxes by Borrower. Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable
law, or at the option of each Lender, timely reimburse it for, Other Taxes.

 

(c)          Evidence
of Payments. As soon as practicable after any payment of Taxes by Borrower to a Governmental Authority pursuant to this Section
5, Borrower shall deliver to Administrative Agent the original or a certified copy of a receipt issued by such Governmental
Authority evidencing such payment.

 

(d)          Indemnification.
Borrower shall reimburse and indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified
Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 5) payable
or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising
therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant
Governmental Authority. A certificate as to the amount of such payment or liability delivered to Borrower by a Lender shall be
conclusive absent manifest error.

 

(e)          Status
of Lenders.

 

(i)           Any
Lender that is entitled to an exemption from, or reduction of withholding Tax with respect to payments made under any Loan Document
shall timely deliver to Borrower (directly or through Administrative Agent) such properly completed and executed documentation
reasonably requested by Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding;
provided that, other than in the case of United States federal withholding Taxes, such Lender has received written notice from
Borrower advising it of the availability of such exemption or reduction and containing all applicable documentation. In addition,
any Lender shall deliver (directly or through Administrative Agent) such other documentation prescribed by applicable law as reasonably
requested by Borrower as will enable Borrower to determine whether or not such Lender is subject to backup withholding or information
reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and
submission of such documentation (other than such documentation set forth in Section 5.03(e)(ii)(A) , (B), (C)
or (D)) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject
such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such
Lender.

 

(ii)          Without
limiting the generality of the foregoing, in the event that Borrower is a U.S. Person:

 

(A)         any
Lender that is a U.S. Person shall deliver to Borrower (directly or through Administrative Agent) on or prior to the date on which
such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower),
executed originals of IRS Form W-9 (or successor form) certifying that such Lender is exempt from United States federal backup
withholding tax;

 

    	 	37	 

     

    

 

(B)          any
Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower (directly or through Administrative Agent
and in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes
a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower), whichever of the following
is applicable:

 

(1)         in
the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect
to payments of interest under any Loan Document, executed originals of IRS Form W-8BEN or W-8BEN-E (or successor forms) establishing
an exemption from, or reduction of, United States federal withholding Tax pursuant to the “interest” article of such
tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or W-8BEN-E (or successor
forms) establishing an exemption from, or reduction of, United States federal withholding Tax pursuant to the “business profits”
or “other income” article of such tax treaty;

 

(2)         executed
originals of IRS Form W-8ECI (or successor form);

 

(3)         in
the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x)
a certificate substantially in the form of Exhibit G to the effect that such Foreign Lender is not a “bank”
within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the applicable Borrower within
the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C)
of the Code and (y) executed originals of IRS Form W-8BEN or W-8BEN-E (or successor forms); or

 

(4)         to
the extent a Foreign Lender is not the beneficial owner, executed originals of IRS Form W-8IMY (or successor form), accompanied
by IRS Form W-8ECI (or successor form), IRS Form W-8BEN or W-8BEN-E (or successor forms), IRS Form W-9 (or successor form), and/or
other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and
one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender
may provide a certificate substantially in the form of Exhibit C on behalf of each such direct and indirect partner.

 

(C)          any
Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower (directly or through Administrative Agent
and in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes
a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower), executed originals of
any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in United States federal withholding
Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit Borrower to
determine the withholding or deduction required to be made; and

 

    	 	38	 

     

    

 

(D)          any
Foreign Lender shall deliver to Borrower (directly or through Administrative Agent) any forms and information necessary to establish
that such Foreign Lender is not subject to withholding tax under FATCA.

 

Each Lender agrees that if any form or certification it previously
delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify
Borrower in writing of its legal inability to do so.

 

(f)           Treatment
of Certain Refunds. If any party determines, in its sole discretion exercised in good faith, that it has received a refund
of any Taxes as to which it has been indemnified pursuant to this Section 5 (including by the payment of additional amounts
pursuant to this Section 5), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent
of indemnity payments made under this Section 5 with respect to the Taxes giving rise to such refund), net of all out-of-pocket
expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental
Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such
indemnified party the amount paid over pursuant to this paragraph (plus any penalties, interest or other charges imposed by the
relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental
Authority. Notwithstanding anything to the contrary in this Section 5.03(f), in no event will the indemnified party be required
to pay any amount to an indemnifying party pursuant to this Section 5.03(f) the payment of which would place the indemnified
party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification
and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional
amounts with respect to such Tax had never been paid. This Section 5.03(f) shall not be construed to require any indemnified
party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying
party or any other Person.

 

(g)         Mitigation
Obligations. If Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental
Authority for the account of any Lender pursuant to Section 5.01 or this Section 5.03, then such Lender shall (at
the request of Borrower) use commercially reasonable efforts to designate a different lending office for funding or booking its
Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates
if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation would (i) eliminate or reduce
amounts payable pursuant to Section 5.01 or this Section 5.03, as the case may be, in the future, (ii) not subject
such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous to such Lender. Borrower hereby agrees
to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation.

 

SECTION 6

CONDITIONS PRECEDENT

 

6.01 The First Borrowing. The first Borrowing was made conditional
upon the following conditions precedent that were satisfied or waived in writing by the Lenders:

 

(a)          Borrowing Date. The first Borrowing was made on June 14, 2016 and remains outstanding as of the date hereof.

 

    	 	39	 

     

    

 

(b)         Amount
of First Borrowing. The amount of such Borrowing shall equal $20,000,000.

 

(c)          Terms
of Material Agreements, Etc. Lenders shall be reasonably satisfied with the terms and conditions of all of the Obligors’
Material Agreements.

 

(d)          No
Law Restraining Transactions. No applicable law or regulation shall restrain, prevent or, in the reasonable judgment of the
Lenders, impose materially adverse conditions upon the Transactions.

 

(e)          Payment
of Fees. Lenders shall be satisfied with the arrangements to deduct the fees set forth in the Fee Letter (including without
limitation the upfront financing fee required pursuant to the Fee Letter) from the proceeds advanced.

 

(f)          Lien
Searches. (i) Lenders shall be satisfied with Lien searches regarding Borrower and the Subsidiary Guarantors (other than the
English Obligors or a Subsidiary Guarantor incorporated or organized in Germany) made within:

 

(A)         five
(5) Business Days prior to such Borrowing in the case of the Borrower; and

 

(B)          fifteen
(15) days prior to such Borrowing in the case of each Obligor organized in the United States of America or any state or political
subdivision thereof; and

 

(ii)          Lenders
shall be satisfied with an excerpt from the Debt Enforcement Registry in respect of each Obligor incorporated in Switzerland or
any state or political subdivison thereof, dated no less than 30 days prior to such Borrowing; and

 

(iii)         Lenders
shall be satisfied with searches regarding the English Obligors made on the date of this Agreement.

 

(g)          Documentary
Deliveries. The Lenders shall have received the following documents, each of which shall be in form and substance satisfactory
to the Lenders:

 

(i)           License Agreement. A duly executed license agreement in form and substance satisfactory to the Administrative Agent between
Durata Therapeutics International B.V. and Correvio International Sárl relating to Dalbavancin.

 

(ii)          Fee Letter. The Fee Letter duly executed and delivered by Borrower and Administrative Agent.

 

(iii)         Security
Documents.

 

(A)         The
Security Documents (other than the Landlord Consent), duly executed and delivered by each of the Obligors.

 

(B)          (1)
Each of the Short-Form IP Security Agreements, duly executed and delivered by the applicable Obligor, and (2) such Intellectual
Property security agreements, duly executed and delivered by the applicable Obligor, as the Lenders
may require with respect to foreign Intellectual Property.

 

    	 	40	 

     

    

 

(C)         [Intentionally
Deleted.].

 

(D)         [Intentionally
Deleted.].

 

(E)          Evidence
of filing of UCC-1 financing statements, PPSA financing statements or similar registrations, if applicable,
against each Obligor (other than the English Obligors, an Obligor incorporated or organized in Germany or with respect to registrations
noted on Schedule 8.17) in its jurisdiction of formation or incorporation, the jurisdictions in which its chief executive
office and registered office are located and/or the jurisdiction where it has assets or carries on business, as the case may be.

 

(F)          [Intentionally
Deleted.]

 

(G)          Without
limitation, all other documents and instruments reasonably required to perfect the Secured Parties’ Lien on, and security
interest in, the Collateral required to be delivered on or prior to such Borrowing Date shall have been duly executed and delivered
and be in proper form for filing, and shall create in favor of the Secured Parties, a perfected Lien on, and security interest
in, the Collateral, subject to no Liens other than Permitted Liens.

 

(iv)         [Intentionally
Deleted.]

 

(v)          Approvals.
Certified copies of all material licenses, consents, authorizations and approvals of, and notices to and filings and registrations
with, any Governmental Authority (including all foreign exchange approvals), and of all third-party consents and approvals, necessary
in connection with the making and performance by the Obligors of the Loan Documents and the Transactions.

 

(vi)         Corporate
Documents. Certified copies of the constitutive documents of each Obligor (if publicly available in such Obligor’s jurisdiction
of formation, certified copies from such public institution or in the case of any Obligor incorporated or organized in Germany
or Switzerland where up- to-date copies retrieved from the online commercial register shall be sufficient), of resolutions of the
Board of Directors (or shareholders, if applicable) of each Obligor authorizing the making and performance by it of the Loan Documents
to which it is a party and a certified true and complete copy of the Borrower’s investment policy.

 

(vii)        Incumbency
Certificate. A certificate (which, for certainty, can be combined with the certificate required pursuant to Section 6.01(g)(vi)
above) of each Obligor (except for an Obligor incorporated or organized in Germany) as to the authority, incumbency and specimen
signatures of the persons who have executed the Loan Documents and any other documents in connection herewith on behalf of the
Obligors. In relation to an Obligor incorporated or organized in Germany, (i) a certificate signed by an authorized signatory with
the power of representation certifying that each document delivered under clause 6.01(g)(vi) above is correct, complete and in
full force and effect and has not been amended or superseded as at the date of the certificate and (ii) the specimen signatures
of each person authorized to execute any Loan Document.

 

    	 	41	 

     

    

 

(viii)       Officer’s
Certificate. A certificate, dated such Borrowing Date and signed by the President, a Vice President or a financial officer
of Borrower, confirming compliance with the conditions set forth in Section 6.04.

 

(ix)          Opinions
of Counsel. Favorable opinions, dated such Borrowing Date, in form acceptable to the Lenders and their counsel, as may include
the requests set forth in Exhibit E, provided by:

 

(A)         Blake,
Cassels & Graydon LLP, in respect of matters of relating to Canadian law and/or any Obligor organized in Canada or any province
or territory thereof;

 

(B)          Skadden,
Arps, Slate, Meagher & Flom LLP, in respect of matters relating to United States law and/or any Obligor organized in the United
States of America or any state or political subdivision thereof;

 

(C)           Baker
& McKenzie LLP, in respect of matters relating to English law and/or any Obligor organized in England and Wales or any state
or political subdivision thereof;

 

(D)          Baker
& McKenzie Partnerschaft von Rechtsanwaelten, Wirtschaftspruefern und Steuerberatern mbB, in respect of certain matters relating
to German law or any state or political subdivision thereof;

 

(E)          Allen
& Overy LLP, in respect of certain matters relating to German law, including corporate matters, relating to any Obligor organized
in Germany or any state or political subdivision thereof; and

 

(F)          Staiger
Schwald & Partner Ltd., in respect of matters relating to the law of Switzerland and/or any Obligor organized in Switzerland
or any state or political subdivision thereof.

 

(x)           Insurance.
Certificates of insurance evidencing the existence of all insurance required to be maintained by Borrower pursuant to Section
8.05 and the designation of the Lenders as the lender’s loss payees or additional named insured, as the case may be,
thereunder.

 

(xi)         [Intentionally
Deleted.]

 

(xii)        Other Liens.
Duly executed and delivered copies of such acknowledgement letters, estoppel letters or similar instruments as are reasonably requested
by Administrative Agent with respect to existing Liens.

 

(xiii)       [Intentionally Deleted.]

 

(xiv)       Existing Indebtedness.
Borrower shall have delivered to the Administrative Agent a payout and discharge statement, in form and substance satisfactory
to the Administrative Agent, in respect of all Indebtedness owing by the Borrower and any Subsidiary guarantor to MidCap, together
with all required draft UCC termination statements, draft PPSA discharge statements and any other related instruments.

 

    	 	42	 

     

    

 

(xv)        Good
Standing Certificates. A certificate from the appropriate Governmental Authority bearing a current date acceptable to the Administrative
Agent, to the effect that each Obligor (other than any English Obligor or any Obligor incorporated or organized in Germany or Switzerland)
is in good standing and qualified to transact business in its jurisdiction of organization and in each other jurisdiction where
it transacts business.

 

6.02       Conditions to Second Borrowing. The second Borrowing
was made conditional upon the following conditions precedent that were satisfied or waived in writing by the Lenders:

 

(a)          Borrowing
Date. The second Borrowing occurred on the First Restatement Date and remains outstanding as of the date hereof.

 

(b)          Amount
of Borrowing. The amount of such Borrowing shall equal $10,000,000.

 

(c)          Terms
of Material Agreements, Etc. Lenders shall be reasonably satisfied with the terms and conditions of all of the Obligors’
Material Agreements.

 

(d)          No
Law Restraining Transactions. No applicable law or regulation shall restrain, prevent or, in the reasonable judgment of the
Lenders, impose materially adverse conditions upon the Transactions.

 

(e)          Payment
of Fees. Lenders shall be satisfied with the arrangements to deduct the fees payable upon the second Borrowing set forth in
the Fee Letter (including without limitation the upfront financing fee required pursuant to the Fee Letter) from the proceeds advanced.

 

(f)          Lien
Searches. Lenders shall be satisfied with Lien searches regarding the Borrower and its respective Subsidiaries (other than
the English Obligors, the Swiss Guarantors or a Subsidiary Guarantor incorporated or organized in Germany) made within two Business
Days prior to such Borrowing.

 

(g)          Documentary
Deliveries. The Lenders shall have received the following documents, each of which shall be in form and substance satisfactory
to the Lenders:

 

(i)           Fee
Letter. An amended Fee Letter in form and substance satisfactory to the Lenders duly executed and delivered by Borrower and
Administrative Agent.

 

(ii)          Warrants. For the Lenders, pro rata in accordance with their Proportionate Shares, the Warrants, duly executed by
Borrower (for such number of shares as indicated on Schedule 1).

 

(iii)         Security Documents. Without limitation, all documents and instruments reasonably required to perfect the Secured Parties’
Lien on, and security interest in, the Collateral required to be delivered on or prior to such Borrowing Date shall have been
duly executed and delivered and be in proper form for filing, and shall create in favor of the Secured Parties, a perfected Lien
on, and security interest in, the Collateral, subject to no Liens other than Permitted Liens.

 

(iv)         Approvals. Certified copies of all material licenses, consents, authorizations and approvals of, and notices to and filings
and registrations with, any Governmental Authority (including all foreign exchange approvals), and of all third-party consents
and approvals, necessary in connection with the making and performance by the Obligors of the Loan Documents and the Transactions.

 

    	 	43	 

     

    

 

(v)          Corporate
Documents. Certified copies of the constitutive documents of each Obligor (if publicly available in such Obligor’s jurisdiction
of formation, certified copies from such public institution), or an officer’s certificate certifying that no changes have
been made to such constitutive documents since the Original Closing Date (or in the case of any Obligor incorporated or organized
in Germany or Switzerland where up-to-date copies retrieved from the online commercial register shall be sufficient), and of resolutions
of the Board of Directors (or shareholders, if applicable) of each Obligor authorizing the making and performance by it of the
Loan Documents to be entered into on the First Restatement Date and pursuant to Section 8.17 of the First A&R Agreement
to which it is a party.

 

(vi)         Incumbency
Certificate. A certificate (which, for certainty, can be combined with the certificate required pursuant to Section 6.02(g)(v)
of the First A&R Agreement) of each Obligor (except for an Obligor incorporated or organized in Germany) as to the authority,
incumbency and specimen signatures of the persons who have executed the Loan Documents and any other documents in connection herewith
on behalf of the Obligors. In relation to an Obligor incorporated or organized in Germany, (i) a certificate signed by an authorized
signatory with the power of representation certifying that each document delivered under clause 6.02(g)(v) of the First
A&R Agreement is correct, complete and in full force and effect and has not been amended or superseded as at the date of the
certificate and (ii) the specimen signatures of each person authorized to execute any Loan Document.

 

(vii)        Officer’s
Certificate. A certificate, dated such Borrowing Date and signed by the President, a Vice President or a financial officer
of Borrower, confirming compliance with the conditions set forth in Section 6.05 of the First A&R Agreement.

 

(viii)       Good
Standing Certificates. A certificate from the appropriate Governmental Authority, bearing a current date acceptable to the
Administrative Agent, to the effect that each Obligor (other than any English Obligor or any Obligor incorporated or organized
in Germany or Switzerland) is in good standing and qualified to transact business in its jurisdiction of organization and in each
other jurisdiction where it transacts business.

 

6.03       Conditions to
Third Borrowing. The third Borrowing was made conditional upon the following conditions precedent that were satisfied or waived
in writing by the Lenders:Borrowing Date. The third Borrowing occurred on August 8, 2017 and remains outstanding as of
the date hereof.

 

(b)          Amount
of Borrowing. The amount of such Borrowing shall equal $10,000,000.

 

(c)          Third
Borrowing Milestone. Confirmation that (i) average Market Capitalization for the consecutive ninety (90) calendar days immediately
preceding the date of the third Borrowing was at least $90,000,000 and (ii) at no time during such ninety (90) calendar day period
has the Market Capitalization been equal to or less than $85,000,000 (collectively, the “Third Borrowing Milestone”),
provided that the Third Borrowing Milestone shall be achieved in time to provide the Administrative Agent with a Notice of Borrowing
in compliance with Section 2.02 of the First A&R Agreement and Section 6.03(a) of the First A&R Agreement.

 

    	 	44	 

     

    

 

(d)          Notice
of Milestone Achievement. Borrower shall have delivered to Administrative Agent a notice certifying satisfaction of the condition
set forth in Section 6.03(c) of the First A&R Agreement no later than 60 days thereafter, and the Lenders shall have
been reasonably satisfied with the accuracy of the information contained in such notice.

 

(e)          Notice
of Borrowing. A Notice of Borrowing shall have been received no later than 60 calendar days after satisfaction of the condition
set forth in Section 6.03(c) of the First A&R Agreement.

 

(f)          Payment
of Fees. Lenders shall be satisfied with the arrangements to deduct the fees payable upon the third Borrowing set forth in
the Fee Letter (including without limitation the upfront financing fee required pursuant to the Fee Letter) from the proceeds advanced.

 

(g)          Post-Closing
Items. Satisfaction of the condition set forth in Section 8.17 of the First A&R Agreement.

 

6.04       Conditions
to Fourth Borrowing. The obligation of each Lender to make a Loan as part of a fourth Borrowing is subject to the following
conditions precedent, which shall have been satisfied or waived in writing by the Lenders:

 

(a)          Borrowing
Date. The fourth Borrowing shall occur following receipt by the Administrative Agent of the Notice of Borrowing referred to
in Section 6.04(e).

 

(b)          Amount
of Borrowing. The amount of such Borrowing shall be in one advance of either $5,000,000 or $10,000,000. For certainty, if Borrower
elects a $5,000,000 advance, Borrower may not receive any further Borrowing under this Section 6.04(b).

 

(c)          Fourth
Borrowing Milestone. Confirmation that the Borrower’s Revenue from the sale of the Products has exceeded $35,000,000
during any consecutive twelve (12) month period (the “Fourth Borrowing Milestone”), provided that the Fourth
Borrowing Milestone shall be achieved no later than March 31, 2018 unless the Administrative Agent extends such deadline in its
sole discretion in connection with a proposed Transaction.

 

(d)          Notice
of Milestone Achievement and Audit. Borrower shall have delivered to Administrative Agent a notice certifying satisfaction
of the condition set forth in Section 6.04(c) no later than 60 days thereafter, and the Lenders shall have been reasonably
satisfied with the results of its audit of Borrower’s Revenue by examining Borrower’s books and records.

 

(e)          Notice
of Borrowing. A Notice of Borrowing shall have been received no later than 60 calendar days after satisfaction of the condition
set forth in Section 6.04(c).

 

(f)          Payment
of Fees. Lenders shall be satisfied with the arrangements to deduct the fees payable upon the fourth Borrowing set forth in
the Fee Letter (including without limitation the upfront financing fee required pursuant to the Fee Letter) from the proceeds advanced.

 

(g)          Post-Closing
Items. Satisfaction of the condition set forth in Section 8.17 of the First A&R Agreement.

 

    	 	45	 

     

    

 

6.05       Conditions
to Each Borrowing. The obligation of each Lender to make a Loan as part of any Borrowing (including the first Borrowing) is
also subject to satisfaction of the following further conditions precedent on the applicable Borrowing
Date, which shall have been satisfied or waived in writing by the Lenders:

 

(a)          Commitment
Period. Such Borrowing Date shall occur during the Commitment Period.

 

(b)          No
Default; Representations and Warranties. Both immediately prior to the making of such Loan and after giving effect thereto
and to the intended use thereof:

 

(i)           no
Default shall have occurred and be continuing; and

 

(ii)          the representations
and warranties made by each Obligor in Section 7 shall be true on and as of the Borrowing Date, and immediately after giving
effect to the application of the proceeds of the Borrowing, with the same force and effect as if made on and as of such date (except
that the representation regarding representations and warranties that refer to a specific earlier date shall be that they were
true on such earlier date).

 

(c)          Notice
of Borrowing. Administrative Agent shall have received a Notice of Borrowing as and when required pursuant to Section 2.02.

 

Each Borrowing shall constitute a certification
by Borrower to the effect that the conditions set forth in this Section 6.04 have been fulfilled as of the applicable Borrowing
Date.

 

6.06       Conditions
to the effectiveness of this Agreement. The effectiveness of this Agreement is subject to the following conditions precedent,
which shall have been satisfied or waived in writing by the Lenders:

 

(a)          Terms
of Material Agreements, Etc. Lenders shall be reasonably satisfied with the terms and conditions of all of the Obligors’
Material Agreements.

 

(b)         No
Law Restraining Transactions. No applicable law or regulation shall restrain, prevent or, in the reasonable judgment of the
Lenders, impose materially adverse conditions upon the Transactions.

 

(c)          Payment
of Fees. Lenders shall be satisfied with the arrangements by Borrower to pay all fees and expenses on the Closing Date (including,
without limitation, legal fees) described in Section 13.03 of this Agreement.

 

(d)          Lien
Searches. Lenders shall be satisfied with Lien searches regarding the Borrower and its respective Subsidiaries (other than
the English Obligors, the Swiss Guarantors or a Subsidiary Guarantor incorporated or organized in Germany) made within two Business
Days prior to the Closing Date or such earlier period agreed to by the Agent.

 

(e)          Documentary
Deliveries. The Lenders shall have received the following documents, each of which shall be in form and substance satisfactory
to the Lenders:

 

(i)           Fee Letter. A second amended and restated
Fee Letter in form and substance satisfactory to the Lenders duly executed and delivered by Borrower and Administrative Agent.

 

    	 	46	 

     

    

 

(ii)          Assignment Agreement.
The Assignment Agreement in form and substance satisfactory to the Lenders duly executed and delivered by Original Borrower, Borrower,
Subsidiary Guarantors and Administrative Agent.

 

(iii)         Warrants . A
warrant assumption agreement with respect to the Warrants being applicable to the Borrower duly executed and delivered by Borrower,
Original Borrower and the Lenders, in form and substance satisfactory to the Lenders.

 

(iv)         Security
Documents.

 

(A)          The
Security Documents, duly executed and delivered by each of the Obligors, to the extent not delivered on the Original Closing Date
or the First Restatement Date or as otherwise required in connection with this Agreement, as the case may be.

 

(B)          (1)
Each of the Short-Form IP Security Agreements, duly executed and delivered by the applicable Obligor, and (2) such Intellectual
Property security agreements, duly executed and delivered by the applicable Obligor, as the Lenders may require with respect to
foreign Intellectual Property, to the extent not previously delivered or as otherwise required in connection with this Agreement,
as the case may be.

 

(C)          Evidence
of filing of PPSA financing statements or similar registrations, if applicable, against the Borrower and Correvio Canada Corp.,
in each applicable jurisdiction of formation or incorporation, the jurisdictions in which its chief executive office and registered
office are located and/or the jurisdiction where it has assets or carries on business, as the case may be.

 

(D)          A
contract transfer agreement between the Original Borrower, the Borrower and the Administrative Agent (acting as security agent),
providing (inter alia) for the assumption by the Borrower, with the Administrative Agent's consent, of the contractual position
of the Original Borrower under the share pledge agreement dated June 13, 2016, between the Original Borrower and the Administrative
Agent in relation to the shares in Cardiome International SA (the “Swiss Share Pledge Transfer Agreement”).

 

(E)          Without
limitation, all other documents and instruments reasonably required to perfect the Secured Parties’ Lien on, and security
interest in, the Collateral required to be delivered on or prior to the Closing Date shall have been duly executed and delivered
and be in proper form for filing, and shall create in favor of the Secured Parties, a perfected Lien on, and security interest
in, the Collateral, subject to no Liens other than Permitted Liens.

 

(v)          Approvals.
Certified copies of all material licenses, consents, authorizations and approvals of, and notices to and filings and registrations
with, any Governmental Authority (including all foreign exchange approvals), and of all third-party consents and approvals, necessary
in connection with the making and performance by the Obligors of the Loan Documents and the Transactions.

 

    	 	47	 

     

    

 

(vi)         Corporate
Documents. Certified copies of the constitutive documents of each Obligor (if publicly available in such Obligor’s jurisdiction
of formation, certified copies from such public institution), or an officer’s certificate certifying that no changes have
been made to such constitutive documents since the Original Closing Date (or in the case of any Obligor incorporated or organized
in Germany or Switzerland where up-to-date copies retrieved from the online commercial register shall be sufficient), and of resolutions
of the Board of Directors (and/or shareholders, if applicable) of each Obligor authorizing the making and performance by it of
the Loan Documents to be entered into on the date hereof and pursuant to Section 8.17 to which it is a party.

 

(vii)        Incumbency
Certificate. A certificate (which, for certainty, can be combined with the certificate required pursuant to Section 6.02(g)(v)
above) of each Obligor (except for an Obligor incorporated or organized in Germany) as to the authority, incumbency and specimen
signatures of the persons who have executed the Loan Documents and any other documents in connection herewith on behalf of the
Obligors. In relation to an Obligor incorporated or organized in Germany, (i) a certificate signed by an authorized signatory with
the power of representation certifying that each document delivered under clause 6.02(g)(v) above is correct, complete and
in full force and effect and has not been amended or superseded as at the date of the certificate and (ii) the specimen signatures
of each person authorized to execute any Loan Document.

 

(viii)       Officer’s
Certificate. A certificate, dated the Closing Date and signed by the President, a Vice President or a financial officer of
Borrower, confirming compliance with the conditions set forth in Section 6.05(b).

 

(ix)         Opinions
of Counsel. Favorable opinions, dated as of the Closing Date, in form acceptable to the Lenders and their counsel, as may include
the requests set forth in Exhibit E, provided by:

 

(A)         Blake,
Cassels & Graydon LLP, in respect of matters of relating to Canadian law and/or any Obligor organized in Canada or any province
or territory thereof;

 

(B)          Skadden,
Arps, Slate, Meagher & Flom LLP, in respect of matters relating to United States law and/or any Obligor organized in the United
States of America or any state or political subdivision thereof;

 

(C)          Baker
& McKenzie LLP, in respect of matters relating to English law and any Obligor organized in England and Wales or any state or
political subdivision thereof;

 

(D)          Allen
& Overy LLP, in respect of certain matters relating to German law, including corporate matters, relating to any Obligor organized
in Germany or any state or political subdivision thereof; and

 

(E)          Eversheds
Sutherland, in respect of matters relating to the law of Switzerland and/or any Obligor organized in Switzerland or any state or
political subdivision thereof.

 

(x)          Good
Standing Certificates. A certificate from the appropriate Governmental Authority, bearing a current date acceptable to the
Administrative Agent, to the effect that each Obligor (other than any English Obligor or any Obligor incorporated or organized
in Germany or Switzerland) is in good standing and qualified to transact business in its jurisdiction of organization and in each
other jurisdiction where it transacts business.

 

    	 	48	 

     

    

 

(xi)         Insurance.
Certificates of insurance evidencing the existence of all insurance required to be maintained by Borrower pursuant to Section
8.05 and the designation of the Lenders as the lender’s loss payees or additional named insured, as the case may be,
thereunder.

 

(xii)        Cipher
Transaction. Evidence satisfactory to the Administrative Agent and the Lenders that the Cipher Transaction has been completed.

 

(xiii)       Miscellaneous.
All other requirements referred to in Sections I.-VI. of the closing agenda attached hereto as Schedule 6.06 have been satisfied
in form and substance satisfactory to the Administrative Agent and the Lenders.

 

SECTION 7

REPRESENTATIONS AND WARRANTIES

 

Each Obligor represents and warrants to Administrative
Agent and the Lenders that:

 

7.01       Power
and Authority. Each of Borrower and its Subsidiaries (a) is a duly organized and validly existing under the laws of its jurisdiction
of organization, (b) has all requisite corporate or other power, and has all material governmental licenses, authorizations, consents
and approvals necessary to own its assets and carry on its business as now being or as proposed to be conducted except to the extent
that failure to have the same could not reasonably be expected to have a Material Adverse Effect, (c) is qualified to do business
and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such qualification necessary
and where failure so to qualify could (either individually or in the aggregate) have a Material Adverse Effect, and (d) has full
power, authority and legal right to make and perform each of the Loan Documents to which it is a party and, in the case of Borrower,
to borrow the Loans hereunder.

 

7.02       Authorization;
Enforceability. The Transactions are within each Obligor’s corporate powers and have been duly authorized by all necessary
corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and delivered by each Obligor
and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute,
a legal, valid and binding obligation of such Obligor, enforceable against each Obligor in accordance with its terms, except as
such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether
such enforceability is considered in a proceeding in equity or at law).

 

7.03       Governmental
and Other Approvals; No Conflicts. The Transactions (a) do not require any consent or approval of, registration or filing with,
or any other action by, any Governmental Authority or any third party, except for (i) such as have been obtained or made and are
in full force and effect and (ii) filings and recordings in respect of the Liens created pursuant to the Security Documents, (b)
will not violate any applicable law or regulation or the charter, bylaws or other organizational documents of Borrower and its
Subsidiaries, (c) will not violate any order of any Governmental Authority, other than any such violations that, individually or
in the aggregate, could not reasonably be expected to have a Material Adverse Effect, (d) will not violate or result in a default
under any indenture, agreement or other instrument binding upon Borrower and its Subsidiaries or
assets, or give rise to a right thereunder to require any payment to be made by any such Person, and (e) will not result in the
creation or imposition of any Lien (other than Permitted Liens) on any asset of Borrower and its Subsidiaries.

 

    	 	49	 

     

    

 

7.04       Financial
Statements; Material Adverse Change.

 

(a)          Financial
Statements. Borrower has heretofore furnished to the Lenders certain financial statements as provided for in Section 8.01.
Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows
of Borrower and its Subsidiaries as of such dates and for such periods in accordance with GAAP (provided that any non-Canadian
and non-United States organized Subsidiary, “GAAP” for non-consolidated statements may refer to generally accepted
accounting principles applicable in the relevant Subsidiary’s jurisdiction), subject to year-end audit adjustments and the
absence of footnotes in the case of the previously-delivered statements of the type described in Section 8.01(b). Neither
Borrower nor any of its Subsidiaries has any material contingent liabilities or unusual forward or long-term commitments not disclosed
in the aforementioned financial statements.

 

(b)          No
Material Adverse Change. Since December 31, 2017, there has been no Material Adverse Change.

 

7.05       Properties.

 

(a)          Property
Generally. Each Obligor has good and marketable fee simple title to, or valid leasehold interests in, all its real and personal
Property material to its business, subject only to Permitted Liens and except for minor defects in title that do not interfere
with its ability to conduct its business as currently conducted or to utilize such properties for their intended purposes.

 

(b)          Intellectual
Property. The Obligors represent and warrant to the Lenders as follows, as of the date hereof, each Borrowing Notice Date and
each Borrowing Date:

 

(i)           Schedule
7.05(b)(i) (as amended from time to time by Borrower in accordance with Section 8.16) contains:

 

(A)          a
complete and accurate list of all applied for or registered Patents owned by the Obligors, including the jurisdiction and patent
number;

 

(B)          a
complete and accurate list of all applied for or registered Trademarks owned by the Obligors, including the jurisdiction, trademark
application or registration number and the application or registration date; and

 

(C)          a
complete and accurate list of all applied for or registered Copyrights;

 

    	 	50	 

     

    

 

(ii)          Each
Obligor is the absolute beneficial owner of all right, title and interest in (other than in the case of licensed Intellectual Property,
in which case it shall have all rights and interest as licensee) and to and have the right to use the Obligor Intellectual Property
with no breaks in chain of title with good and marketable title, free and clear of any Liens or Claims
of any kind whatsoever other than Permitted Liens. Without limiting the foregoing, and except as set forth in Schedule 7.05(b)(ii):

 

(A)         other
than with respect to the Material Agreements, or as permitted by Section 9.09, the Obligors have not transferred ownership
of Material Intellectual Property, in whole or in part, to any other Person who is not an Obligor;

 

(B)          other
than (i) the Material Agreements, (ii) customary restrictions in in-bound licenses of Intellectual Property and non-disclosure
agreements, or (iii) as would have been or is permitted by Section 9.09, there are no judgments, covenants not to sue, permits,
grants, licenses, Liens (other than Permitted Liens), Claims, or other agreements or arrangements relating to Borrower’s
Material Intellectual Property, including any development, submission, services, research, license or support agreements, which
bind, obligate or otherwise restrict the Obligors;

 

(C)          the
use of any of the Obligor Intellectual Property, to any Obligor’s Knowledge, does not breach, violate, infringe or interfere
with or constitute a misappropriation of any valid rights arising under any Intellectual Property of any other Person;

 

(D)          to
any Obligor’s Knowledge, there are no pending or threatened Claims against the Obligors asserted by any other Person relating
to the Obligor Intellectual Property, including any Claims of adverse ownership, invalidity, infringement, misappropriation, violation
or other opposition to or conflict with such Intellectual Property; no Obligor has received any written notice from any Person
that any Obligor business, the use of the Obligor Intellectual Property, or the manufacture, use or sale of any product or the
performance of any service by any Obligor infringes upon, violates or constitutes a misappropriation of, or may infringe upon,
violate or constitute a misappropriation of, or otherwise interfere with, any other Intellectual Property of any other Person;

 

(E)          no
Obligor has any Knowledge that the Obligor Intellectual Property is being infringed, violated, misappropriated or otherwise used
by any other Person without the express authorization of the Obligors. Without limiting the foregoing, no Obligor has put any other
Person on notice of actual or potential infringement, violation or misappropriation of any of the Obligor Intellectual Property;
no Obligor has initiated the enforcement of any Claim with respect to any of the Obligor Intellectual Property;

 

(F)          all
relevant current and former employees and contractors of each Obligor have executed written confidentiality and invention assignment
Contracts with such Obligor that irrevocably assign to such Obligor or its designee all of their rights to any Inventions relating
to any of Obligor’s business;

 

(G)          to
the Knowledge of the Obligors, the Obligor Intellectual Property is all the Intellectual Property necessary for the operation of
Obligors’ business as it is currently conducted or as currently contemplated to be conducted;

 

(H)          each
Obligor has taken reasonable precautions to protect the secrecy, confidentiality and value of its Obligor Intellectual Property
consisting of trade secrets and confidential information;

 

    	 	51	 

     

    

 

(I)           each Obligor has delivered to Administrative Agent accurate and complete copies of all Material Agreements relating to the Obligor
Intellectual Property;

 

(J)           there
are no pending or, to the Knowledge of any of the Obligors, threatened in writing Claims against the Obligors asserted by any other
Person relating to the Material Agreements, including any Claims of breach or default under such Material Agreements;

 

(iii)         With
respect to the Obligor Intellectual Property consisting of Patents, except as set forth in Schedule 7.05(b)(ii), and without
limiting the representations and warranties in Section 7.05(b)(ii):

 

(A)         each
of the issued claims in such Patents, to Obligors’ Knowledge, is valid and enforceable;

 

(B)          the
inventors claimed in such Patents (other than in the case of licensed Patents) have executed written Contracts with an Obligor
or its predecessor-in-interest that properly and irrevocably assigns to an Obligor or predecessor-in-interest all of their rights
to any of the Inventions claimed in such Patents to the extent permitted by applicable law;

 

(C)          none
of the Patents, or the Inventions claimed in them, have been dedicated to the public except as a result of intentional decisions
made by the applicable Obligor;

 

(D)          to
any Obligor’s Knowledge, all prior art material to such Patents (other than in the case of licensed Patents) was adequately
disclosed to or considered by the respective patent offices during prosecution of such Patents to the extent required by applicable
law or regulation;

 

(E)          subsequent
to the issuance of such Patents, neither any Obligor nor their predecessors in interest, have filed any disclaimer or filed any
other voluntary reduction in the scope of the Inventions claimed in such Patents;

 

(F)          no
allowable or allowed subject matter of such Patents, to any Obligor’s Knowledge, is subject to any competing conception claims
of allowable or allowed subject matter of any patent applications or patents of any third party and have not been the subject of
any interference, re-examination or opposition proceedings, nor are the Obligors aware of any basis for any such interference,
re-examination or opposition proceedings;

 

(G)          no
such Patents, to any Obligor’s Knowledge, have ever been finally adjudicated to be invalid, unpatentable or unenforceable
for any reason in any administrative, arbitration, judicial or other proceeding, and, with the exception of publicly available
documents in the applicable patent office recorded with respect to any Patents, no Obligor has received any notice asserting that
such Patents are invalid, unpatentable or unenforceable; if any of such Patents is terminally disclaimed to another patent or patent
application, all patents and patent applications subject to such terminal disclaimer are included in the Collateral;

 

(H)          other
than in the case of licensed Patents, Obligor has received an opinion, whether preliminary in nature or qualified in any manner,
which concludes that a challenge to the validity or enforceability of any of such Patents is more
likely than not to succeed;

 

    	 	52	 

     

    

 

(I)           no
Obligor has any Knowledge that any Obligor or any prior owner of such Patents (other than in the case of licensed Patents) or their
respective agents or representatives have engaged in any conduct, or omitted to perform any necessary act, the result of which
would invalidate or render unpatentable or unenforceable any such Patents; and

 

(J)           all
maintenance fees, annuities, and the like due or payable on the Patents (other than in the case of licensed Patents in which case
all licensing and similar fees) have been timely paid or the failure to so pay was the result of an intentional decision by the
applicable Obligor or would not reasonably be expected to result in a Material Adverse Change.

 

(iv)         none
of the foregoing representations and statements of fact contains any untrue statement of material fact or omits to state any material
fact necessary to make any such statement or representation not misleading to a prospective Lender seeking full information as
to the Obligor Intellectual Property and Borrower’s business.

 

(c)          Material
Intellectual Property. Schedule 7.05(c) (as amended from time to time by Borrower in accordance with Section 8.16)
contains an accurate list of the Obligor Intellectual Property that is material to any Obligor’s business with an indication
as to whether the applicable Obligor owns or has an exclusive or non-exclusive license to such Obligor Intellectual Property.

 

7.06       No
Actions or Proceedings.

 

(a)          Litigation.
There is no litigation, investigation or proceeding pending or, to any Obligor’s Knowledge, threatened with respect to Borrower
and its Subsidiaries by or before any Governmental Authority or arbitrator (i) that either individually or in the aggregate could
reasonably be expected to have a Material Adverse Effect, except as specified in Schedule 7.06 (as amended from time to
time by Borrower in accordance with Section 8.16) or (ii) that involves this Agreement or the Transactions.

 

(b)          Environmental
Matters. The operations and Property of Borrower and its Subsidiaries comply with all applicable Environmental Laws, except
to the extent the failure to so comply (either individually or in the aggregate) could not reasonably be expected to have a Material
Adverse Effect.

 

(c)          Labor
Matters. Borrower has not engaged in unfair labor practices and there are no material labor actions or disputes involving the
employees of Borrower.

 

7.07         Compliance
with Laws and Agreements. Each of the Obligors is in compliance with all laws, regulations and orders of any Governmental Authority
applicable to it or its property and all indentures, agreements and other instruments binding upon it or its property, except where
the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.
No Default has occurred and is continuing.

 

    	 	53	 

     

    

 

7.08         Taxes. Except
as set forth on Schedule 7.08, each of the Obligors has timely filed or caused to be filed all tax returns and reports
required to have been filed and has paid or caused to be paid all Taxes required to have been paid by it, except Taxes that
are being contested in good faith by appropriate proceedings and for which such Obligor has set aside on its books
adequate reserves with respect thereto in accordance with GAAP (including, in the case of any non-Canadian and non-United
States organized Subsidiary Guarantor, in accordance with generally accepted accounting principles applicable in the relevant
Subsidiary Guarantor’s jurisdiction). Payments of interest made by the Borrower pursuant to this Agreement are not
treated as United States sourced payments for United States federal income tax purposes.

 

7.09       Full
Disclosure. Obligors have disclosed to Administrative Agent and the Lenders all Material Agreements to which any Obligor is
subject, and all other matters to any Obligor’s Knowledge that, individually or in the aggregate, could reasonably be expected
to result in a Material Adverse Effect. None of the reports, financial statements, certificates or other written information furnished
by or on behalf of any Obligor to Administrative Agent or any Lender in connection with the negotiation of this Agreement and the
other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished) contains
any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial
information, Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable
at the time.

 

7.10       Regulation.

 

(a)          Investment
Company Act. Neither Borrower nor any of its Subsidiaries is an “investment company” as defined in, or subject
to regulation under, the Investment Company Act of 1940.

 

(b)          Margin
Stock. Neither Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business
of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part
of the proceeds of the Loans will be used to buy or carry any Margin Stock in violation of Regulation T, U or X.

 

7.11       Solvency.
Each Obligor is, and immediately after giving effect to the Borrowings and the use of proceeds thereof will be, Solvent; provided
that intercompany balances shall be excluded when determining such Solvency.

 

7.12       Subsidiaries.
Set forth on Schedule 7.12 is a complete and correct list of all Subsidiaries as of the date hereof. Each such Subsidiary
is duly organized and validly existing under the jurisdiction of its organization shown in said Schedule 7.12, and the percentage
ownership by Borrower of each such Subsidiary is as shown in said Schedule 7.12.

 

7.13       Indebtedness
and Liens. Set forth on Schedule 7.13(a) is a complete and correct list of all Indebtedness of each Obligor outstanding
as of the date hereof. Schedule 7.13(b) is a complete and correct list of all Liens granted by Borrower and other Obligors
with respect to their respective Property and outstanding as of the date hereof.

 

    	 	54	 

     

    

 

7.14       Material
Agreements. Set forth on Schedule 7.14 (as amended from time to time by Borrower in accordance with Section 8.16)
is a complete and correct list of (i) each Material Agreement and (ii) each agreement creating or evidencing any Material Indebtedness.
No Obligor is in material default under any such Material Agreement or agreement creating or evidencing any Material Indebtedness.
Except as otherwise disclosed on Schedule 7.14, all material vendor purchase agreements and provider contracts of the Obligors
are in full force and effect without material modification from the form in which the same were disclosed to Administrative Agent
and the Lenders.

 

7.15       Restrictive
Agreements. None of the Obligors is subject to any indenture, agreement, instrument or other arrangement that prohibits, restricts
or imposes any condition upon (a) the ability of Borrower or any Subsidiary to create, incur or permit to exist any Lien upon any
of its property or assets (other than (x) customary provisions in contracts (including without limitation leases and in-bound licenses
of Intellectual Property) restricting the assignment thereof and (y) restrictions or conditions imposed by any agreement governing
secured Permitted Indebtedness permitted under Section 9.01(h), to the extent that such restrictions or conditions apply
only to the property or assets securing such Indebtedness), or (b) the ability of any Subsidiary to pay dividends or other distributions
with respect to any shares of its capital stock or to make or repay loans or advances to Borrower or any other Subsidiary or to
Guarantee Indebtedness of Borrower or any other Subsidiary (each, a “Restrictive Agreement”), except
those listed on Schedule 7.15 or otherwise permitted under Section 9.11.

 

7.16       Real
Property.

 

(a)          Generally.
Neither Borrower nor any of its Subsidiaries owns or leases (as tenant thereof) any real property, except as described on Schedule
7.16 (as amended from time to time by Borrower in accordance with Section 8.16).

 

(b)         Borrower
Lease. (i) Borrower has delivered a true, accurate and complete copy of the Borrower Lease to Administrative Agent.

 

(ii)          The
Borrower Lease is in full force and effect and no default has occurred under the Borrower Lease and, to the Knowledge of Borrower,
there is no existing condition which, but for the passage of time or the giving of notice, could reasonably be expected to result
in a default under the terms of the Borrower Lease.

 

(iii)         Borrower
is the tenant under the Borrower Lease and has not transferred, sold, assigned, conveyed, disposed of, mortgaged, pledged, hypothecated,
or encumbered any of its interest in, the Borrower Lease.

 

    	 	55	 

     

    

 

7.17       Pension
Matters. Schedule 7.17 sets forth, as of the date hereof, a complete and correct list of, and that separately identifies, (a)
all Title IV Plans, (b) all Multiemployer Plans and (c) all material Benefit Plans. Each Benefit Plan, and each trust thereunder,
intended to qualify for tax exempt status under Section 401 or 501 of the Code or other Requirements of Law is the subject of a
favorable determination letter from the IRS and no event or condition exists which could reasonably be expected to result in revocation
of such qualified status. Except for those that could not, in the aggregate, have a Material Adverse Effect, (x) each Benefit Plan
is in compliance with applicable provisions of ERISA, the Code and other Requirements of Law, (y) there are no existing or pending
(or to the Knowledge of any Obligor or Subsidiary thereof, threatened) claims (other than routine claims for benefits in the normal
course), sanctions, actions, lawsuits or other proceedings or investigation involving any Benefit Plan to which any Obligor
or Subsidiary thereof incurs or otherwise has or could have an obligation or any liability or Claim and (z) no ERISA Event is reasonably
expected to occur. Borrower and each of its ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules
with respect to each Title IV Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied
for or obtained. As of the most recent valuation date for any Title IV Plan, the funding target attainment percentage (as defined
in Section 430(d)(2) of the Code) is at least 60%, and neither Borrower nor any of its ERISA Affiliates knows of any facts or circumstances
that could reasonably be expected to cause the funding target attainment percentage to fall below 60% as of the most recent valuation
date. As of the date hereof, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or otherwise)
remain outstanding. No ERISA Affiliate would have any Withdrawal Liability as a result of a complete withdrawal from any Multiemployer
Plan on the date this representation is made.

 

7.18       Collateral;
Security Interest. Each Security Document is effective to create in favor of the Secured Parties a legal, valid and enforceable
security interest in the Collateral subject thereto and each such security interest is perfected to the extent required by (and
has the priority required by) the applicable Security Document. The Security Documents collectively are effective to create in
favor of the Secured Parties a legal, valid and enforceable security interest in the Collateral, which security interests are,
but in relation to German Security Documents only in relation to the German Account Pledge Agreements and the German Share Pledge
Agreements, with the ranking in priority which it is expressed to have in the German Account Pledge Agreements and the German Share
Pledge Agreements (as the case may be) subject only to Permitted Priority Liens and any pledges granted under the Security Documents
entered into in connection with the Original Agreement).

 

7.19       Regulatory
Approvals. Borrower and its Subsidiaries hold, and will continue to hold, either directly or through licensees and agents,
all Regulatory Approvals, licenses, permits and similar governmental authorizations of a Governmental Authority necessary or required
for Borrower and its Subsidiaries to conduct their operations and business in the manner currently conducted.

 

7.20       Canadian
Pension or Benefit Plans. No Obligor has at any time in the past or present established or been associated with any Canadian
Pension Plans or any Canadian Benefit Plans.

 

7.21       Series
A Shares. The Borrower has not as of the date of this Agreement issued any Series A Shares and has not issued or granted any
warrants, options or other rights to acquire any Series A Shares.

 

7.22       The
Toronto-Dominion Bank Account. The registration filed against the Borrower in the personal property security registry for British
Columbia, Canada with base registration # 125132H relates to Indebtedness owing by the Borrower to The Toronto-Dominion Bank that
in aggregate does not at any time exceed 50,000 dollars in the lawful currency of Canadian.

 

    	 	56	 

     

    

 

SECTION 8

AFFIRMATIVE COVENANTS

 

Each Obligor covenants and agrees with Administrative
Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations have been paid in full indefeasibly
in cash:

 

8.01       Financial
Statements and Other Information. Borrower will furnish to Administrative Agent:

 

(a)          as
soon as available and in any event within 45 days after the end of the first three fiscal quarters of each fiscal year (or 60 days,
in the case of the fourth fiscal quarter), the consolidated and consolidating balance sheets of the Obligors as of the end of such
quarter, and the related consolidated and consolidating statements of income, shareholders’ equity and cash flows of Borrower
and its Subsidiaries for such quarter and the portion of the fiscal year through the end of such quarter, prepared in accordance
with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the corresponding
period in the preceding fiscal year, together with a certificate of a Responsible Officer of Borrower stating that such financial
statements fairly present the financial condition of Borrower and its Subsidiaries as at such date and the results of operations
of Borrower and its Subsidiaries for the period ended on such date and have been prepared in accordance with GAAP consistently
applied, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes;

 

(b)          as
soon as available and in any event within 90 days after the end of each fiscal year, the consolidated and consolidating balance
sheets of Borrower and its Subsidiaries as of the end of such fiscal year, and the related consolidated and consolidating statements
of income, shareholders’ equity and cash flows of Borrower and its Subsidiaries for such fiscal year, prepared in accordance
with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal
year, accompanied by a report and opinion thereon of KPMG LLP or another firm of independent certified public accountants of recognized
national standing acceptable to the Lenders, which report and opinion shall be prepared in accordance with generally accepted auditing
standards and shall not be subject to any qualification or exception as to the scope of such audit, and in the case of such consolidating
financial statements, certified by a Responsible Officer of Borrower;

 

(c)          [Intentionally
Deleted.]

 

(d)          together
with the financial statements required pursuant to Sections 8.01(a) and (b) a compliance
certificate of a Responsible Officer as of the end of the applicable accounting period (which delivery may, unless a Lender requests
executed originals, be by electronic communication including fax or email and shall be deemed to be an original authentic counterpart
thereof for all purposes) in the form of Exhibit D (a “Compliance Certificate”) including details
of any issues that are material that are raised by auditors;

 

(e)          promptly
upon receipt thereof, copies of all letters of representation signed by an Obligor to its auditors and copies of all auditor reports
delivered for each fiscal quarter;

 

    	 	57	 

     

    

 

(f)          as
soon as available, a consolidated financial forecast for Borrower and its Subsidiaries for the following five fiscal years, including
forecasted consolidated statements of income and cash flows of Borrower and its Subsidiaries;

 

(g)          [Intentionally
Deleted.]

 

(h)          promptly,
and in any event within five Business Days after receipt thereof by an Obligor thereof, copies of each notice or other correspondence
received from any securities regulator or exchange to the authority of which Borrower may become subject from time to time concerning
any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of
such Obligor;

 

(i)           the
information regarding insurance maintained by Borrower and its Subsidiaries as required under Section 8.05;

 

(j)           promptly
following Administrative Agent’s request at any time, proof of Borrower’s compliance with Section 10.01; and

 

(k)          within
five (5) Business Days of each quarterly board meeting, copies of statements, reports and forecasts presented at such meetings
of Borrower’s board of directors which are, in the sole reasonable judgment of Borrower’s CEO and/or CFO, necessary
to understand the state of or outlook for the Borrower’s business operations, and which may be redacted. For avoidance of
doubt for purposes of compliance with this Section 8.01(k) only, Borrower shall not be required to provide competitively
sensitive information, confidential employee information, materials which fall under the attorney-client privilege, or materials
provided to committees of the board of directors. In any case, Borrower will provide all information provided to holders of Permitted
Cure Debt, provided that any such material may be redacted by Borrower to exclude information relating to the Lenders (including
Borrower’s strategy regarding the Loans).

 

8.02         Notices
of Material Events. Borrower will furnish to Administrative Agent written notice of the following promptly after a Responsible
Officer first learns of the existence of:

 

(a)          the
occurrence of any Default;

 

(b)          notice
of the occurrence of any event with respect to its property or assets resulting in a Loss aggregating $500,000 (or the Equivalent
Amount in other currencies) or more;

 

(c)          (A)
any proposed acquisition of stock, assets or property by any Obligor that would reasonably be expected to result in environmental
liability under Environmental Laws, and (B)(1) spillage, leakage, discharge, disposal, leaching, migration or release of any Hazardous
Material required to be reported to any Governmental Authority under applicable Environmental Laws, and (2) all actions, suits,
claims, notices of violation, hearings, investigations or proceedings pending, or to any Obligor’s Knowledge, threatened
against or affecting Borrower or any of its Subsidiaries or with respect to the ownership, use, maintenance and operation of their
respective businesses, operations or properties, relating to Environmental Laws or Hazardous Material;

 

    	 	58	 

     

    

 

(d)          the
assertion of any environmental matter by any Person against, or with respect to the activities of, Borrower or any of its Subsidiaries
and any alleged violation of or non-compliance with any Environmental Laws or any permits, licenses or authorizations which could
reasonably be expected to involve damages in excess of $500,000 other than any environmental matter or alleged violation that,
if adversely determined, could not (either individually or in the aggregate) have a Material Adverse Effect;

 

(e)          the
filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or affecting
Borrower or any of its Affiliates that, if adversely determined, could reasonably be expected to result in a Material Adverse Effect;

 

(f)          (i)
on or prior to any filing by any ERISA Affiliate of any notice of intent to terminate any Title IV Plan, a copy of such notice
and (ii) promptly, and in any event within ten days, after any Responsible Officer of any ERISA Affiliate knows or has reason to
know that a request for a minimum funding waiver under Section 412 of the Code has been filed with respect to any Title IV Plan
or Multiemployer Plan, a notice (which may be made by telephone if promptly confirmed in writing) describing such waiver request
and any action that any ERISA Affiliate proposes to take with respect thereto, together with a copy of any notice filed with the
PBGC or the IRS pertaining thereto;

 

(g)          (i)
the termination of any Material Agreement; (ii) the receipt by Borrower or any of its Subsidiaries of any material notice under
any Material Agreement; (iii) the entering into of any new Material Agreement by an Obligor; or (iv) any material amendment to
a Material Agreement;

 

(h)          the
reports and notices as required by the Security Documents;

 

(i)           within
30 days of the date thereof, or, if earlier, on the date of delivery of any financial statements pursuant to Section 8.01,
notice of any material change in accounting policies or financial reporting practices by the Obligors;

 

(j)           promptly
after the occurrence thereof, notice of any labor controversy resulting in or threatening to result in any strike, work stoppage,
boycott, shutdown or other material labor disruption against or involving an Obligor;

 

(k)          a
licensing agreement or arrangement entered into by Borrower or any Subsidiary in connection with any infringement or alleged infringement
of the Intellectual Property of another Person;

 

(l)           any
other development that results in, or could reasonably be expected to result in, a Material Adverse Effect;

 

(m)         concurrently
with the delivery of financial statements under Section 8.01(b), the creation or other acquisition of any Intellectual Property
by Borrower or any Subsidiary after the date hereof and during such prior fiscal year which is registered or becomes registered
or the subject of an application for registration with the Canadian Intellectual Property Office, the United States Copyright Office
or the United States Patent and Trademark Office, as applicable, or with any other equivalent foreign Governmental Authority;

 

    	 	59	 

     

    

 

(n)         any
change to any Obligor’s ownership of Deposit Accounts, Securities Accounts and Commodity Accounts, by delivering to Administrative
Agent an updated Annex 7 to the Canadian Security Agreement, U.S. Security Agreement or such annex, schedule, exhibit or similar
list contained in any other applicable Security Document, in each case setting forth a complete and correct list of all such accounts
as of the date of such change; or

 

(o)         such
other information respecting the operations, properties, business or condition (financial or otherwise) of the Obligors (including
with respect to the Collateral) as Administrative Agent may from time to time reasonably request.

 

Each notice delivered under this Section 8.02
shall be accompanied by a statement of a financial officer or other executive officer of Borrower setting forth the details of
the event or development requiring such notice and any action taken or proposed to be taken with respect thereto.

 

8.03       Existence;
Conduct of Business. Such Obligor will, and will cause each of its Subsidiaries to, do or cause to be done all things necessary
to preserve, renew and keep in full force and effect its legal existence and the rights, licenses, permits, privileges and franchises
material to the conduct of its business; provided that the foregoing shall not prohibit any merger, amalgamation, consolidation,
liquidation or dissolution permitted under Section 9.03.

 

8.04       Payment
of Taxes and Other Claims. Such Obligor will, and will cause each of its Subsidiaries to, pay and discharge (i) all Taxes,
fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which
penalties attach thereto, and all lawful claims for labor, materials and supplies which, if unpaid, might become a Lien upon any
properties or assets of Borrower or any Subsidiary, except to the extent such Taxes, fees, assessments or governmental charges
or levies, or such claims are being contested in good faith by appropriate proceedings and are adequately reserved against in accordance
with GAAP (including, in the case of any non-Canadian and non-United States organized Subsidiary, in accordance with generally
accepted accounting principles applicable in the relevant Subsidiary’s jurisdiction); and (ii) all lawful claims which, if
unpaid, would by law become a Lien upon its property not constituting a Permitted Lien.

 

8.05       Insurance.
Such Obligor will, and will cause each of its Subsidiaries to maintain, with financially sound and reputable insurance companies,
insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses
operating in the same or similar locations. Upon the request of Administrative Agent or the Majority Lenders, Borrower shall furnish
Administrative Agent from time to time with full information as to the insurance carried by it and, if so requested, copies of
all such insurance policies. Borrower also shall furnish to Administrative Agent from time to time upon the request of Administrative
Agent or the Majority Lenders a certificate from Borrower’s insurance broker or other insurance specialist stating that all
premiums then due on the policies relating to insurance on the Collateral have been paid, that such policies are in full force
and effect. Borrower shall use commercially reasonable efforts to ensure, or cause others to ensure, that all insurance policies
required under this Section 8.05 shall provide that they shall not be terminated or cancelled nor shall any such policy
be materially changed in a manner adverse to Borrower without at least 30 days’ prior written notice to Borrower and Administrative
Agent. Receipt of notice of termination or cancellation of any such insurance policies or reduction of coverages or amounts thereunder
shall entitle the Secured Parties to renew any such policies, cause the coverages and amounts thereof to be maintained at levels
required pursuant to the first sentence of this Section 8.05 or otherwise to obtain similar insurance in place of such policies,
in each case at the expense of Borrower (payable on demand). The amount of any such expenses shall accrue interest at the Default
Rate if not paid on demand, and shall constitute “Obligations”.

 

    	 	60	 

     

    

 

8.06       Books
and Records; Inspection Rights. Such Obligor will, and will cause each of its Subsidiaries to, keep proper books of record
and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities.
Such Obligor will, and will cause each of its Subsidiaries to, permit any representatives designated by Administrative Agent, upon
reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss
its affairs, finances and condition with its officers and independent accountants, all at such reasonable times (but not more often
than once a year unless an Event of Default has occurred and is continuing) as Administrative Agent may request. The Obligors shall
pay all reasonable and documented out-of-pocket costs of all such inspections.

 

8.07       Compliance
with Laws and Other Obligations. Such Obligor will, and will cause each of its Subsidiaries to, (i) comply in all material
respects with all laws, rules, regulations and orders of any Governmental Authority applicable to it or its property (including
Environmental Laws) and (ii) comply in all material respects with all terms of Indebtedness and all other Material Agreements,
except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse
Effect.

 

8.08         Maintenance
of Properties, Etc.

 

(a)          Such
Obligor shall, and shall cause each of its Subsidiaries to, maintain and preserve all of its properties necessary or useful in
the proper conduct of its business in good working order and condition in accordance with the general practice of other Persons
of similar character and size, ordinary wear and tear and damage from casualty or condemnation excepted.

 

(b)          Without
limiting the generality of Section 8.08(a), the Borrower shall comply with each of the following covenants with respect
to the Borrower Lease:

 

(i)           Borrower
shall diligently perform and timely observe all of the terms, covenants and conditions of the Borrower Lease on the part of Borrower
to be performed and observed prior to the expiration of any applicable grace period therein provided and do everything necessary
to preserve and to keep unimpaired and in full force and effect the Borrower Lease.

 

(ii)          Borrower
shall promptly notify Administrative Agent of the giving of any written notice by Borrower Landlord to Borrower of any default
by Borrower thereunder, and promptly deliver to Administrative Agent a true copy of each such notice.

 

8.09       Licenses. Such
Obligor shall, and shall cause each of its Subsidiaries to, obtain and maintain all licenses, authorizations, consents,
filings, exemptions, registrations and other Governmental Approvals necessary in connection with the execution, delivery and
performance of the Loan Documents, the consummation of the Transactions or the operation and conduct of its business and
ownership of its properties, except where failure to do so could not reasonably be expected to have a Material Adverse
Effect.

 

    	 	61	 

     

    

 

8.10         Action
under Environmental Laws. Such Obligor shall, and shall cause each of its Subsidiaries to, upon becoming aware of the presence
of any Hazardous Materials in contravention of applicable Environmental Laws or the existence of any environmental liability under
applicable Environmental Laws with respect to their respective businesses, operations or properties, take all actions, at their
cost and expense, as shall be necessary or advisable to investigate and clean up the condition of their respective businesses,
operations or properties, including all required removal, containment and remedial actions, and restore their respective businesses,
operations or properties to a condition in compliance with applicable Environmental Laws.

 

8.11       Use
of Proceeds. The proceeds of the Loans will be used only as provided in Section 2.4. No
part of the proceeds of the Loans will be used, whether directly or indirectly, for any purpose that entails a violation of Regulations
T, U and X.

 

8.12       Certain
Obligations Respecting Subsidiaries; Further Assurances.

 

(a)          Subsidiary
Guarantors. Each Obligor will take such action, and will cause each of its Subsidiaries to take such action, from time to time
as shall be necessary to ensure that, subject to Section 8.12(b) with respect to requirements for Foreign Subsidiaries,
all Subsidiaries are “Subsidiary Guarantors” hereunder. Without limiting the generality of the foregoing, in the event
that Borrower or any of its Subsidiaries shall form or acquire any new Subsidiary, such Obligor and its Subsidiaries concurrently
will, subject to Section 8.12(b) with respect to requirements for Foreign Subsidiaries:

 

(i)           cause
such new Subsidiary to become a “Subsidiary Guarantor” hereunder, and a “Grantor” or similar granting party,
as applicable, under the Security Documents, pursuant to a Guarantee Assumption Agreement;

 

(ii)          take
such action or cause such Subsidiary to take such action (including, if applicable, delivering such shares of stock together with
undated transfer powers executed in blank) as shall be necessary to create and perfect valid and enforceable first priority (subject
to Permitted Priority Liens) Liens on substantially all of the property of such new Subsidiary as collateral security for the obligations
of such new Subsidiary hereunder;

 

(iii)         to
the extent that the parent of such Subsidiary is not a party to the Canadian Security Agreement, U.S. Security Agreement or such
other Security Document, as applicable, or has not otherwise pledged Equity Interests in its Subsidiaries in accordance with the
terms of the Security Documents, as applicable, and this Agreement, cause the parent of such Subsidiary to execute and deliver
a pledge agreement in favor of the Secured Parties in respect of all outstanding issued shares of such Subsidiary; and

 

(iv)         deliver
such proof of corporate action, incumbency of officers, opinions of counsel and other documents as is consistent with those delivered
by each Obligor pursuant to Section 6.01 or as Administrative Agent or the Majority Lenders shall have requested.

 

    	 	62	 

     

    

 

(b)          Foreign
Subsidiaries.

 

(i)           In
the event that, at any time, Foreign Subsidiaries have, in the aggregate, (x) total revenues constituting 5% or more of
the total revenues of Borrower and its Subsidiaries on a consolidated basis, or (y) total net assets constituting 5% or more of
the total net assets of Borrower and its Subsidiaries on a consolidated basis, promptly (and, in any event, within 30 days after
such time) Obligors shall cause one or more of such Foreign Subsidiaries to become Subsidiary Guarantors in the manner set forth
in Section 8.12(a), such that, after such Subsidiaries become Subsidiary Guarantors, the non-guarantor Foreign Subsidiaries
in the aggregate shall cease to have revenues or assets, as applicable, that meet the thresholds set forth in clauses (x) and (y)
above; provided that no Foreign Subsidiary shall be required to become a Subsidiary Guarantor if doing so would result in material
adverse tax consequences for Borrower and its Subsidiaries, taken as a whole;

 

(ii)          In
the event that, at any time, any Foreign Subsidiary that is not a Subsidiary Guarantor has cash or deposits on account in excess
of $300,000 or the aggregate of such cash or deposits on account for all such Foreign Subsidiaries is in excess of $1,000,000,
Borrower shall cause such Foreign Subsidiary(s) to (x) immediately transfer all funds that exceed the amounts identified above
to its direct or indirect parent that is a Subsidiary Guarantor or (y) become a Subsidiary Guarantor in the manner set forth in
Section 8.12(a). Notwithstanding the foregoing, this Section 8.12(b)(ii) shall not apply to the Italian Account provided
that the balance of assets in the Italian Account does not exceed $2,000,000 (or the equivalent amount in another currency based
upon the then current applicable Exchange Rate) or to the Escrow Account provided that the balance of assets in the Escrow Account
does not exceed $1,000,000 (or the equivalent amount in another currency based upon the then current applicable Exchange Rate).
For certainty, all cash and deposits on accounts of any Foreign Subsidiary that is not a Subsidiary Guarantor which is not required
to be transferred in accordance with part (x) above shall not be included in the calculation of Liquidity; and

 

(iii)         In
addition to Section 8.12(b)(ii) above, while the Escrow Account exists the Borrower shall, within twenty (20) Business Days
after receiving prior written notice from the Administrative Agent (which the Administrative Agent may provide in its sole discretion),
cause any Foreign Subsidiary that is not already a Subsidiary Guarantor but which has cash or deposits on account from time to
time to become a Subsidiary Guarantor in the manner set forth in Section 8.12(a), including for certainty providing all
necessary security and control agreements, notwithstanding that such Foreign Subsidiary would not otherwise be required to become
a Subsidiary Guarantor pursuant to the other terms of this Section 8.12.

 

(c)          Further
Assurances. Such Obligor will, and will cause each of its Subsidiaries to, take such action from time to time as shall reasonably
be requested by Administrative Agent or the Majority Lenders to effectuate the purposes and objectives of this Agreement.

 

Without limiting the generality of the foregoing, each Obligor will,
and will cause each Person that is required to be a Subsidiary Guarantor to, take such action from time to time (including executing
and delivering such assignments, security agreements, control agreements and other instruments) as shall be reasonably requested
by Administrative Agent or the Majority Lenders to create, in favor of the Secured Parties, perfected security interests and Liens
in substantially all of the property of such Obligor as collateral security for the Obligations; provided that any such
security interest or Lien shall be subject to the relevant requirements of the Security Documents.

 

    	 	63	 

     

    

 

8.13       Termination
of Non-Permitted Liens. In the event that Borrower or any of its Subsidiaries shall become aware or be notified by Administrative
Agent or any Lender of the existence of any outstanding Lien against any Property of Borrower or any of its Subsidiaries, which
Lien is not a Permitted Lien, Borrower shall use its best efforts to promptly terminate or cause the termination of such Lien.

 

8.14       Intellectual
Property. In the event that the Obligors acquire Obligor Intellectual Property during the term of this Agreement, then the
provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute
part of the Collateral under the Security Documents, without further action by any party, in each case from and after the date
of such acquisition (except that any representations or warranties of any Obligor shall apply to any such Obligor Intellectual
Property only from and after the date, if any, subsequent to such acquisition that such representations and warranties are brought
down or made anew as provided herein).

 

8.15       Owned
Real Property. In the event that any Obligor acquires any owned real property during the term of this Agreement for consideration
in excess of $500,000, such Obligor shall concurrently with such acquisition (i) execute and deliver any mortgage or deed of trust
or any other real property security document required by the Administrative Agent to be executed by such Obligor in favor of the
Secured Parties, (ii) provide evidence of registration in the appropriate offices of such real property security document with
respect to all such real property owned by such Obligor, and (iii) such other real property security documents and instruments
as may be required by the Administrative Agent.

 

8.16       Update
of Schedules. Each of Schedules 7.05(b)(i), 7.05(c), 7.06, 7.14 and 7.16 shall be updated
by Borrower from time to time in order to insure the continued accuracy of such Schedule as of any upcoming date on which representations
and warranties are made incorporating the information contained on such Schedule. Such update may be accomplished by Borrower providing
to Administrative Agent, in writing (including by electronic means), a revised version of such Schedule in accordance with the
provisions of Section 13.02. Each such updated Schedule shall be effective immediately upon the receipt thereof by the Lenders.

 

8.17       Post-Closing
Items. Borrower will deliver, or cause the applicable Subsidiary Guarantor to deliver, the items set forth in Schedule 8.17
on the dates set forth therein. Any post-closing obligation set forth in Schedule 8.17 or the time period applicable to
any such post-closing obligation may in each case be waived or extended by the Administrative Agent, from time to time, in its
sole discretion.

 

8.18       Swiss
Guarantors Each Swiss Guarantor will comply with the Non-Qualifying Bank Creditor Rules; provided that, for this purpose, each
Swiss Guarantor shall assume at all times that the number of existing Lenders and Participants hereunder which are not, in each
case, Qualifying Bank Creditors shall be ten (10).

 

    	 	64	 

     

    

 

8.19       Loan
Proceeds. Borrower shall use a portion of the proceeds of the Loans for the benefit of Foreign Subsidiaries that are Subsidiary
Guarantors, including the disbursement by the Borrower of a portion of such proceeds to such Subsidiary Guarantors.

 

8.20       Cipher
Transaction Proceeds. Upon completion of the Cipher Transaction, Borrower shall immediately deposit all proceeds from the Cipher
Transaction into one of its accounts at HSBC Bank Canada.

 

SECTION 9

NEGATIVE COVENANTS

 

Each Obligor covenants and agrees with Administrative
Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations have been paid in full indefeasibly
in cash:

 

9.01      Indebtedness.
Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness,
whether directly or indirectly, except:

 

(a)          the
Obligations;

 

(b)          Indebtedness
existing on the date hereof and set forth in Part II of Schedule 7.13(a) and Permitted Refinancings thereof; provided
that, in each case, such Indebtedness is subordinated to the Obligations on terms satisfactory to the Majority Lenders;

 

(c)          [Intentionally
Deleted.];

 

(d)          accounts
payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing of money)
incurred in the ordinary course of Borrower’s or such Subsidiary’s business in accordance with customary terms and
paid within the specified time, unless contested in good faith by appropriate proceedings and reserved for in accordance with GAAP;

 

(e)           Indebtedness
consisting of guarantees resulting from endorsement of negotiable instruments for collection by any Obligor in the ordinary course
of business;

 

(f)           Indebtedness
owing by any Obligor to any other Obligor;

 

(g)          Guarantees
by any Obligor of Indebtedness of any other Obligor;

 

(h)          normal
course of business equipment financing; provided that (i) if secured, the collateral therefor consists solely of the assets
being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal
amount of such Indebtedness does not exceed $1,000,000 (or the Equivalent Amount in other currencies) at any time;

 

(i)           Permitted
Cure Debt;

 

(j)           Permitted
Credit Card Indebtedness in an aggregate amount for all Obligors not to exceed $500,000;

 

    	 	65	 

     

    

 

(k)          Indebtedness
approved in advance in writing by the Majority Lenders; and

 

(l)           Indebtedness
arising under any bank guarantee, surety (Bürgschaft) or any other instrument issued by a bank or financial institution
upon request of an Obligor incorporated in Germany to comply with the requirments of section 8a of the German Act on Partial Retirement
(Altersteilzeitgesetz) or of section 7e of the German Social Security Code Part IV (Sozialgesetzbuch IV).

 

9.02         Liens.
Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on
any property or asset now owned by it, or assign or sell any income or revenues (including accounts receivable) or rights in respect
of any thereof, except:

 

(a)          Liens
securing the Obligations;

 

(b)          any
Lien on any property or asset of Borrower or any of its Subsidiaries existing on the date hereof and set forth in Part II
of Schedule 7.13(b); provided that (i) no such Lien shall extend to any other property or asset of Borrower or any
of its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and extensions,
renewals and replacements thereof that do not increase the outstanding principal amount thereof;

 

(c)          [Intentionally
Deleted.];

 

(d)          Liens
securing Indebtedness permitted under Section 9.01(j); provided that such Liens do not secure property or assets
of the Obligors with an aggregate value in excess of the amount permitted in Section 9.01(j) and the Administrative Agent
has received estoppel letters or other agreements, in form and substance satisfactory to the Administrative Agent, in respect of
such Liens;

 

(e)          [Intentionally
Deleted.]

 

(f)           Liens
securing Indebtedness permitted under Section 9.01(h); provided that such Liens are restricted solely to the collateral
described in Section 9.01(h);

 

(g)          Liens
imposed by law which were incurred in the ordinary course of business, including (but not limited to) carriers’, warehousemen’s
and mechanics’ liens and other similar liens arising in the ordinary course of business and which (x) do not in the aggregate
materially detract from the value of the Property subject thereto or materially impair the use thereof in the operations of the
business of such Person or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect
of preventing the forfeiture or sale of the Property subject to such liens and for which adequate reserves have been made if required
in accordance with GAAP;

 

(h)          pledges
or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance or other
similar social security legislation;

 

(i)           Liens
securing taxes, assessments and other governmental charges, the payment of which is not yet due or is being contested in good faith
by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions,
if any, as shall be required by GAAP shall have been made;

 

    	 	66	 

     

    

 

(j)           servitudes,
easements, rights of way, restrictions and other similar encumbrances on real Property imposed by applicable Laws and encumbrances
consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor imperfections
in title thereto which, in the aggregate, are not material, and which do not in any case materially detract from the value of the
property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors;

 

(k)          with
respect to any real Property, (A) such defects or encroachments as might be revealed by an up-to-date survey of such real Property;
(B) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by
the original owner of such real Property pursuant to applicable Laws; and (C) rights of expropriation, access or user or any similar
right conferred or reserved by or in applicable Laws, which, in the aggregate for (A), (B) and (C), are not material, and which
do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of
the business of any of the Obligors; and

 

(l)          Bankers
liens, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business;

 

(m)          any
liens arising under the general terms and conditions of banks and Sparkassen (Allgemeine Geschäftsbedingungen der Banken
und Sparkassen) or similar general terms and conditions of banks with whom any Obligor maintains a banking relationship in
the ordinary course of business;

 

(n)          any
landlord’s pledge (Vermieterpfandrecht) arising by operation of law under a lease in favour of the relevant third
party landlord in Germany; and

 

(o)          any
Liens required to be created or subsisting in order to comply with sections 7b and 7e of the German Social Security Code Part IV
(Sozialgesetzbuch IV), section 8a of the German Partial Retirement Act (Altersteilzeitgesetz) and section 4 of the
German Act for the Improvement of Occupational Pensions Schemes (Gesetz zur Verbesserung der betrieblichen Altersvorsorge);

 

provided that no Lien otherwise permitted under any of the
foregoing Sections 9.02(b) through (i) shall apply to any Material Intellectual Property.

 

9.03       Fundamental Changes and Acquisitions. Such Obligor will
not, and will not permit any of its Subsidiaries to, (i) enter into any transaction of merger, amalgamation or consolidation (ii)
liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution), or (iii) make any Acquisition or otherwise acquire
any business or substantially all the property from, or capital stock of, or be a party to any acquisition of, any Person, except:

 

(a)          Investments
permitted under Section 9.05(e);

 

    	 	67	 

     

    

 

(b)          the
merger, amalgamation or consolidation of any Subsidiary Guarantor with or into any other Obligor from the same country of organization
of such Subsidiary Guarantor, provided that the Administrative Agent has confirmed in writing to
such Obligors that all applicable Liens granted under the applicable Security Documents will not negatively be affected by such
merger, amalgamation or consolidation and that the surviving Obligor shall assume all obligations of the applicable Obligors under
the applicable Security Documents;

 

(c)          the
sale, lease, transfer or other disposition by any Subsidiary Guarantor of any or all of its property (upon voluntary liquidation
or otherwise) to any other Obligor from the same country of organization of such Subsidiary Guarantor;

 

(d)          the
sale, transfer or other disposition of the capital stock of any Subsidiary Guarantor to any other Obligor; and

 

(e)          Permitted
Acquisitions in an amount not exceeding $5,000,000 in the aggregate during the term of this Agreement.

 

9.04       Lines
of Business. Such Obligor will not, and will not permit any of its Subsidiaries to, engage to any material extent in any business
other than the business engaged in on the date hereof by Borrower or any Subsidiary or a business reasonably related thereto.

 

9.05       Investments.
Such Obligor will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding
any Investments except:

 

(a)          Investments
outstanding on the date hereof and identified in Schedule 9.05;

 

(b)         operating
deposit accounts with banks;

 

(c)          extensions
of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services in the ordinary
course of business;

 

(d)         Permitted
Cash Equivalent Investments;

 

(e)          Investments
by any Obligor in Borrower’s wholly-owned Subsidiary Guarantors (for greater certainty, Borrower shall not be permitted to
have any direct or indirect Subsidiaries that are not wholly-owned Subsidiaries);

 

(f)          Hedging
Agreements entered into in the ordinary course of Borrower’s financial planning solely to hedge currency risks (and not for
speculative purposes);

 

(g)         Investments
consisting of security deposits with utilities and other like Persons made in the ordinary course of business;

 

(h)         employee
loans, travel advances and guarantees in accordance with Borrower’s usual and customary practices with respect thereto (if
permitted by applicable law) which in the aggregate shall not exceed $200,000 outstanding at any time (or the Equivalent Amount
in other currencies);

 

    	 	68	 

     

    

 

(i)           Investments
received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and in settlement of delinquent
obligations of, and other disputes with, customers, suppliers or clients;

 

(j)           Investments
permitted under Section 9.03; and

 

(k)          any
Investments incurred in relation to any part time worker arrangements in accordance with section 8a of the German Partial Retirement
Act (Altersteilzeitgesetz) or section 7b and/or 7e of the German Social Security Code Part IV (Sozialgesetzbuch IV).

 

9.06       Restricted
Payments. Such Obligor will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay or make,
directly or indirectly, any Restricted Payment, except:

 

(a)          Borrower
may purchase, redeem, retire, or otherwise acquire shares of its capital stock or other Equity Interests with the proceeds received
from a substantially concurrent issue of new shares of its capital stock or other Equity Interests; and

 

(b)          any
Subsidiary Guarantor may pay dividends to any other Obligor.

 

9.07       Payments
of Indebtedness. Such Obligor will not, and will not permit any of its Subsidiaries to, make any payments in respect of any
Indebtedness other than (i) payments of the Obligations, (ii) scheduled payments of other Indebtedness and (iii) repayment of intercompany
Indebtedness permitted in reliance upon Section 9.01(f).

 

9.08       Change
in Fiscal Year. Such Obligor will not, and will not permit any of its Subsidiaries to, change the last day of its fiscal year
from that in effect on the date hereof, except to change the fiscal year of a Subsidiary acquired in connection with an Acquisition
to conform its fiscal year to that of Borrower.

 

9.09       Sales
of Assets, Etc. Such Obligor will not, and will not permit any of its Subsidiaries to, sell, lease, exclusively license (in
terms of geography or field of use), transfer, or otherwise dispose of any of its Property (including accounts receivable and capital
stock of Subsidiaries) to any Person in one transaction or series of transactions (any thereof, an “Asset Sale”),
except:

 

(a)          transfers
of cash in the ordinary course of its business for equivalent value;

 

(b)          sales
of inventory in the ordinary course of its business on ordinary business terms;

 

(c)          development
and other collaborative arrangements where such arrangements provide for the licenses or disclosure of Patents, Trademarks, Copyrights
or other Intellectual Property rights in the ordinary course of business and consistent with general market practices where such
license requires periodic payments based on per unit sales of a product over a period of time and provided that such licenses must
be true licenses as opposed to licenses that are sales transactions in substance;

 

(d)          transfers
of Property by any Subsidiary Guarantor to any other Obligor from the same country of organization of such Subsidiary Guarantor;

 

    	 	69	 

     

    

 

(e)          dispositions
of any Property that is obsolete or worn out or no longer used or useful in such Obligor’s business;

 

(f)           to
comply with the requirements of section 7f of the German Social Security Code Part IV (Sozialgesetzbuch IV) or section 4
of the German Act for the Improvement of Occupational Pension Schemes (Gesetz zur Verbesserung der betrieblichen Altersversorgung);

 

(g)          any
transaction permitted under Section 9.03 or 9.05; and

 

(h)          any
other Disposition the Net Cash Proceeds of which are applied as required under Section 3.03(b)(i).

 

9.10       Transactions
with Affiliates. Such Obligor will not, and will not permit any of its Subsidiaries to, sell, lease, license or otherwise transfer
any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions
with, any of its Affiliates, except:

 

(a)          transactions
between or among Obligors;

 

(b)          any
transaction permitted under Section 9.01, 9.05, 9.06 or 9.09;

 

(c)          customary
compensation and indemnification of, and other employment arrangements with, directors, officers and employees of Borrower or any
Subsidiary in the ordinary course of business,

 

(d)         Borrower
may issue Equity Interests to Affiliates in exchange for cash, provided that the terms thereof are no less favorable (including
the amount of cash received by Borrower) to Borrower than those that would be obtained in a comparable arm’s-length transaction
with a Person not an Affiliate of Borrower; and

 

(e)          the
transactions set forth on Schedule 9.10.

 

9.11       Restrictive
Agreements. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into,
incur or permit to exist any Restrictive Agreement other than (a) restrictions and conditions imposed by law or by this
Agreement and (b) Restrictive Agreements listed on Schedule 7.15.

 

9.12       Amendments
to Material Agreements. Such Obligor will not, and will not permit any of its Subsidiaries to, enter into any material amendment
to or modification of any Material Agreement or terminate any Material Agreement (unless replaced with another agreement that,
viewed as a whole, is on substantially similar or better terms for Borrower or such Subsidiary) without in each case the prior
written consent of the Lender (which consent shall not be unreasonably withheld or delayed).

 

9.13       Operating
Leases. Borrower will not, and will not permit any of its Subsidiaries to, make any expenditures in respect of operating leases,
except for:

 

(a)          real
estate operating leases;

 

    	 	70	 

     

    

 

(b)          operating
leases between Borrower and any of its wholly-owned Subsidiaries or between any of Borrower’s wholly-owned Subsidiaries;
and

 

(c)          operating
leases that would not cause Borrower and its Subsidiaries, on a consolidated basis, to make payments exceeding $1,000,000 (or the
Equivalent Amount in other currencies) in any fiscal year.

 

9.14       Sales
and Leasebacks. Except as disclosed on Schedule 9.14, such Obligor will not, and will not permit any of its Subsidiaries
to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation,
of any property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which Borrower or such Subsidiary
has sold or transferred or is to sell or transfer to any other Person and (ii) which Borrower or such Subsidiary intends to use
for substantially the same purposes as property which has been or is to be sold or transferred.

 

9.15       Hazardous
Material. Such Obligor will not, and will not permit any of its Subsidiaries to, use, generate, manufacture, install, treat,
release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure
to comply could not reasonably be expected to result in a Material Adverse Change.

 

9.16       Accounting
Changes. Such Obligor will not, and will not permit any of its Subsidiaries to, make any significant change in accounting treatment
or reporting practices, except as required or permitted by GAAP (including, in the case of any non-Canadian and non-United States
organized Subsidiary, as permitted by generally accepted accounting principles applicable in the relevant Subsidiary’s jurisdiction).

 

9.17       Compliance
with ERISA. No ERISA Affiliate shall cause or suffer to exist (a) any event that could result in the imposition of a Lien with
respect to any Title IV Plan or Multiemployer Plan or (b) any other ERISA Event that would, in the aggregate, have a Material Adverse
Effect. No Obligor or Subsidiary thereof shall cause or suffer to exist any event that could result in the imposition of a Lien
with respect to any Plan.

 

9.18       Canadian
Benefit Plans. No Obligor shall, nor shall it permit any of its Subsidiaries to, (a) establish or commence contribution
to or otherwise participate in any retirement or pension arrangement that provides defined benefits; (b) acquire an interest
in any Person if such Person sponsors, administers, participates in, or has any liability in respect of, any retirement or
pension arrangement that provides defined benefits; or (c) establish a Canadian Pension Plan or Canadian Benefit Plan.

 

9.19       [Reserved.]

 

9.20       Series
A Shares. Borrower shall not issue any Series A Shares unless prior to any such issuance the Borrower amends its constating
documents (including its articles of amalgamation) to remove any right of any holder or beneficiary of any such Series A Shares
to receive cash or other payment (other than the issuance of common shares pursuant to a conversion of such Series A Shares) in
respect of such Series A Shares.

 

9.21         Swiss
Indebtedness. In addition to the covenant in Section 9.01 above, if such Obligor is a Swiss Guarantor, it will not,
and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or
indirectly, with any non-Obligor unless such non-Obligor is a Qualifying Bank Creditor.

 

    	 	71	 

     

    

 

SECTION 10

FINANCIAL COVENANTS

 

10.01    Minimum
Liquidity. The Obligors shall maintain at all times Liquidity (which for certainty shall exclude amounts in the Italian Account
and the Escrow Account) in an aggregate amount which shall exceed (i) $5,000,000 from the date hereof to and including December
31, 2018, and (ii) $10,000,000 beginning January 1, 2019 and thereafter.

 

10.02    Minimum
Revenue. Borrower and its Subsidiaries shall have annual Revenue from sales of the Product (for each respective calendar year,
the “Minimum Required Revenue”):

 

(a)          during
the twelve month period beginning on January 1, 2016, of at least $24,000,000;

 

(b)          during
the twelve month period beginning on January 1, 2017, of at least $24,000,000;

 

(c)          during
the twelve month period beginning on January 1, 2018, of at least $27,000,000;

 

(d)          during
the twelve month period beginning on January 1, 2019, of at least $36,000,000;

 

(e)          during
the twelve month period beginning on January 1, 2020, of at least $60,000,000;

 

(f)          during
the twelve month period beginning on January 1, 2021 and all successive twelve month periods thereafter, of at least $75,000,000;

 

(g)          during
the twelve month period beginning on January 1, 2022 and all successive twelve month periods thereafter, of at least $85,000,000,

 

or, in each case above, an Equivalent Amount in Canadian dollars
if all annual Revenue from sales of the Product is received in Canadian dollars.

 

10.03    Cure
Right.

 

(a)          Notwithstanding
anything to the contrary contained in Section 11, in the event that Borrower fails to comply with the covenants contained
in Section 10.02(a) through (d) (such covenants for such applicable periods being the “Specified Financial
Covenants”), Borrower shall have the right within 90 (ninety) days of the end of the respective calendar year:

 

(i)           to
issue additional shares of Equity Interests in exchange for cash (the “Equity Cure Right”), or

 

    	 	72	 

     

    

 

(ii)          to
borrow Permitted Cure Debt (the “Subordinated Debt Cure Right” and, collectively with the Equity Cure
Right, the “Cure Right”), in an amount (the “Cure Amount ”) equal to
(x) two (2) multiplied by (y) the difference between the Minimum Required Revenue less Borrower’s annual Revenue. The Cure
Amount immediately shall be contributed as equity or subordinated debt (only as permitted pursuant to Section 9.01), as
applicable, to Borrower, and upon the receipt by Borrower of the Cure Amount pursuant to the exercise of such Cure Right, such
Cure Amount shall be deemed to constitute Revenue of Borrower for purposes of the Specified Financial Covenants and the Specified
Financial Covenants shall be recalculated for all purposes under the Loan Documents. If, after giving effect to the foregoing recalculation,
Borrower shall then be in compliance with the requirements of the Specified Financial Covenants, Borrower shall be deemed to have
satisfied the requirements of the Specified Financial Covenants as of the relevant date of determination with the same effect as
though there had been no failure to comply therewith at such date, and the applicable breach of the Specified Financial Covenants
that had occurred, the related Default and Event of Default, shall be deemed cured without any further action of Borrower or Lenders
for all purposes under the Loan Documents.

 

(b)          Notwithstanding
anything herein to the contrary the Cure Amount received by Borrower from investors investing in or lending to Borrower pursuant
to Section 10.03(a) shall be used to immediately prepay the Loans, without any Prepayment Premium (including for certainty
any Backend Facility Fee), credited in the order set forth in Sections 3.03(b)(i)(A)-(F).

 

SECTION 11

EVENTS OF DEFAULT

 

11.01     Events
of Default. Each of the following events shall constitute an “Event of Default”:

 

(a)          Borrower
shall fail to pay any principal of any Loan when and as the same shall become due and payable, whether at the due date thereof
or at a date fixed for prepayment thereof or otherwise;

 

(b)          any
Obligor shall fail to pay any Obligation (other than an amount referred to in Section 11.01(a)) when and as the same shall
become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days;

 

(c)          any
representation or warranty made or deemed made by or on behalf of Borrower or any of its Subsidiaries in or in connection with
this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial
statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment
or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to the extent that such representation
or warranty contains any materiality or Material Adverse Effect qualifier; or (ii) prove to have been incorrect in any material
respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality
or Material Adverse Effect qualifier;

 

(d)          any
Obligor shall fail to observe or perform any covenant, condition or agreement contained in Section 8.02, 8.03 (with
respect to Borrower’s existence), 8.11, 8.12, 8.14, 8.17, 8.18, 9 or 10;

 

    	 	73	 

     

    

 

(e)          any
Obligor shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than those specified
in Section 11.01(a), (b) or (d)) or any other Loan Document, and, in the case of any failure that is capable
of cure, if such failure shall continue unremedied for a period of twenty-five (25) or more days;

 

(f)           Borrower
or any of its Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount) in respect
of any Material Indebtedness, when and as the same shall become due and payable after giving effect to any applicable grace or
cure period as originally provided by the terms of such Indebtedness;

 

(g)          (i)
any material breach of, or “event of default” or similar event by any Obligor under, any Material Agreement, (ii) any
material breach of, or “event of default” or similar event under, the documentation governing any Material Indebtedness
shall occur, or (iii) any event or condition occurs (A) that results in any Material Indebtedness becoming due prior to its scheduled
maturity or (B) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders
of such Material Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due,
or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that
this Section 11.01(g) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer
of the property or assets securing such Material Indebtedness.

 

(h)          any
Obligor:

 

(i)          becomes
insolvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become due, or admits in
writing its inability to pay its debts generally, or declares any general moratorium on its indebtedness, or proposes a compromise
or arrangement or deed of company arrangement between it and any class of its creditors;

 

(ii)         commits
an act of bankruptcy or makes an assignment of its property for the general benefit of its creditors or makes a proposal (or files
a notice of its intention to do so);

 

(iii)        institutes
any proceeding seeking to adjudicate it an insolvent, or seeking liquidation, dissolution, winding-up, reorganization, compromise,
arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors),
or composition of it or its debts or any other relief, under any federal, provincial, territorial or foreign Law now or hereafter
in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection
of debtors or at common law or in equity, or files an answer admitting the material allegations of a petition filed against it
in any such proceeding;

 

(iv)        applies
for the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator,
custodian, administrator, trustee, liquidator, voluntary administrator, administrative receiver, receiver and manager or other
similar official for it or any substantial part of its property; or

 

(v)         takes
any action, corporate or otherwise, to approve, effect, consent to or authorize any of the actions described in Section 11.01(h)
or (i), or otherwise acts in furtherance thereof or fails to act in a timely and appropriate manner in defense thereof;

 

    	 	74	 

     

    

 

(i)           any petition is filed, application made or other proceeding instituted against or in respect of Borrower or any Subsidiary:

 

(i)           seeking
to adjudicate it an insolvent;

 

(ii)          seeking
a receiving order against it;

 

(iii)         seeking liquidation,
dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings
of creditors generally (or any class of creditors), deed of company arrangement or composition of it or its debts or any other
relief under any federal, provincial, territorial or foreign law now or hereafter in effect relating to bankruptcy, winding-up,
insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity;
or

 

(iv)         seeking
the entry of an order for relief or the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager,
sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, administrative receiver, receiver
and manager or other similar official for it or any substantial part of its property, and such petition, application or proceeding
continues undismissed, or unstayed and in effect, for a period of thirty (30) days after the institution thereof; provided that
if an order, decree or judgment is granted or entered (whether or not entered or subject to appeal) against Borrower or such Subsidiary
thereunder in the interim, such grace period will cease to apply; provided further that if Borrower or such Subsidiary files
an answer admitting the material allegations of a petition filed against it in any such proceeding, such grace period will cease
to apply;

 

(j)           any
other event occurs which, under the laws of any applicable jurisdiction, has an effect equivalent to any of the events referred
to in either of Section 11.01(h) or (i) (in particular, in relation to an Obligor incorporated or organized in Germany,
(x) it is unable to pay its debts as they fall due (zahlungsunfähig) within the meaning of section 17 German Insolvency
Code (Insolvenzordnung, InsO) or over indebted within the meaning of section 19 InsO and/or

 

(y)          the
filing for insolvency (Antrag auf Eröffnung des Insolvenzverfahrens) for any of the reasons set out in sections 17
or 19 InsO by either the management or a creditor of an Obligor incorporated in Germany or a competent court taking any of the
actions set out in section 21 InsO, instituting insolvency proceedings against such Obligor or refusing the opening of insolvency
proceedings for insufficiency of assets (Abweisung mangels Masse) (within the meaning of section 26 InsO);

 

(k)          one
or more judgments for the payment of money in an aggregate amount in excess of $500,000 (or the Equivalent Amount in other currencies)
shall be rendered against any Obligor or any combination thereof and the same shall remain undischarged for a period of 45 consecutive
days during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach
or levy upon any assets of any Obligor to enforce any such judgment;

 

(l)           (i)
an ERISA Event shall have occurred that, in the opinion of the Lenders, when taken together with all other ERISA Events that have
occurred, could reasonably be expected to result in liability of Borrower and its Subsidiaries in an aggregate amount exceeding
(i) $250,000 in any year or (ii) $750,000 for all periods until repayment of all Obligations;

 

    	 	75	 

     

    

 

(m)          [Intentionally
Deleted.]

 

(n)          a
Material Adverse Change shall have occurred;

 

(o)          [Intentionally
Deleted];

 

(p)          (i)
any Lien created by any of the Security Documents shall at any time not constitute a valid and perfected Lien on the applicable
Collateral in favor of the Secured Parties, free and clear of all other Liens (other than Permitted Liens), (ii) except for expiration
in accordance with its terms, any of the Security Documents or any Guarantee of any of the Obligations (including that contained
in Section 14) shall for whatever reason cease to be in full force and effect, or (iii) any of the Security Documents or
any Guarantee of any of the Obligations (including that contained in Section 14), or the enforceability thereof, shall be
repudiated or contested by any Obligor; and

 

(q)          any
injunction, whether temporary or permanent, shall be rendered against any Obligor that prevents the Obligors from selling or manufacturing
the Product or its commercially available successors, or any of their other material and commercially available products for more
than 45 consecutive calendar days in a country or region which accounts for ten percent (10%) or more of the Revenue of Borrower
and its Subsidiaries taken as a whole.

 

11.2       Remedies.
(a) Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of Default described in
Section 11.01(h), (i) or (j)), and at any time thereafter during the continuance of such event, the Majority
Lenders may, by notice to Borrower, take either or both of the following actions, at the same or different times: (i) terminate
the Commitments, and thereupon the Commitments shall terminate immediately, and (ii) declare the Loans then outstanding to be due
and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared
to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest
thereon and all fees and other Obligations, shall become due and payable immediately (in the case of the Loans, at the Redemption
Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.

 

(b)          Upon
the occurrence of any Event of Default described in Section 11.01(h), (i) or (j),
the Commitments shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon
and all fees and other Obligations, shall automatically become due and payable immediately (in the case of the Loans, at the Redemption
Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.

 

(c)          Upon
the occurrence of any Event of Default, the Obligors agree to immediately take any actions requested by the Administrative Agent
that the Administrative Agent in its sole discretion determines are required in order to permit the Administrative Agent to enforce
the guarantees by the Swiss Guarantors pursuant to Section 14.01 and the Swiss Security Documents in a manner such that
no Swiss Withholding Tax will be applicable.

 

    	 	76	 

     

    

 

(d)          Prepayment
Premium and Redemption Price. (i) For the avoidance of doubt, the Prepayment Premium (as a component of the Redemption
Price) shall be due and payable whenever so stated in this Agreement, or by any applicable operation of law, regardless of
the circumstances causing any related acceleration or payment prior to the Stated Maturity Date, including without limitation
any Event of Default or other failure to comply with the terms of this Agreement, whether or not notice thereof has been
given, or any acceleration by, through, or on account of any bankruptcy filing.

 

(ii)          For
the avoidance of doubt, the Prepayment Premium (as a component of the Redemption Price) shall be due and payable at any time the
Loans become due and payable prior to the Stated Maturity Date for any reason, whether due to acceleration pursuant to the terms
of this Agreement (in which case it shall be due immediately, upon the giving of notice to Borrower in accordance with Section
11.02(a), or automatically, in accordance with Section 11.02(b)), by operation of law or otherwise (including, without
limitation, where bankruptcy filings or the exercise of any bankruptcy right or power, whether in any plan of reorganization or
otherwise, results or would result in a payment, discharge, modification or other treatment of the Loans or Loan Documents that
would otherwise evade, avoid, or otherwise disappoint the expectations of Lenders in receiving the full benefit of their bargained-for
Prepayment Premium or Redemption Price as provided herein). The Obligors and Lenders acknowledge and agree that any Prepayment
Premium due and payable in accordance with this Agreement shall not constitute unmatured interest, whether under section 502(b)(3)
of the Bankruptcy Code or otherwise, but instead is reasonably calculated to ensure that the Lenders receive the benefit of their
bargain under the terms of this Agreement.

 

(iii)         Each
Obligor acknowledges and agrees that the Lenders shall be entitled to recover the full amount of the Redemption Price in each and
every circumstance such amount is due pursuant to or in connection with this Agreement, including without limitation in the case
of any Obligor’s bankruptcy filing, so that the Lenders shall receive the benefit of their bargain hereunder and otherwise
receive full recovery as agreed under every possible circumstance, and Borrower hereby waives any defense to payment, whether such
defense may be based in public policy, ambiguity, or otherwise. Each Obligor further acknowledges and agrees, and waives any argument
to the contrary, that payment of such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation.
Any damages that the Lenders may suffer or incur resulting from or arising in connection with any breach by Borrower shall constitute
secured obligations owing to the Lenders.

 

SECTION 12

ADMINISTRATIVE AGENT

 

12.01     Appointment
and Duties.

 

(a)          Appointment
of Administrative Agent. Each Lender hereby appoints CRG Servicing (together with any successor Administrative Agent pursuant
to Section 12.09) as Administrative Agent hereunder and authorizes Administrative Agent to (i) execute and deliver the Loan
Documents and accept delivery thereof on its behalf from any Obligor or any of its Subsidiaries, (ii) take such action on its behalf
and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to Administrative Agent under
such Loan Documents, (iii) act as agent of such Lender for purposes of acquiring, holding, enforcing and perfecting all Liens granted
by the Obligors on the Collateral to secure any of the Obligations and (iv) exercise such powers as are reasonably incidental thereto.

 

    	 	77	 

     

    

 

(b)          Italian
Appointment. For the purposes of Section 1704 of the Italian Civil Code, each Lender hereby:

 

(i)           appoints
CRG Servicing (together with any successor Administrative Agent pursuant to Section 12.09) to be its mandatario con rappresentanza
and common representative for the purposes of executing in the name and on behalf of the Lenders any Security Document which is
expressed to be governed by Italian law;

 

(ii)          grants
CRG Servicing (together with any successor Administrative Agent pursuant to Section 12.09) the power to negotiate and approve
the terms and conditions of such Security Documents, execute any other agreement or instrument, give or receive any notice or declaration,
identify and specify to third parties the names of the Lenders at any given date, and take any other action in relation to the
creation, perfection, maintenance, enforcement and release of the security created thereunder in the name and on behalf of the
Lenders; and

 

(iii)         confirms that,
in the event that any security created under the Security Documents expressed to be governed by Italian law remains registered
in the name of a Lender after it has ceased to be a Lender, then CRG Servicing (or any successor Administrative Agent pursuant
to Section 12.10) shall remain empowered to execute a release of such security in its name and on its behalf.

 

(c)          Swiss
Appointment. For the purposes of the Security Documents governed by Swiss law, each Lender hereby agrees that the Administrative
Agent has entered into or, as applicable, shall enter into, and hold any proceeds or other benefits of any security created under
such Security Documents by way of assignment as indirect representative (indirekter Stellvertreter), i.e. in its own name
but for the account of the Lenders. Furthermore, each present and future Lender shall be deemed, in relation to any security created
under such Security Documents (each, a “Pledge Document”) by way of pledge, to have authorized the Administrative
Agent, in each case in accordance with this Agreement, to (i) accept such pledge as the direct representative (direkter Stellvertreter)
of such Lender, (ii) hold, administer and, if necessary, enforce such pledge on behalf of such Lender, (iii) agree as the direct
representative (direkter Stellvertreter) of such Lender to any variation of or waiver of any right under such Pledge Document,
(iv) effect as the direct representative (direkter Stellvertreter) of such Lender any release of such pledge, and (v) exercise
as the direct representative (direkter Stellvertreter) of such Lender such other rights granted to the Administrative Agent under
or in respect of such pledge.

 

    	 	78	 

     

    

 

12.02     Duties
as Collateral and Disbursing Agent. Without limiting the generality of Section 12.01(a), Administrative Agent shall
have the sole and exclusive right and authority (to the exclusion of the Lenders), and is hereby authorized, to (i) act as the
disbursing and collecting agent for the Lenders with respect to all payments and collections arising in connection with the Loan
Documents (including in any proceeding described in Section 11.01(h), (i) or (j) or any other bankruptcy,
insolvency or similar proceeding), and each Person making any payment in connection with any Loan Document to any Secured Party
is hereby authorized to make such payment to Administrative Agent, (ii) file and prove claims and file other documents necessary
or desirable to allow the claims of the Secured Parties with respect to any Obligation in any proceeding described in Section
11.01(h), (i) or (j) or any other bankruptcy, insolvency or similar proceeding (but not to vote, consent or otherwise
act on behalf of such Secured Party), (iii) act as collateral agent for each Secured Party for purposes of acquiring, holding,
enforcing and perfecting all Liens created by the Loan Documents and all other purposes stated therein, (iv) manage, supervise
and otherwise deal with the Collateral, (v) take such other action as is necessary or desirable to maintain the perfection and
priority of the Liens created or purported to be created by the Loan Documents, (vi) except as may be otherwise specified in any
Loan Document, exercise all remedies given to Administrative Agent and the other Secured Parties with respect to the Collateral,
whether under the Loan Documents, applicable Requirements of Law or otherwise, (vii) enter into subordination agreements with respect
to Permitted Cure Debt or any other subordination agreement or intercreditor agreement with respect to Indebtedness of an Obligor
and (viii) execute any amendment, consent or waiver under the Loan Documents on behalf of any Lender that has consented in writing
to such amendment, consent or waiver; provided, however, that Administrative Agent hereby appoints, authorizes and directs
each Lender to act as collateral sub-agent for Administrative Agent and the Secured Parties for purposes of the perfection of all
Liens with respect to the Collateral, including any deposit account maintained by a Obligor with, and cash and Permitted Cash Equivalent
Investments held by, such Lender, and may further authorize and direct any Lender to take further actions as collateral sub-agents
for purposes of enforcing such Liens or otherwise to transfer the Collateral subject thereto to Administrative Agent, and each
Lender hereby agrees to take such further actions to the extent, and only to the extent, so authorized and directed.

 

(a)          Limited
Duties. Under the Loan Documents, Administrative Agent (i) is acting solely on behalf of the Lenders (except to the limited
extent provided in Section 12.07), with duties that are entirely administrative in nature, notwithstanding the use of the
defined term “Administrative Agent”, the terms “agent”, “administrative agent” and “collateral
agent” and similar terms in any Loan Document to refer to Administrative Agent, which terms are used for title purposes only,
(ii) is not assuming any obligation under any Loan Document other than as expressly set forth therein or any role as agent, fiduciary
or trustee of or for any Lender or any other Secured Party and (iii) shall have no implied functions, responsibilities, duties,
obligations or other liabilities under any Loan Document, and each Lender hereby waives and agrees not to assert any claim against
Administrative Agent based on the roles, duties and legal relationships expressly disclaimed in the foregoing clauses (i)
through (iii).

 

12.03    Binding
Effect. Each Lender agrees that (i) any action taken by Administrative Agent or the Majority Lenders (or, if expressly required
hereby, a greater proportion of the Lenders) in accordance with the provisions of the Loan Documents, (ii) any action taken by
Administrative Agent in reliance upon the instructions of the Majority Lenders (or, where so required, such greater proportion)
and (iii) the exercise by Administrative Agent or the Majority Lenders (or, where so required, such greater proportion) of the
powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and
binding upon all of the Secured Parties.

 

12.04    Use
of Discretion. (a) No Action without Instructions. Administrative Agent shall not be required to exercise any discretion
or take, or to omit to take, any action, including with respect to enforcement or collection, except any action it is required
to take or omit to take (i) under any Loan Document or (ii) pursuant to instructions from the Majority Lenders (or, where expressly
required by the terms of this Agreement, a greater proportion of the Lenders).

 

(b)          Right Not to Follow Certain Instructions.
Notwithstanding Section 12.04(a), Administrative Agent shall not be required to take, or to omit to take, any action (i)
unless, upon demand, Administrative Agent receives an indemnification satisfactory to it from the Lenders (or, to the extent applicable
and acceptable to Administrative Agent, any other Secured Party) against all liabilities that, by
reason of such action or omission, may be imposed on, incurred by or asserted against Administrative Agent or any Related Person
thereof or (ii) that is, in the opinion of Administrative Agent or its counsel, contrary to any Loan Document or applicable Requirement
of Law.

 

    	 	79	 

     

    

 

12.05     Delegation
of Rights and Duties. Administrative Agent may, upon any term or condition it specifies, delegate or exercise any of its rights,
powers and remedies under, and delegate or perform any of its duties or any other action with respect to, any Loan Document by
or through or to any trustee, co-agent, sub-agent, employee, attorney-in-fact and any other Person (including any other Secured
Party). Any such Person shall benefit from this Section 12 to the extent provided by Administrative Agent. Administrative
Agent shall not be responsible for the negligence or misconduct of any sub-agent except to the extent that a court of competent
jurisdiction determines in a final and nonappealable judgment that Administrative Agent acted with gross negligence or willful
misconduct in the selection of such sub-agent.

 

12.06     Reliance
and Liability. (a) Administrative Agent may, without incurring any liability hereunder, (i) consult with any of its Related
Persons and, whether or not selected by it, any other advisors, accountants and other experts (including advisors to, and accountants
and experts engaged by, any Obligor) and (ii) rely and act upon any document and information and any telephone message or conversation,
in each case believed by it to be genuine and transmitted, signed or otherwise authenticated by the appropriate parties.

 

(b)          None
of Administrative Agent and its Related Persons shall be liable for any action taken or omitted to be taken by any of them under
or in connection with any Loan Document, and each Lender and each Obligor hereby waives and shall not assert any right, claim or
cause of action based thereon, except to the extent of liabilities resulting primarily from the gross negligence or willful misconduct
of Administrative Agent or, as the case may be, such Related Person (each as determined in a final, non-appealable judgment by
a court of competent jurisdiction) in connection with the duties expressly set forth herein. Without limiting the foregoing, Administrative
Agent:

 

(i)          shall
not be responsible or otherwise incur liability for any action or omission taken in reliance upon the instructions of the Majority
Lenders or for the actions or omissions of any of its Related Persons selected with reasonable care (other than employees, officers
and directors of Administrative Agent, when acting on behalf of Administrative Agent);

 

(ii)         shall
not be responsible to any Secured Party for the due execution, legality, validity, enforceability, effectiveness, genuineness,
sufficiency or value of, or the attachment, perfection or priority of any Lien created or purported to be created under or in connection
with, any Loan Document;

 

(iii)        makes
no warranty or representation, and shall not be responsible, to any Secured Party for any statement, document, information, representation
or warranty made or furnished by or on behalf of any Related Person, in or in connection with any Loan Document or any transaction
contemplated therein, whether or not transmitted by Administrative Agent, including as to completeness, accuracy, scope or adequacy
thereof, or for the scope, nature or results of any due diligence performed by Administrative Agent in connection with the Loan
Documents; and

 

    	 	80	 

     

    

 

(iv)        shall
not have any duty to ascertain or to inquire as to the performance or observance of any provision of any Loan Document, whether
any condition set forth in any Loan Document is satisfied or waived, as to the financial condition of any Obligor or as to the
existence or continuation or possible occurrence or continuation of any Default or Event of Default and shall not be deemed to
have notice or knowledge of such occurrence or continuation unless it has received a notice from Borrower, any Lender describing
such Default or Event of Default clearly labeled “notice of default” (in which case Administrative Agent shall promptly
give notice of such receipt to all Lenders);

 

and, for each of the items set forth in clauses
(i) through (iv) above, each Lender and each Obligor hereby waives and agrees not to assert any right, claim or cause of action
it might have against Administrative Agent based thereon.

 

12.07     Administrative Agent Individually. Administrative Agent
and its Affiliates may make loans and other extensions of credit to, acquire Equity Interests of, engage in any kind of business
with, any Obligor or Affiliate thereof as though it were not acting Administrative Agent and may receive separate fees and other
payments therefor. To the extent Administrative Agent or any of its Affiliates makes any Loan or otherwise becomes a Lender hereunder,
it shall have and may exercise the same rights and powers hereunder and shall be subject to the same obligations and liabilities
as any other Lender and the terms “Lender”, “Majority Lender”, and any similar terms shall, except where
otherwise expressly provided in any Loan Document, include, without limitation, Administrative Agent or such Affiliate, as the
case may be, in its individual capacity as Lender or as one of the Majority Lenders, respectively.

 

12.08    Lender Credit Decision. Each Lender acknowledges that
it shall, independently and without reliance upon Administrative Agent, any Lender or any of their Related Persons or upon any
document solely or in part because such document was transmitted by Administrative Agent or any of its Related Persons, conduct
its own independent investigation of the financial condition and affairs of each Obligor and make and continue to make its own
credit decisions in connection with entering into, and taking or not taking any action under, any Loan Document or with respect
to any transaction contemplated in any Loan Document, in each case based on such documents and information as it shall deem appropriate.

 

12.09     Expenses; Indemnities. (a) Each Lender agrees to reimburse
Administrative Agent and each of its Related Persons (to the extent not reimbursed by any Obligor) promptly upon demand for such
Lender’s Proportionate Share of any costs and expenses (including fees, charges and disbursements of financial, legal and
other advisors and Other Taxes paid in the name of, or on behalf of, any Obligor) that may be incurred by Administrative Agent
or any of its Related Persons in connection with the preparation, syndication, execution, delivery, administration, modification,
consent, waiver or enforcement (whether through negotiations, through any work- out, bankruptcy, restructuring or other legal or
other proceeding or otherwise) of, or legal advice in respect of its rights or responsibilities under, any Loan Document.

 

(b)          Each Lender
further agrees to indemnify Administrative Agent and each of its Related Persons (to the extent not reimbursed by any Obligor),
from and against such Lender’s aggregate Proportionate Share of the liabilities (including taxes, interests and penalties
imposed for not properly withholding or backup withholding on payments made to on or for the account of any Lender) that may be
imposed on, incurred by or asserted against Administrative Agent or any of its Related Persons in any matter relating to or arising
out of, in connection with or as a result of any Loan Document, any related document or any other act, event or transaction
related, contemplated in or attendant to any such document, or, in each case, any action taken or omitted to be taken by Administrative
Agent or any of its Related Persons under or with respect to any of the foregoing; provided, however, that no Lender shall
be liable to Administrative Agent or any of its Related Persons to the extent such liability is found in a final, non-appealable
judgment by a court of competent jurisdiction to have resulted from such Administrative Agent’s or such Related Person’s
gross negligence or willful misconduct.

 

    	 	81	 

     

    

 

12.10     Resignation
of Administrative Agent. (a) Administrative Agent may resign at any time by delivering notice of such resignation to the Lenders
and Borrower, effective on the date set forth in such notice or, if not such date is set forth therein, upon the date such notice
shall be effective. If Administrative Agent delivers any such notice, the Majority Lenders shall have the right to appoint a successor
Administrative Agent. If, within thirty (30) days after the retiring Administrative Agent having given notice of resignation, no
successor Administrative Agent has been appointed by the Majority Lenders that has accepted such appointment, then the retiring
Administrative Agent may, on behalf of the Lenders, appoint a successor Administrative Agent from among the Lenders. Each appointment
under this Section 12.10(a) shall be subject to the prior consent of Borrower, which may not be unreasonably withheld but
shall not be required during the continuance of an Event of Default.

 

(b)          Effective
immediately upon its resignation, (i) the retiring Administrative Agent shall be discharged from its duties and obligations under
the Loan Documents, (ii) the Lenders shall assume and perform all of the duties of Administrative Agent until a successor Administrative
Agent shall have accepted a valid appointment hereunder, (iii) the retiring Administrative Agent and its Related Persons shall
no longer have the benefit of any provision of any Loan Document other than with respect to any actions taken or omitted to be
taken while such retiring Administrative Agent was, or because such Administrative Agent had been, validly acting as Administrative
Agent under the Loan Documents and (iv) subject to its rights under Section 12.03, the retiring Administrative Agent shall
take such action as may be reasonably necessary to assign to the successor Administrative Agent its rights as Administrative Agent
under the Loan Documents. Effective immediately upon its acceptance of a valid appointment as Administrative Agent, a successor
Administrative Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the retiring Administrative
Agent under the Loan Documents.

 

12.11     Release
of Collateral or Guarantors. Each Lender hereby consents to the release and hereby directs Administrative Agent to release
(or, in the case of Section 12.11(b)(ii), release or subordinate) the following:

 

(a)          any
Subsidiary of Borrower from its guaranty of any Obligation of any Obligor if all of the Equity Interests in such Subsidiary owned
by any Obligor or any of its Subsidiaries are disposed of in an Asset Sale permitted under the Loan Documents (including pursuant
to a waiver or consent), to the extent that, after giving effect to such Asset Sale, such Subsidiary would not be required to guaranty
any Obligations pursuant to Section 8.12; and

 

    	 	82	 

     

    

 

(b)          any
Lien held by Administrative Agent for the benefit of the Secured Parties against (i) any Collateral that is disposed of by an Obligor
in an Asset Sale permitted by the Loan Documents (including pursuant to a valid waiver or consent), to the extent all Liens required
to be granted in such Collateral pursuant to Section 8.12 after giving effect to such Asset Sale have been granted,
(ii) any property subject to a Lien described in Section 9.02(f) and (iii) all of the Collateral and all Obligors, upon
(A) termination of the Commitments, (B) payment and satisfaction in full of all Loans and all other Obligations that Administrative
Agent has been notified in writing are then due and payable, (C) deposit of cash collateral with respect to all contingent Obligations,
in amounts and on terms and conditions and with parties satisfactory to the Majority Lenders and each indemnitee that is owed such
Obligations and (D) to the extent requested by Administrative Agent, receipt by the Secured Parties of liability releases from
the Obligors each in form and substance acceptable to Administrative Agent.

 

Each Lender hereby directs Administrative Agent,
and Administrative Agent hereby agrees, upon receipt of reasonable advance notice from Borrower, to execute and deliver or file
such documents and to perform other actions reasonably necessary to release the guaranties and Liens when and as directed in this
Section 12.11.

 

12.12     Additional
Secured Parties. The benefit of the provisions of the Loan Documents directly relating to the Collateral or any Lien granted
thereunder shall extend to and be available to any Secured Party that is not a Lender as long as, by accepting such benefits, such
Secured Party agrees, as among Administrative Agent and all other Secured Parties, that such Secured Party is bound by (and, if
requested by Administrative Agent, shall confirm such agreement in a writing in form and substance acceptable to Administrative
Agent) this Section 12 and the decisions and actions of Administrative Agent and the Majority Lenders (or, where expressly
required by the terms of this Agreement, a greater proportion of the Lenders) to the same extent a Lender is bound; provided, however,
that, notwithstanding the foregoing, (a) such Secured Party shall be bound by Section 12.09 only to the extent of liabilities,
costs and expenses with respect to or otherwise relating to the Collateral held for the benefit of such Secured Party, in which
case the obligations of such Secured Party thereunder shall not be limited by any concept of Proportionate Share or similar concept,
(b) each of Administrative Agent and each Lender shall be entitled to act at its sole discretion, without regard to the interest
of such Secured Party, regardless of whether any Obligation to such Secured Party thereafter remains outstanding, is deprived of
the benefit of the Collateral, becomes unsecured or is otherwise affected or put in jeopardy thereby, and without any duty or liability
to such Secured Party or any such Obligation and (c) such Secured Party shall not have any right to be notified of, consent to,
direct, require or be heard with respect to, any action taken or omitted in respect of the Collateral or under any Loan Document.

 

12.13     Quebec
Security. For the purposes of the grant of security under the laws of the Province of Quebec which may now or in the future
be required to be provided by the Borrower or any other Obligor, the Administrative Agent is hereby irrevocably authorized and
appointed to act as the hypothecary representative (within the meaning of Article 2692 of the Civil Code of Québec) on behalf
of all Secured Parties in order to hold any hypothec granted under the laws of the Province of Quebec pursuant to any deed of hypothec
as security for the Obligations and to exercise such rights and duties as are conferred upon a hypothecary representative under
the relevant deed of hypothec and applicable laws (with the power to delegate any such rights or duties). The execution prior to
the date hereof by the Administrative Agent of any deed of hypothec made pursuant to the laws of the Province of Quebec, is hereby
ratified and confirmed. For greater certainty, the Administrative Agent, acting as hypothecary representative, shall have the same
rights, powers, immunities, indemnities and exclusions from liability as are prescribed in favour of the Administrative Agent,
which shall apply mutatis mutandis. In the event of the resignation and appointment of a successor Administrative Agent,
such successor Administrative Agent shall automatically (and without any further action) become the successor hypothecary representative
on behalf of all Secured Parties. Notwithstanding Section 17, this provision shall be governed and construed in accordance
with the laws of the Province of Quebec.

 

    	 	83	 

     

    

 

12.14     French
Security.

 

(a)          Without
prejudice to the generality of Section 12.01 above and only to the extent necessary, each Secured Party (i) appoints the
Administrative Agent to act as agent (mandataire) pursuant to Article 1984 of the French Civil Code (Code civil)
for the purpose of executing any Security Documents expressed to be or construed to be governed by French law (together, the “French
Security Documents”) in its name, (ii) confirms its approval of the French Security Documents creating or expressed to
create a security interest benefiting to it and any security interest created or to be created pursuant thereto and, (iii) irrevocably
authorises, empowers and directs the Administrative Agent (by itself or by such person(s) as it may nominate) on its behalf, to
perform the duties and to exercise the rights, powers and discretions that are specifically delegated to it under or in connection
with the French Security Documents, to take any action and exercise any right, power, authorities and discretion upon the terms
and conditions set out in this Agreement under or in connection with the French Security Documents, in each case together with
any other rights, powers and discretions which are incidental thereto, to give a good discharge for any moneys payable under the
French Security Documents and to release any security interest created under the French Security Documents, it being understood
that each Secured Party (other than the Administrative Agent) shall issue special powers of attorneys in all cases where the exercise
of powers granted under this Agreement requires the issuance of any such special powers of attorney, and the Administrative Agent
accepts such appointment.

 

(b)          It
is expressly agreed amongst the parties to this Agreement that the security interest created pursuant to the Security Documents
subject to French law shall be reserved (réservés) for the benefit of any new Lenders or new Secured Parties
in accordance with the terms of article 1278 of the French Civil Code (Code civil) in case of any novation, assignment or
transfer under Section 13. For the purposes of articles 1278 et seq. of the French Civil Code (Code civil),
each existing Lender expressly reserves such security interest to the benefit of each new Lender and the obligations of each Obligor
under the above mentioned security interest under the French law governed Security Documents will continue in full force and effect
for the benefit of the new Lenders following any novation, assignment or transfer under Section 13, which is expressly agreed
and confirmed by the existing Lenders and the relevant Obligors and all other parties from time to time to this Agreement.

 

SECTION 13

MISCELLANEOUS

 

13.01     No
Waiver. No failure on the part of Administrative Agent or any Lender to exercise and no delay in exercising, and no course
of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall
any single or partial exercise of any right, power or privilege under any Loan Document preclude any other or further exercise
thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of
any remedies provided by law.

 

    	 	84	 

     

    

 

13.02     Notices.
All notices, requests, instructions, directions and other communications provided for herein (including any modifications of,
or waivers, requests or consents under, this Agreement) shall be given or made in writing (including by telecopy) delivered, if
to Borrower, another Obligor, Administrative Agent or any Lender, to its address specified on the signature pages hereto or its
Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a notice to
the other parties. Except as otherwise provided in this Agreement, all such communications shall be deemed to have been duly given
upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein
by telecopy shall be confirmed in writing promptly after the delivery of such communication (it being understood that non-receipt
of written confirmation of such communication shall not invalidate such communication).

 

13.03     Expenses,
Indemnification, Etc.

 

(a)          Expenses.
Borrower agrees to pay or reimburse (i) Administrative Agent and the Lenders for all of their reasonable out of pocket costs and
expenses (including the reasonable fees and expenses of Osler, Hoskin & Harcourt LLP, Baker & McKenzie LLP and Foley Hoag
LLP, each as special counsel to Administrative Agent and the Lenders, and any sales, goods and services or other similar taxes
applicable thereto, and printing, reproduction, document delivery, communication and travel costs) in connection with (x) the negotiation,
preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Loans (exclusive of post-closing
costs) and the consideration and review of the Cipher Transaction, (y) post-closing costs including, without limitation, post-closing
costs arising as a direct or indirect result of the Cipher Transaction and (z) the negotiation or preparation of any modification,
supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not consummated) and
(ii) Administrative Agent and the Lenders for all of their out of pocket costs and expenses (including the fees and expenses of
legal counsel) in connection with any enforcement or collection proceedings resulting from the occurrence of an Event of Default.

 

(b)          Indemnification.
Borrower hereby indemnifies Administrative Agent, each Lender, their respective Affiliates, and their respective directors, officers,
employees, attorneys, agents, advisors and controlling parties (each, an “Indemnified Party”) from and
against, and agrees to hold them harmless against, any and all Claims and Losses of any kind (including reasonable fees and disbursements
of counsel), joint or several, that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising
out of or in connection with or relating to any investigation, litigation or proceeding or the preparation of any defense with
respect thereto arising out of or in connection with or relating to this Agreement or any of the other Loan Documents or the transactions
contemplated hereby or thereby or any use made or proposed to be made with the proceeds of the Loans, whether or not such investigation,
litigation or proceeding is brought by Borrower, any of its shareholders or creditors, an Indemnified Party or any other Person,
or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in Section
6 are satisfied or the other transactions contemplated by this Agreement are consummated, except to the extent such Claim or
Loss is found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party’s
gross negligence or willful misconduct. No Obligor shall assert any claim against any Indemnified Party, on any theory of liability,
for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other
Loan Documents or any of the transactions contemplated hereby or thereby or the actual or proposed use of the proceeds of the Loans.
Borrower, its Subsidiaries and Affiliates and their respective directors, officers, employees, attorneys, agents, advisors and
controlling parties are each sometimes referred to in this Agreement as a “Borrower Party.” No Lender
shall assert any claim against any Borrower Party, on any theory of liability, for consequential, indirect, special or punitive
damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the transactions contemplated
hereby or thereby or the actual or proposed use of the proceeds of the Loans.

 

    	 	85	 

     

    

 

13.04     Amendments,
Etc. Except as otherwise expressly provided in this Agreement, any provision of this Agreement may be modified or supplemented
only by an instrument in writing signed by Borrower and the Majority Lenders (or Administrative Agent on behalf of such the Majority
Lenders); provided however, that:

 

(a)          the
consent of all of the Lenders shall be required to:

 

(i)           amend,
modify, discharge, terminate or waive any of the terms of this Agreement if such amendment, modification, discharge, termination
or waiver would increase the amount of the Loans, reduce the fees payable hereunder, reduce interest rates or other amounts payable
with respect to the Loans, extend any date fixed for payment of principal, interest or other amounts payable relating to the Loans
or extend the repayment dates of the Loans;

 

(ii)         amend
the provisions of Section 6;

 

(iii)        amend, modify,
discharge, terminate or waive any Security Document if the effect is to release a material part of
the Collateral subject thereto other than pursuant to the terms hereof or thereof; or

 

(iv)        amend this Section
13.04; and

 

(b)          no
amendment, waiver or consent shall affect the rights or duties under any Loan Document of, or any payment to, Administrative Agent
(or otherwise modify any provision of Section 12 or the application thereof) unless in writing and signed by Administrative
Agent in addition to any signature otherwise required.

 

Notwithstanding anything to the contrary herein, a Defaulting Lender
shall not have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent
which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable
Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended
without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected
Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of
such Defaulting Lender.

 

    	 	86	 

     

    

 

13.05     Successors
and Assigns.

 

(a)          General.
The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and assigns permitted hereby, except that Borrower may not assign or otherwise transfer
any of its rights or obligations hereunder or under any of the other Loan Documents without the prior written consent of the Lenders.
Any of the Lenders may assign or otherwise transfer any of their rights or obligations hereunder or under any of the other Loan
Documents to an assignee in accordance with the provisions of Section 13.05(b), (ii) by way of participation in accordance
with the provisions of Section 13.05(e) or (iii) by way of pledge or assignment of a security interest subject to the restrictions
of Section 13.05(g). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other
than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in Section
13.05(e) and, to the extent expressly contemplated hereby, the Indemnified Parties) any legal or equitable right, remedy or
claim under or by reason of this Agreement.

 

(b)          Assignments
by Lenders. Any of the Lenders may at any time assign to one or more Eligible Transferees (or, if an Event of Default has occurred
and is continuing, to any Person) all or a portion of their rights and obligations under this Agreement (including all or a portion
of the Commitment and the Loans at the time owing to it); provided, however, that no such assignment shall be made to Borrower,
an Affiliate of Borrower, or any employees or directors of Borrower at any time. Subject to the recording thereof by Administrative
Agent pursuant to Section 13.05(d), from and after the effective date specified in each Assignment and Assumption, the assignee
thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have
the rights and obligations of the Lenders under this Agreement and the other Loan Documents, and correspondingly the assigning
Lender shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under
this Agreement (and, in the case of an Assignment and Assumption covering all of a Lender’s rights and obligations under
this Agreement, such Lender shall cease to be a party hereto) and the other Loan Documents but shall continue to be entitled to
the benefits of Section 5 and Section 13.03. Any assignment or transfer by a Lender of rights or obligations under
this Agreement that does not comply with this Section 13.05(b) shall be treated for purposes of this Agreement as a sale
by such Lender of a participation in such rights and obligations in accordance with Section 13.05(e).

 

(c)          Amendments
to Loan Documents. Each of Administrative Agent, the Lenders and the Obligors agrees to enter into such amendments to the Loan
Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably
acceptable to Administrative Agent, the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect
to any assignment made under this Section 13.05.

 

(d)          Register.
Administrative Agent, acting solely for this purpose as an agent of Borrower, shall maintain at one of its offices in the United
States of America a register for the recordation of the name and address of any assignee of the Lenders and the Commitment and
outstanding principal amount of the Loans owing thereto (the “Register”). The entries in the Register
shall be conclusive, absent manifest error, and Borrower shall treat each Person whose name is recorded in the Register pursuant
to the terms hereof as the “Lender” hereunder for all purposes of this Agreement, notwithstanding notice to the contrary.
The Register shall be available for inspection by Borrower, at any reasonable time and from time to time upon reasonable prior
notice.

 

    	 	87	 

     

    

 

(e)          Participations.
Any of the Lenders may at any time, without the consent of, or notice to, Borrower, sell participations to one or more Eligible
Transferees, or, if an Event of Default has occurred and is continuing, to any Person (each, a “Participant”),
in each case other than a natural person or Borrower or any of Borrower’s Affiliates or Subsidiaries, in all or a portion
of such Lender’s rights and/or obligations under this Agreement (including all or a portion of the Commitment and/or the
Loans owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii)
such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) Borrower
shall continue to deal solely and directly with the Lenders in connection therewith.

 

Any agreement or instrument pursuant to which a Lender sells such
a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment,
modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such
Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase
or extend the term of such Lender’s Commitment, (ii) extend the date fixed for the payment of principal of or interest on
the Loans or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal,
or (iv) reduce the rate at which interest is payable thereon to a level below the rate at which the Participant is entitled to
receive such interest. Subject to Section 13.05(e) , Borrower agrees that each Participant shall be entitled to the benefits
of Section 5 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section
13.05(b). To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 4.04(a)
as though it were the Lender.

 

(f)          Limitations
on Rights of Participants. A Participant shall not be entitled to receive any greater payment under Section 5.01 or
5.03 than a Lender would have been entitled to receive with respect to the participation sold to such Participant, unless
the sale of the participation to such Participant is made with Borrower’s prior written consent.

 

(g)          Certain
Pledges. The Lenders may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement
and any other Loan Document to secure obligations of the Lenders, including any pledge or assignment to secure obligations to a
Federal Reserve Bank; provided that no such pledge or assignment shall release the Lenders from any of their obligations
hereunder or substitute any such pledgee or assignee for the Lenders as a party hereto.

 

13.06     Survival.
The obligations of Borrower under Sections 5.01, 5.02, 5.03, 12.03, 12.05, 12.09,
12.10, 12.11, 12.12, 12.13, 12.14 and Section 14 (solely to the extent guaranteeing any
of the obligations under the foregoing Sections) shall survive the repayment of the Obligations and the termination of the Commitment
and, in the case of the Lenders’ assignment of any interest in the Commitment or the Loans hereunder, shall survive, in the
case of any event or circumstance that occurred prior to the effective date of such assignment, the making of such assignment,
notwithstanding that the Lenders may cease to be “Lenders” hereunder. In addition, each representation and warranty
made, or deemed to be made by a Notice of Borrowing, herein or pursuant hereto shall survive the making of such representation
and warranty.

 

13.07     Captions.
The table of contents and captions and section headings appearing herein are included solely for convenience of reference and
are not intended to affect the interpretation of any provision of this Agreement.

 

    	 	88	 

     

    

 

13.08         Counterparts.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same
instrument and any of the parties hereto may execute this Agreement by signing any such counterpart.

 

13.9         Governing
Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance
with, the law of the State of New York.

 

13.10         Jurisdiction,
Service of Process and Venue.

 

(a)          Submission
to Jurisdiction.

 

(i)           Each
Obligor, other than any such party incorporated or established in France and with respect to which Section 13.10(a)(ii)
below shall apply, agrees that any suit, action or proceeding with respect to this Agreement or any other Loan Document to which
it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in
Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non- exclusive jurisdiction of each
such court for the purpose of any such suit, action, proceeding or judgment. This Section 13.10(a)(i) is for the benefit
of Administrative Agent and the Lenders only and, as a result, neither Administrative Agent nor any Lender shall be prevented from
taking proceedings in any other courts with jurisdiction. To the extent allowed by applicable Laws, Administrative Agent and the
Lenders may take concurrent proceedings in any number of jurisdictions.

 

(ii)          Each
Obligor incorporated or established in France, the Administrative Agent and each Lender agrees that any suit, action or proceeding
with respect to this Agreement or any other Loan Document to which it is a party or any judgment entered by any court in respect
thereof may be brought initially in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile
and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding
or judgment.

 

(b)          Alternative
Process. Subject to Section 13.10(a)(ii) above, nothing herein shall in any way be deemed to limit the ability of Administrative
Agent or the Lenders to serve any such process or summonses in any other manner permitted by applicable law.

 

(c)          Waiver
of Venue, Etc. Each Obligor irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter
have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan
Document and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding
brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals
has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of
which such Obligor is or may be subject, by suit upon judgment.

 

(d)          Jurisdiction
Clauses of Swiss Security Documents. Notwithstanding the jurisdiction clauses set out in the Swiss Security Documents entered
into prior to the date of this Agreement, each of the Administrative Agent, the Lenders, the Borrower and the Swiss Guarantors
hereby agrees that all disputes arising out of or in connection with any Swiss Security Document to which it is a party, including
disputes on the conclusion, binding effect, amendment and termination of such Swiss Security Document, shall be resolved exclusively
by the ordinary courts of the Republic and Canton of Geneva, Switzerland. The Administrative Agent (acting as administrative and
collateral agent and, in relation to security created under the Swiss Security Documents by way of pledge, as direct representative
of the Lenders) and each of the Lenders party to a Swiss Security Document in addition have the right to institute legal proceedings
against the relevant security provider at the competent court designated in this Agreement, in which case Swiss law shall nevertheless
be applicable to such Swiss Security Document.

 

    	 	89	 

     

    

 

13.11     Waiver
of Jury Trial. EACH OBLIGOR AND EACH LENDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND
ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

13.12     Waiver
of Immunity. To the extent that any Obligor may be or become entitled to claim for itself or its Property or revenues any immunity
on the ground of sovereignty or the like from suit, court jurisdiction, attachment prior to judgment, attachment in aid of execution
of a judgment or execution of a judgment, and to the extent that in any such jurisdiction there may be attributed such an immunity
(whether or not claimed), such Obligor, to the fullest extent permitted by law, hereby irrevocably agrees not to claim and hereby
irrevocably waives such immunity with respect to its obligations under this Agreement and the other Loan Documents.

 

13.13     Entire
Agreement. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the
subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to
the subject matter hereof. EACH OBLIGOR ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS AGREEMENT AND
THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED, AND WILL NOT RELY, ON
ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF OR WITH ADMINISTRATIVE
AGENT OR THE LENDERS OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.

 

13.14     Severability.
If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by applicable law
the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision
hereof.

 

13.15     No
Fiduciary Relationship. Borrower acknowledges that Administrative Agent and the Lenders have no fiduciary relationship with,
or fiduciary duty to, Borrower arising out of or in connection with this Agreement or the other Loan Documents, and the relationship
between the Lenders and Borrower is solely that of creditor and debtor. This Agreement and the other Loan Documents do not create
a joint venture among the parties.

 

13.16     Confidentiality.
Administrative Agent and the Lenders agree to maintain the confidentiality of the Confidential Information (as defined in the
Non-Disclosure Agreement (defined below)) in accordance with the terms of that certain confidentiality agreement dated January
27, 2014 between Borrower and Capital Royalty L.P. (the “Non-Disclosure Agreement”). Any new Lender that
becomes party to this Agreement hereby agrees to be bound by the terms of the Non-Disclosure Agreement.
The parties to this Agreement shall prepare a mutually agreeable press release announcing the completion of this transaction on
the first Borrowing Date.

 

    	 	90	 

     

    

 

13.17     USA
PATRIOT Act. Administrative Agent and the Lenders hereby notify Borrower that pursuant to the requirements of the USA PATRIOT
Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), they are required to
obtain, verify and record information that identifies Borrower, which information includes the name and address of Borrower and
other information that will allow such Lender to identify Borrower in accordance with the Act.

 

13.18     Maximum
Rate of Interest. (a) Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed
to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (in
each case, the “Maximum Rate”). If the Lenders shall receive interest in an amount that exceeds the Maximum
Rate, the excess interest shall be applied to the principal of the Loans, and not to the payment of interest, or, if the excessive
interest exceeds such unpaid principal, the amount exceeding the unpaid balance shall be refunded to the applicable Obligor. In
determining whether the interest contracted for, charged, or received by the Lenders exceeds the Maximum Rate, the Lenders may,
to the extent permitted by applicable Law, (i) characterize any payment that is not principal as an expense, fee, or premium rather
than interest, (ii) exclude voluntary prepayments and the effects thereof, (iii) amortize, prorate, allocate, and spread in equal
or unequal parts the total amount of interest throughout the contemplated term of the Indebtedness and other obligations of any
Obligor hereunder, or (iv) allocate interest between portions of such Indebtedness and other obligations under the Loan Documents
to the end that no such portion shall bear interest at a rate greater than that permitted by applicable Law.

 

(b)          If
any provision of this Agreement or of any of the other Loan Documents would obligate Borrower or any other Obligor to make
any payment of interest or other amount payable to any Lender in an amount or calculated at a rate which would be prohibited
by law or would result in a receipt by such Lender of interest at a criminal rate (as such terms are construed under the Criminal
Code (Canada)) then, notwithstanding such provisions, such amount or rate shall be deemed to have been adjusted with
retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by law or so
result in a receipt by such Lender of interest at a criminal rate, such adjustment to be effected, to the extent necessary,
as follows: (i) firstly, by reducing the amount or rate of interest required to be paid to such Lender, and (ii) thereafter,
by reducing any fees, commissions, premiums and other amounts required to be paid to such Lender which would constitute
“interest” for purposes of Section 347 of the Criminal Code (Canada). Any amount or rate of interest
referred to in this Section 13.18(b) shall be determined in accordance with generally accepted actuarial practices and
principles as an effective annual rate of interest over the term that the applicable Loan remains outstanding on the
assumption that any charges, fees or expenses that fall within the meaning of “interest” (as defined in the Criminal
Code (Canada)) shall, if they relate to a specific period of time, be pro-rated over that period of time and, in the
event of a dispute, a certificate of a Fellow of the Canadian Institute of Actuaries appointed by the Administrative Agent
shall be conclusive for the purposes of such determination.

 

    	 	91	 

     

    

 

13.19     Certain
Waivers.

 

(a)          Real
Property Security Waivers.

 

(i)           Each
Obligor acknowledges that all or any portion of the Obligations may be secured by a Lien or Liens upon real property evidenced
by certain documents including, without limitation, mortgages, debentures, deeds of trust and assignments of rents. The Secured
Parties may, pursuant to the terms of said real property security documents and applicable law, foreclose under all or any portion
of one or more of said Liens by means of judicial or nonjudicial sale or sales. Each Obligor agrees that the Secured Parties may
exercise whatever rights and remedies they may have with respect to said real property security, all without affecting the liability
of any Obligor under the Loan Documents, except to the extent the Secured Parties realize payment by such action or proceeding.
No election to proceed in one form of action or against any party, or on any obligation shall constitute a waiver of any Secured
Party’s rights to proceed in any other form of action or against any Obligor or any other Person, or diminish the liability
of any Obligor, or affect the right of the Secured Parties to proceed against any Obligor for any deficiency, except to the extent
the Secured Parties realize payment by such action, notwithstanding the effect of such action upon any Obligor’s rights of
subrogation, reimbursement or indemnity, if any, against Obligor or any other Person.

 

(ii)          To
the extent permitted under applicable law, each Obligor hereby waives any rights and defenses that are or may become available
to such Obligor by reason of Sections 2787 to 2855, inclusive, of the California Civil Code.

 

(iii)         To
the extent permitted under applicable law, each Obligor hereby waives all rights and defenses that such Obligor may have because
the Obligations are or may be secured by real property. This means, among other things:

 

(A)         the
Secured Parties may collect from any Obligor without first foreclosing on any real or personal property collateral pledged by any
other Obligor;

 

(B)          If
the Secured Parties foreclose on any real property collateral pledged by any Obligor:

 

(1)         The
amount of the Loans may be reduced only by the price for which that collateral is sold at the foreclosure sale, even if the collateral
is worth more than the sale price; and

 

(2)         the
Secured Parties may collect from each Obligor even if the Secured Parties, by foreclosing on the real property collateral, have
destroyed any right that such Obligor may have to collect from any other Obligor.

 

(3)         To
the extent permitted under applicable law, this is an unconditional and irrevocable waiver of any rights and defenses each Obligor
may have because the Obligations are or may be secured by real property. These rights and defenses include, but are not limited
to, any rights or defenses based upon Section 580a, 580b, 580d or 726 of the California Code of Civil Procedure.

 

    	 	92	 

     

    

 

(iv)         To
the extent permitted under applicable law, each Obligor waives all rights and defenses arising out of an election of remedies by
the Secured Parties, even though that election of remedies, such as a nonjudicial foreclosure with respect to security for a guaranteed
obligation, has destroyed such Obligor’s rights of subrogation and reimbursement against the principal by the operation of
Section 580d of the California Code of Civil Procedure or otherwise.

 

(b)          Waiver
of Marshaling. WITHOUT LIMITING THE FOREGOING IN ANY WAY, EACH OBLIGOR HEREBY IRREVOCABLY WAIVES AND RELEASES, TO THE EXTENT
PERMITTED BY LAW, ANY AND ALL RIGHTS IT MAY HAVE AT ANY TIME (WHETHER ARISING DIRECTLY OR INDIRECTLY, BY OPERATION OF LAW, CONTRACT
OR OTHERWISE) TO REQUIRE THE MARSHALING OF ANY ASSETS OF ANY OBLIGOR, WHICH RIGHT OF MARSHALING MIGHT OTHERWISE ARISE FROM ANY
PAYMENTS MADE OR OBLIGATIONS PERFORMED.

 

13.20     Judgment
Currency. If for the purpose of obtaining judgment in any court it is necessary to convert any amount owing or payable to the
Lenders under this Agreement from the currency in which it is due (the “Agreed Currency”) into a particular
currency (the “Judgment Currency”), the rate of exchange applied in that conversion shall be that at
which such Lenders in accordance with their normal procedures, could purchase the Agreed Currency with the Judgment Currency at
or about noon on the Business Day immediately preceding the date on which judgment is given. The obligation of any Obligor in respect
of any amount owing or payable under this Agreement to the Lenders in the Agreed Currency shall, notwithstanding any judgment and
payment in the Judgment Currency, be satisfied only to the extent that the Lenders in accordance with its normal procedures, could
purchase the Agreed Currency with the amount of the Judgment Currency so paid at or about noon on the next Business Day following
that payment; and if the amount of the Agreed Currency which the Lenders could so purchase is less than the amount originally due
in the Agreed Currency, the applicable Obligor shall, as a separate obligation and notwithstanding the judgment or payment, indemnify
the Lenders against any loss.

 

13.21     Limitations.
Each of the parties hereto agree that any and all limitation periods provided for in any applicable law in respect of any action
that may be commenced in respect of any Obligation, including the Limitations Act, 2002 (Ontario), shall be excluded from application
to the Obligations and any undertaking, covenant, indemnity or other agreement of any Obligor provided for in any Loan Document
to which it is a party in respect thereof, in each case to fullest extent permitted by such applicable law.

 

13.22     Permitted
Liens. Any reference in any of the Loan Documents to a Permitted Lien is not intended to subordinate or postpone, and shall
not be interpreted as subordinating or postponing, or as any agreement to subordinate or postpone, any Lien created by any of the
Loan Documents to any such Permitted Lien.

 

13.23     Amendment
and Restatement of the First A&R Agreement. The parties to this Agreement agree that, upon the execution and delivery by
each of the parties hereto of this Agreement, the terms and provisions of the First A&R Agreement shall be and hereby are amended,
superseded and restated in their entirety by the terms and provisions of this Agreement. This Agreement is not intended to and
shall not constitute a novation. All “Loans” made and “Obligations” incurred or arising under the First
A&R Agreement which are outstanding on the date hereof shall continue and be re-evidenced as Obligations under (and shall be
governed by the terms of) this Agreement and the other Loan Documents. Each Obligor agrees, acknowledges and affirms that (i) each
of the Loan Documents to which it is a party shall remain in full force and effect and, to the extent legally possible under the
respective governing law, shall constitute security for all extensions of credit pursuant to the First A&R Agreement as amended
and restated hereby and (ii) any reference to the First A&R Agreement appearing in any such Loan Document shall on and after
the date hereof shall be deemed to refer to the First A&R Agreement as amended and restated hereby.

 

    	 	93	 

     

    

 

13.24     English
Guarantee and Security Confirmation.

 

(a)          In
this Section 13.24:

 

“English Security Providers”
means the English Obligors, the Borrower and Cardiome International SA.

 

“Guarantee Obligations”
means the guarantee and indemnity obligations of each English Obligor contained in the English Guarantee; and

 

“Secured Obligations”
means (i) in the case of the English Debenture, the “Secured Liabilities” as defined therein; and (ii) in the case
of the English Share Charges, the “Secured Sums” as defined therein.

 

(b)          Each
English Obligor confirms for the benefit of the Administrative Agent and the Lenders that the Guarantee and all Guarantee Obligations
shall:

 

(i)           remain
in full force and effect notwithstanding the amendment and restatement of the First A&R Agreement on the terms of this Agreement
(the “Amendment and Restatement”); and

 

(ii)          extend
to any new obligations assumed by any Obligor under the Loan Documents as a result of the Amendment and Restatement (including,
but not limited to, under this Agreement).

 

(c)          Each
English Security Provider confirms for the benefit of the Administrative Agent and the Lenders that the Security (as defined in
the applicable English Security Document) created by it pursuant to each English Security Document to which it is a party shall:

 

(i)           remain
in full force and effect notwithstanding the Amendment and Restatement; and

 

(ii)          continue
to secure its relevant Secured Obligations under the Loan Documents as amended (including, but not limited to, under this Agreement).

 

    	 	94	 

     

    

 

SECTION 14

 

GUARANTEE

 

14.01     The
Guarantee. The Subsidiary Guarantors hereby jointly and severally guarantee to the Secured Parties and their respective successors
and assigns the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the principal of
and interest on the Loans and all fees and other amounts from time to time owing to the Secured Parties by Borrower under this
Agreement or under any other Loan Document and by any other Obligor under any of the Loan Documents, in each case strictly in accordance
with the terms thereof (such obligations being herein collectively called the “Guaranteed Obligations”)
.. The Subsidiary Guarantors hereby further jointly and severally agree that if Borrower shall fail to pay in full when due (whether
at stated maturity, by acceleration or otherwise) any of the Guaranteed Obligations, the Subsidiary Guarantors will promptly pay
the same, without any demand or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of
the Guaranteed Obligations, the same will be promptly paid in full when due (whether at extended maturity, by acceleration or otherwise)
in accordance with the terms of such extension or renewal.

 

14.02     Obligations
Unconditional. The obligations of the Subsidiary Guarantors under Section 14.01 are absolute and unconditional, joint
and several, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of Borrower under
this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee
of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by applicable law, irrespective of any
other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor,
it being the intent of this Section 14.02 that the obligations of the Subsidiary Guarantors hereunder shall be absolute
and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is
agreed that the occurrence of any one or more of the following shall not alter or impair the liability of the Subsidiary Guarantors
hereunder, which shall remain absolute and unconditional as described above:

 

(a)          at
any time or from time to time, without notice to the Subsidiary Guarantors, the time for any performance of or compliance with
any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived;

 

(b)          any
of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to herein shall
be done or omitted;

 

(c)          the
maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be modified, supplemented
or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived
or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or
in part or otherwise dealt with; or

 

(d)          any
lien or security interest granted to, or in favor of, the Secured Parties as security for any of the Guaranteed Obligations shall
fail to be perfected.

 

The Subsidiary Guarantors hereby expressly waive
diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that any Secured Party exhaust
any right, power or remedy or proceed against Borrower under this Agreement or any other agreement or instrument referred to herein,
or against any other Person under any other guarantee of, or security for, any of the Guaranteed Obligations.

 

    	 	95	 

     

    

 

14.03     Reinstatement.
The obligations of the Subsidiary Guarantors under this Section 14 shall be automatically reinstated if and to the extent
that for any reason any payment by or on behalf of Borrower in respect of the Guaranteed Obligations is rescinded or must be otherwise
restored by any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization
or otherwise, and the Subsidiary Guarantors jointly and severally agree that they will indemnify the Secured Parties on demand
for all reasonable costs and expenses (including fees of counsel) incurred by the Lenders in connection with such rescission or
restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted
a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar law.

 

14.04     Subrogation.
The Subsidiary Guarantors hereby jointly and severally agree that until the payment and satisfaction in full of all Guaranteed
Obligations and the expiration and termination of the Commitments under this Agreement, they shall not exercise any right or remedy
arising by reason of any performance by them of their guarantee in Section 14.01, whether by subrogation or otherwise, against
Borrower or any other guarantor of any of the Guaranteed Obligations or any security for any of the Guaranteed Obligations.

 

14.05     Remedies.
The Subsidiary Guarantors jointly and severally agree that, as between the Subsidiary Guarantors and the Secured Parties, the
obligations of Borrower under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable
as provided in Section 11 (and shall be deemed to have become automatically due and payable in the circumstances provided
in Section 11) for purposes of Section 14.01 notwithstanding any stay, injunction or other prohibition preventing
such declaration (or such obligations from becoming automatically due and payable) as against Borrower and that, in the event of
such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or
not due and payable by Borrower) shall forthwith become due and payable by the Subsidiary Guarantors for purposes of Section
14.01.

 

14.06     Instrument
for the Payment of Money. Each Subsidiary Guarantor hereby acknowledges that the guarantee in this Section 14 constitutes
an instrument for the payment of money, and consents and agrees that the Secured Parties, at their sole option, in the event of
a dispute by such Subsidiary Guarantor in the payment of any moneys due hereunder, shall have the right to proceed by motion for
summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&R § 3213.

 

14.07     Continuing
Guarantee. The guarantee in this Section 14 is a continuing guarantee, and shall apply to all Guaranteed Obligations
whenever arising.

 

14.08     Rights
of Contribution. The Subsidiary Guarantors hereby agree, as between themselves, that if any Subsidiary Guarantor shall become
an Excess Funding Guarantor (as defined below) by reason of the payment by such Subsidiary Guarantor of any Guaranteed Obligations,
each other Subsidiary Guarantor shall, on demand of such Excess Funding Guarantor (but subject to the next sentence), pay to such
Excess Funding Guarantor an amount equal to such Subsidiary Guarantor’s Pro Rata Share (as defined below and determined,
for this purpose, without reference to the properties, debts and liabilities of such Excess Funding Guarantor) of the Excess Payment
(as defined below) in respect of such Guaranteed Obligations. The payment obligation of a Subsidiary Guarantor to any Excess Funding
Guarantor under this Section 14.08 shall be subordinate and subject in right of payment to the prior payment in full of
the obligations of such Subsidiary Guarantor under the other provisions of this Section 14 and such Excess Funding Guarantor
shall not exercise any right or remedy with respect to such excess until payment and satisfaction in full of all of such obligations.

 

    	 	96	 

     

    

 

For purposes of this Section 14.08, (i)
“Excess Funding Guarantor” means, in respect of any Guaranteed Obligations, a Subsidiary Guarantor that
has paid an amount in excess of its Pro Rata Share of such Guaranteed Obligations, (ii) “Excess Payment”
means, in respect of any Guaranteed Obligations, the amount paid by an Excess Funding Guarantor in excess of its Pro Rata Share
of such Guaranteed Obligations and (iii) “Pro Rata Share” means, for any Subsidiary Guarantor, the
ratio (expressed as a percentage) of (x) the amount by which the aggregate present fair saleable value of all properties of such
Subsidiary Guarantor (excluding any shares of stock of any other Subsidiary Guarantor) exceeds the amount of all the debts and
liabilities of such Subsidiary Guarantor (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding
the obligations of such Subsidiary Guarantor hereunder and any obligations of any other Subsidiary Guarantor that have been guaranteed
by such Subsidiary Guarantor) to (y) the amount by which the aggregate fair saleable value of all properties of all of the Subsidiary
Guarantors exceeds the amount of all the debts and liabilities (including contingent, subordinated, unmatured and unliquidated
liabilities, but excluding the obligations of Borrower and the Subsidiary Guarantors hereunder and under the other Loan Documents)
of all of the Subsidiary Guarantors, determined (A) with respect to any Subsidiary Guarantor that is a party hereto on the first
Borrowing Date, as of such Borrowing Date, and (B) with respect to any other Subsidiary Guarantor, as of the date such Subsidiary
Guarantor becomes a Subsidiary Guarantor hereunder.

 

14.09     General
Limitation on Guarantee Obligations. In any action or proceeding involving any provincial, territorial or state corporate law,
or any state, provincial, territorial or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors
generally, if the obligations of any Subsidiary Guarantor under Section 14.01 would otherwise, taking into account the provisions
of Section 14.08, be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other
creditors, on account of the amount of its liability under Section 14.01, then, notwithstanding any other provision hereof
to the contrary, the amount of such liability shall, without any further action by such Subsidiary Guarantor, any Secured Party
or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated
to the claims of other creditors as determined in such action or proceeding.

 

14.10     Joint
and Several Obligations. Notwithstanding any other provision contained herein or in any other Loan Document, if a “secured
creditor” (as that term is defined under the Bankruptcy and Insolvency Act (Canada)) is determined by a court of competent
jurisdiction not to include a Person to whom obligations are owed on a joint or joint and several basis, then the Borrower’s
Obligations (and the Obligations of each other Obligor), to the extent such Obligations are secured, shall be several obligations
and not joint or joint and several obligations.

 

    	 	97	 

     

    

 

14.11     Restricted
Obligations – Switzerland.

 

(a)          If
and to the extent that a payment in fulfilling a liability of any Swiss Guarantor under this Agreement other than such Swiss Guarantor’s
own liabilities or liabilities of one of its wholly-owned Subsidiaries (i.e. liabilities of such Swiss Guarantor’s direct
or indirect parent companies (up-stream liabilities) or sister companies (cross-stream liabilities) or respective liabilities of
the Swiss Guarantor or of any other party securing obligations of the Swiss Guarantor’s direct or indirect parent companies
(up-stream liabilities) or sister companies (cross-stream liabilities)) would, at the time payment is due, under Swiss law and
practice (inter alia, prohibiting capital repayments or restricting profit distributions) not be permitted (such obligations, “Restricted
Obligations”), then such obligations and payment amount shall from time to time be limited to the amount permitted to
be paid; provided, however, that such limited amount shall at no time be less than such Swiss Guarantor’s profits and reserves
available for distribution as dividends (being, according to Swiss law as of the date of this Agreement, the balance sheet profits
and any reserves available for this purpose, in each case in accordance with Swiss law and jurisprudence and Swiss accounting rules)
at the time or times the relevant payment is requested from such Swiss Guarantor; which amount shall be determined on the basis
of an audited balance sheet of such Swiss Guarantor and (i) be confirmed by the auditors of such Swiss Guarantor as distributable
amount, and - to the extent required by Swiss law at the relevant time - (ii) be duly approved as distribution by a duly convened
meeting of the shareholders of such Swiss Guarantor and further provided that such limitation (as may apply from time to time or
not) shall not (generally or definitively) free such Swiss Guarantor from payment obligations hereunder in excess thereof, but
merely postpone the payment date therefor until such times as payment is again permitted notwithstanding such limitation. Any and
all indemnities and guarantees contained in the Loan Documents including, in particular, Section 4.04 shall be construed
in a manner consistent with the provisions herein contained.

 

(b)          In
respect of Restricted Obligations, each Swiss Guarantor shall:

 

(i)           if
and to the extent required by applicable law in force at the relevant time:

 

(A)         subject
to any applicable double taxation treaty, deduct Swiss anticipatory tax (impôt anticipé/Verrechnungssteuer)
at the rate of 35% (or such other rate as in force from time to time) from any payment made by it in respect of Restricted Obligations;

 

(B)          pay
any such deduction to the Swiss Federal Tax Administration; and

 

(C)          notify
the Administrative Agent that such a deduction has been made and provide the Administrative Agent with evidence that such a deduction
has been paid to the Swiss Federal Tax Administration; and

 

(ii)          to
the extent such a deduction is made, any payment under this Agreement shall be increased to the extent necessary to ensure that
the Lenders will receive a sum net of any such deduction or withholding equal to the sum which the Lenders would have received
had no such deduction or withholding been made or required to be made.

 

(c)          If
and to the extent requested by the Administrative Agent and if and to the extent this is from time to time required under Swiss
law (restricting profit distributions), in order to allow the Administrative Agent and each Lender to obtain a maximum benefit
from the relevant Swiss Guarantor’s liabilities under this Agreement, each Swiss Guarantor undertakes to promptly implement
all such measures and/or to promptly obtain the fulfillment of all prerequisites allowing it to promptly make the requested payment(s)
hereunder from time to time, including the following:

 

(i)           preparation
of an up-to-date audited balance sheet of such Swiss Guarantor;

 

    	 	98	 

     

    

 

(ii)          confirmation
of the auditors of such Swiss Guarantor that the relevant amount represents the maximum freely distributable profits;

 

(iii)         approval
by a shareholders’ or quotaholders’ (as applicable) meeting of the relevant Swiss Guarantor of the resulting profit
distribution;

 

(iv)         if
any obligation or payment amount would be limited as stated above, and to the extent permitted by applicable law, write up any
of the assets of the relevant Swiss Guarantor that are shown in its balance sheet with a book value that is significantly lower
than the market value of the assets, only to the extent that such assets are not necessary for the Swiss Guarantor’s business
(nicht betriebsnotwending); and

 

(v)          all
such other measures necessary or useful to enable the Swiss Guarantor to make payments and perform its obligations hereunder with
a minimum of limitations.

 

14.12     Restricted
Obligations – Germany.

 

(a)          In
this Section 14.12:

 

“Auditors’ Determination”
shall have the meaning ascribed to that term in Section 14.12(f).

 

“Enforcement Notice”
shall have the meaning ascribed to that term in Section 14.12(e).

 

“German Guarantor”
means any Subsidiary Guarantor incorporated in Germany as (x) a limited liability company (Gesellschaft mit beschränkter
Haftung - GmbH) (a “German GmbH Guarantor”) or (y) a limited partnership (Kommanditgesellschaft)
with a limited liability company as general partner (a “German GmbH & Co. KG Guarantor ”) in relation
to whom any of the Lenders intends to demand payment under the guarantee set out in Article 14.

 

“Guaranteed Obligor”
shall have the meaning ascribed to that term in Section 14.12(b).

 

“Management Determination”
shall have the meaning ascribed to that term in Section 14.12(e).

 

“Net Assets” means
the relevant company’s assets (Section 266 para.(2) A, B, C, D and E German Commercial Code (Handelsgesetzbuch), less
the aggregate of its liabilities (Section 266 para. (3) B (but disregarding any accruals (Rückstellungen) in respect
of a potential enforcement of the Guarantee (as defined below) or any Transaction Security), C, D and E German Commercial Code),
the amount of profits (Gewinne ) not available for distribution to its shareholders in accordance with section 268 para.
8 German Commercial Code and the amount of its stated share capital (Stammkapital).

 

(b)          Each Lender
agrees not to enforce the guarantee created under this Agreement (the “Guarantee”) if and to the extent that
the Guarantee secures any liability of an Obligor which is an affiliated company (verbundenes Unternehmen) within the meaning
of section 15 of the German Stock Corporation Act (Aktiengesetz) of a German Guarantor (other than that German Guarantor’s
wholly -owned Subsidiaries) (the “Guaranteed Obligor”) and if and to the extent that a payment under
the Guarantee would cause that German Guarantor’s (or, in the case of a German GmbH & Co. KG as Guarantor, its general
partners’) Net Assets (determined pursuant to Section 14.12(c), (e) and/or (f)) to be reduced
below zero (Begründung einer Unterbilanz), or further reduced (Vertiefung einer Unterbilanz) if already below
zero.

 

    	 	99	 

     

    

 

(c)          For the purposes of the calculation of the
Net Assets the following balance sheet items shall be adjusted as follows:

 

(i)           the
amount of any increase of the stated share capital (Erhöhungen des Stammkapitals) of the relevant German Guarantor
after the date hereof that has been effected without the consent of the Lenders, shall be deducted from the stated share capital
at that time;

 

(ii)          liabilities
incurred by the relevant German Guarantor in violation of the Loan Documents; and

 

(iii)         indebtedness which is subordinated to any Indebtedness outstanding under this Agreement (including indebtedness in respect of
guarantees for financial indebtedness which is so subordinated),

 

shall be disregarded.

 

(d)          In
addition, the German Guarantor and, where the guarantor is a German GmbH &Co. KG Guarantor, also its general partner,
shall realize, to the extent legally permitted and commercially reasonable with respect to the cost of such sale, in a
situation where the enforcement of the Guarantee would cause the Net Assets to fall below zero or be further reduced if
already below zero, any and all of its assets that are shown in in the balance sheet with a book value (Buchwert) that
is significantly lower than the market value of the asset if such asset is not ncesessary for the German Guarantor’s
or, as the case may be, its general partner’s, business (betriebsnotwendig).

 

(e)          The
relevant German Guarantor shall deliver to the Lenders, within 20 Business Days after receipt from the Lenders of a notice stating
that the Lenders intend to demand payment under this Guarantee (the “Enforcement Notice”), its up-to-date
balance sheet, or in the case of a German GmbH & Co. KG Guarantor its and its general partner’s balance sheet, together
with a reasonably detailed calculation of the amount of its Net Assets taking into account the adjustments set forth in Section
14.12(c) (the “Management Determination”). The Management Determination shall be prepared as of the
date of receipt of the Enforcement Notice.

 

(f)          Following
the Lenders’ receipt of the Management Determination, upon request by the Lenders, the relevant German Guarantor shall deliver
to the Lenders within 30 Business Days of such request its up-to-date balance sheet, or in the case of a German GmbH & Co.
KG Guarantor its and its general partner’s balance sheet, drawn-up by its auditor together with a detailed calculation of
the amount of the Net Assets taking into account the adjustments set forth in Section 14.12(c) (the “Auditors’
Determination”). Such balance sheet and Auditors’ Determination shall be prepared in accordance with the accounting
principles as consistently applied by the German Guarantors. The Auditors’ Determination shall be prepared as of the date
of receipt of the Enforcement Notice.

 

    	 	100	 

     

    

 

(g)          The
Lenders shall be entitled to demand payment under this Guarantee in an amount which would, in accordance with the Management Determination
or, if applicable and taking into account any previous enforcement in accordance with the Management Determination, the Auditors’
Determination, not cause the German Guarantor’s Net Assets, or in the case of a German GmbH & Co. KG Guarantor, its general
partner’s Net Assets, to be reduced below zero or further reduced if already below zero. If and to the extent that the Net
Assets as determined by the Auditors’ Determination are lower than the amount enforced (i) in accordance with the Management
Determination or (ii) without regard to the Management and/or Auditors’ Determination, the Lenders shall release to the relevant
German Guarantor (or in case of a German GmbH & Co. KG Guarantor to its general partner) such excess enforcement proceeds.

 

(h)          The
restriction under Section 14.12(b) shall not apply:

 

(i)           to
the extent that the Guarantee secures (A) any Loans that are on-lent, otherwise been passed on or actually disbursed to the relevant
German Guarantor or any of its Subsidiaries and not repaid or (B) any guarantees issued under this Agreement for the benefit of
the relevant German Guarantor or any of its Subsidiaries which are not returned;

 

(ii)          if
the relevant German Guarantor (as dominated entity) is subject to a domination and/or profit transfer agreement (Beherrschungs-
und/oder Gewinnabführungsvertrag) (a “DPTA”) with the Guaranteed Obligor, whether directly or
indirectly through a chain of DPTAs between each company and its shareholder (or in case of a German GmbH & Co. KG Guarantor
between its general partner and its shareholder) unless the existence of that DPTA does not prevent the violation of section 30
of the German Act on Companies with Limited Liabilities (Gesetz betreffend die Gesellschaften mit beschränkter Haftung)
or

 

(iii)         if
and to extent the relevant German Guarantor has on the date of enforcement of the Guarantee a fully recoverable indemnity or claim
for refund (“vollwertiger Gegenleistungs- oder Rückgewähranspruch”) against its shareholder or the
Guaranteed Obligor.

 

(i)           The
limitations set forth in this Section 14.12 shall not affect the right of a Lender to claim again any amount outstanding
at a later point in time if and to the extent that this Section 14.12 would allow this at such later point in time.

 

14.13     Restricted
Obligations – France.

 

(a)          Notwithstanding
any provision to the contrary in this Agreement, the obligations and liabilities of French Subsidiary Guarantor in respect of the
guarantee under this Section 14 shall be subject to the following limitations:

 

(i)           The
obligations and liabilities of any French Subsidiary Guarantor under this Section 14 shall not include any obligation or
liability which, if incurred, would constitute the provision of financial assistance within the meaning of article L.225-216 of
the French Commercial Code (Code de commerce) and/or would constitute a misuse of corporate assets within the meaning of
article L.241-3, L.242-6 or L.244-1 of the French Commercial Code (Code de commerce) or any other law or regulation having
the same effect, as interpreted by the French courts.

 

    	 	101	 

     

    

 

(ii)          Subject
always to the provisions of Section 14.13(a)(i) above, the obligations and liabilities of any French Subsidiary Guarantor
under this Section 14 for the obligations under this Agreement and the other Loan Documents of any other Obligor
which is not a Subsidiary of such French Subsidiary Guarantor shall be limited at any time to an amount equal to the aggregate
of all amounts directly or indirectly borrowed under this Agreement by such other Obligor to the extent directly or indirectly
on-lent to such French Subsidiary Guarantor under intercompany loan agreement(s) and outstanding at the date a payment is made
by such French Subsidiary Guarantor under this Section 14, it being specified that any payment made by this French Subsidiary
Guarantor under this Section 14 in respect of the obligations of such Obligor shall reduce pro tanto the outstanding
amount of the intercompany loan(s) due by such French Subsidiary Guarantor under the intercompany loan agreement(s) referred to
above and that any repayment of such intercompany loan(s) by the French Subsidiary Guarantor shall reduce pro tanto the
amount payable by it under this Section 14.

 

(iii)        Subject
always to the provisions of Section 14.13(a)(i) above, the obligations and liabilities of any French Subsidiary Guarantor
under this Section 14 for the obligations under this Agreement and the other Loan Documents of any other Obligor which is
its Subsidiary shall not be limited and shall therefore cover all amounts due by such Obligor as Borrower and/or as Guarantor,
provided that where such Subsidiary is not incorporated or established in France, the amounts payable by such French
Subsidiary Guarantor for its obligations and liabilities referred to above in this Section 14.13(a)(iii) in respect of the
obligations of this Subsidiary as Guarantor shall be limited as set out in Section 14.13(a)(ii) above (for the avoidance
of doubt only, by reference to and within the limit of the amounts directly or indirectly on-lent to the French Subsidiary Guarantor
by the Obligor whose obligations are guaranteed hereunder by the French Subsidiary Guarantor’s Subsidiary).

 

(b)          Notwithstanding
any provision to the contrary in this Agreement, the representations made in Section 7 by a French Subsidiary Guarantor
shall be made for itself and for each of its Subsidiaries only and the covenants made in Section 8, Section 9 and
Section 10 by a French Subsidiary Guarantor shall be made for itself and for each of its Subsidiaries only.

 

(c)          For
the purpose of this Section 14.13, “Subsidiary” means, in relation to any company, another company which
is controlled by it within the meaning of article L.233-3 of the French Commercial Code (Code de commerce).

 

14.14     English
Obligors. Notwithstanding any other provision of this Article 14, no English Obligor shall be subject to this Article 14. Each
English Obligor shall at all times be subject to the English Guarantee.

 

[Signature Pages Follow]

 

    	 	102	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first
above written.

 

	 	BORROWER:

 

	 	CORREVIO PHARMA
    CORP.

 

	 	By:	/s/
    Justin Renz
	 	 	Name: Justin Renz
	 	 	Title: Chief Financial Officer

 

	 	By:	/s/
    William Hunter
	 	 	Name: William Hunter
	 	 	Title: President, CEO and Director

 

	 	Address for Notices:
	 	Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC Canada V6J 4S7
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	SUBSIDIARY GUARANTORS: 

 

	 	CORREVIO
    CANADA CORP.

 

	 	By:	/s/
    Justin
    Renz
	 	 	Name:
    Justin Renz 
	 	 	Title:
    Director

 

	 	By:	/s/
    Sheila Grant
	 	 	Name: Sheila Grant 
	 	 	Title: Director

 

	 	Address for Notices:
	 	Correvio Canada Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC Canada V6J 4S7
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CORREVIO
    LLC

 

	 	By:	/s/
    William Hunter
	 	 	Name:
    William Hunter 
	 	 	Title:
    President

 

	 	By:	/s/
    Justin Renz
	 	 	Name: Justin Renz 
	 	 	Title: Chief Financial Officer

 

	 	Address for Notices:
	 	Correvio LLC
	 	3 Dickinson Drive
	 	Suite 101
	 	Chadds Ford, PA 19317 USA
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CARDIOME,
    INC.

 

	 	By:	/s/ Justin
    Renz
	 	 	Name:
    Justin Renz
	 	 	Title:
    Director

 

	 	Address for Notices:
	 	c/o Corporation Service Company
	 	2711 Centerville Road
	 	Suite 400
	 	Wilmington, DE 19808 USA
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	ARTESIAN THERAPEUTICS,
    INC.

 

	 	By:	/s/ Justin
    Renz
	 	 	Name:
    Justin Renz
	 	 	Title:
    Director

 

	 	Address for Notices:
	 	c/o Corporation Service Company
	 	2711 Centerville Road
	 	Suite 400
	 	Wilmington, DE 19808 USA
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CARDIOME
    INTERNATIONAL SA

 

	 	By:	/s/ Justin
    Renz
	 	 	Name:
    Justin Renz
	 	 	Title:
    Director

 

	 	By:	/s/
    David
    McMasters
	 	 	Name:
    David McMasters
	 	 	Title:
    Director

 

	 	Address for Notices:
	 	Rue des Alpes 21
	 	Case postale 1674
	 	1201 Geneva, Switzerland
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CORREVIO
    INTERNATIONAL SARL

 

	 	By:	/s/ Justin
    Renz
	 	 	Name:
    Justin Renz 
	 	 	Title:
    Director

 

	 	By:	/s/
    David
    McMasters
	 	 	Name:
    David McMasters
	 	 	Title:
    Director

 

	 	Address for Notices:
	 	Rue des Alpes 21
	 	1201 Geneva Switzerland
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CORREVIO
    (UK) LTD.

 

	 	By:	/s/ Justin
    Renz
	 	 	Name:
    Justin Renz 
	 	 	Title:
    Director

 

	 	By:	/s/
    Sheila Grant
	 	 	Name: Sheila Grant 
	 	 	Title: Director

 

	 	Address for Notices:
	 	Lakeside House
	 	1 Furzeground Way,
	 	Stockley Park,
	 	Uxbridge, Middlesex,
	 	UB11 1BD
	 	United Kingdom
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CARDIOME
    UK LIMITED

 

	 	By:	/s/ Justin
    Renz
	 	 	Name:
    Justin Renz 
	 	 	Title:
    Director

 

	 	Address for Notices:
	 	Lakeside House
	 	1 Furzeground Way,
	 	Stockley Park,
	 	Uxbridge, Middlesex,
	 	UB11 1BD
	 	United Kingdom
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CORREVIO
    GMBH

 

	 	By:	/s/ Justin
    Renz
	 	 	Name:
    Justin Renz 
	 	 	Title:
    Director

 

	 	By:	/s/
    David
    McMasters
	 	 	Name:
    David McMasters
	 	 	Title:
    Director

 

	 	Address for Notices:
	 	Nikolaus Durkopp Str. 4A
	 	33602 Bielefeld Germany
	 	 
	 	with a copy to:
	 	c/o Correvio Pharma Corp.
	 	1441 Creekside Drive
	 	6th Floor
	 	Vancouver, BC V6J 4S7 Canada
	 	 
	 	Attn: Legal Affairs
	 	Tel.: (604) 677-6905
	 	Fax: (604) 677-6915
	 	Email: legalaffairs@cardiome.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	ADMINISTRATIVE
    AGENT: 

 

	 	CRG
    SERVICING LLC

 

	 	By:	/s/
    Andrei
    Dorenbaum
	 	 	Name:
    Andrei Dorenbaum
	 	 	Title:
    Authorized Signatory

 

	 	Address
    for Notices:
	 	1000
    Main Street
	 	Suite
    2500
	 	Houston,
    TX 77002
	 	 
	 	Attn:
    General Counsel
	 	Tel.:
    (713) 209-7350
	 	Fax:
    (713) 209-7351
	 	Email:
    adorenbaum@crglp.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	LENDERS:

 

	 	CRG PARTNERS III L.P.
	 	By CRG PARTNERS III GP L.P., its
	 	General Partner
	 	By CRG PARTNERS III GP LLC, its 
	 	General Partner

 

	 	By:	/s/
    Andrei Dorenbaum
	 	 	Name:
    Andrei Dorenbaum 
	 	 	Title:
    Authorized Signatory

 

	 	Address
    for Notices:
	 	1000
    Main Street
	 	Suite
    2500
	 	Houston,
    TX 77002
	 	 
	 	Attn:
    General Counsel
	 	Tel.:
    (713) 209-7350
	 	Fax:
    (713) 209-7351
	 	Email:
    adorenbaum@crglp.com

 

	 	CRG PARTNERS III – PARALLEL FUND
    “A” L.P.
	 	By CRG PARTNERS III – PARALLEL FUND “A”
    GP L.P., its General Partner 
	 	By CRG PARTNERS III – PARALLEL FUND “A”
    GP LLC, its General Partner

 

	 	By:	/s/ Andrei
    Dorenbaum
	 	 	Name:
    Andrei Dorenbaum
	 	 	Title:
    Authorized Signatory

 

	 	Address
    for Notices:
	 	1000
    Main Street
	 	Suite
    2500
	 	Houston,
    TX 77002
	 	 
	 	Attn:
    General Counsel
	 	Tel.:
    (713) 209-7350
	 	Fax:
    (713) 209-7351
	 	Email:
    adorenbaum@crglp.com

 

    Second A&R Term Loan Agreement

     

    

 

	 	CRG PARTNERS III (CAYMAN) L.P.
	 	By CRG PARTNERS III (CAYMAN) GP L.P., its General
    Partner 
	 	By CRG PARTNERS III (CAYMAN) GP LLC, its General
    Partner

 

	 	By:	/s/ Andrei
    Dorenbaum
	 	 	Name:
    Andrei Dorenbaum
	 	 	Title:
    Authorized Signatory

 

	 	Address
    for Notices:
	 	1000
    Main Street
	 	Suite
    2500
	 	Houston,
    TX 77002
	 	 
	 	Attn:
    General Counsel
	 	Tel.:
    (713) 209-7350
	 	Fax:
    (713) 209-7351
	 	Email:
    adorenbaum@crglp.com

 

	 	CRG PARTNERS III - PARALLEL FUND
    “B” (CAYMAN) L.P.
	 	By CRG PARTNERS III (CAYMAN) GP L.P., its General
    Partner
	 	By CRG PARTNERS III (CAYMAN) GP LLC, its General
    Partner

 

	 	By:	/s/ Andrei
    Dorenbaum
	 	 	Name:
    Andrei Dorenbaum
	 	 	Title:
    Authorized Signatory

 

	 	Address
    for Notices:
	 	1000
    Main Street
	 	Suite
    2500
	 	Houston,
    TX 77002
	 	 
	 	Attn:
    General Counsel
	 	Tel.:
    (713) 209-7350
	 	Fax:
    (713) 209-7351
	 	Email:
    adorenbaum@crglp.com

 

    Second A&R Term Loan Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]